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Lyophilization of nanoparticle (NP) suspensions is a promising technology to improve stability, 
especially during long-term storage, and offers new routes of administration in solid state. 
Although considered as a gentle drying process, freeze-drying is also known to cause several 
stresses leading to physical instability, e.g. aggregation, fusion, or content leakage. NPs are 
heterogeneous regarding their physico-chemical properties which renders them different in 
their sensitivity to lyophilization stress and upon storage. But still basic concepts can be 
deducted. We summarize basic colloidal stabilization mechanisms of NPs in the liquid and 
the dried state. Furthermore, we give information about stresses occurring during the freezing 
and the drying step of lyophilization. Subsequently, we review the most commonly 
investigated NP types including lipophilic, polymeric, or vesicular NPs regarding their particle 
properties, stabilization mechanisms in the liquid state, and important freeze-drying process, 
formulation and storage strategies. Finally, practical advice is provided to facilitate purposeful 
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The significant efforts to develop nanoparticulate systems (NPs) for drug delivery (e.g. 
polyplexes, vaccines, liposomes) and to overcome the bioavailability hurdle of poorly 
water-soluble APIs lead to a growing number of NP-based medicines on the market, 
especially for parenteral use [1]. However, development of nanomedicine is challenging. Most 
NPs are produced in aqueous solution and suffer from both: chemical and physical instability. 
Depending on the NP type and cargo, chemical instabilities may include oxidation, hydrolysis, 
deamidation, browning reaction, and disulfide bond formation/exchange [2], while physical 
instability is mainly related to particle aggregation or uncontrolled release kinetics. 
Electrostatic stabilization, as described by the Derjaguin-Landau-Verwey-Overbeek (DLVO) 
theory, may overcome physical instability, but is formally only applicable for charged colloids 
[3]. Consequently, many NP preparations can only be used for a short time or have to be 
stored frozen. Still, NP long-term stability at room temperature (RT) is an important 
development goal. 
Freeze-drying, also known as lyophilization, is a well-established process to improve the 
stability of labile drugs [4]. This gentle water removal process consists of sublimation of ice 
from the frozen state followed by desorption under vacuum. Freeze-drying of pharmaceutics 
received a boost in the 1990s with the rise of biologics, specifically proteins, which are highly 
sensitive and require parenteral application and convenient handling. Lyophilization enables 
the preparation of dry NP presentations with enhanced long-term storage, which helps to 
avoid cost-intensive and effortful cold-chain supply, as known for many vaccines [5–7]. As for 
biopharmaceuticals, the lyophilizates have to come with preservation of the original product 
properties, low residual moisture, elegant cake appearance, and fast reconstitution. 
The lyophilization process itself comes with several stresses which can lead to colloidal 
instability, specifically particle aggregation. To this end, both the process itself, e.g. freezing 
protocol, product temperature during primary drying, and the formulation, e.g. the use of 
cryoprotectants to embed particles in an amorphous matrix, or addition of surfactants to 
reduce interaction with the ice surface, are key factors to ensure process and storage stability. 
Still, except of empirical principles, little is known about the mutual dependency of formulation 
and process design as well as particle properties when freeze-drying NPs. 
Depending on the definition, the size distribution of NPs can range from 1 nm to 100 nm or 
up to 500 nm [8,9]. Besides their particle size, they can be differentiated into material 
categories based on physico-chemical properties, e.g. polymeric, crystalline, or liposomal 
NPs. As new materials and NP types arise, a meaningful classification of the broad spectrum 





becomes obvious that NP types that differ in size, material, charge, morphological structure, 
and chemical stability require different formulation, process and storage considerations. 
Therefore, it is important to combine the knowledge and experience of the multiple studies to 
guide new developments and generate fundamental understanding. 
Our review first briefly summarizes the mechanisms of colloidal NP stabilization in the liquid 
and the dried state. It subsequently elucidates stresses occurring during freezing and drying. 
Consequently, we provide individual information on lyophilization of different NP types 
regarding important formulation and process aspects. Understanding the sensitivity of 
different NP types towards different stress factors leads to optimized and purposeful 
lyophilization development. 
 
2 Mechanisms of nanoparticle stabilization 
2.1 Stability in the liquid state 
Formulation design for NP lyophilizates must consider colloidal stabilization mechanisms in 
the liquid state since they fundamentally affect the sensitivity of the NPs to aggregate during 
freezing, drying, storage in the dry state, and reconstitution. The three main stabilization 
mechanisms leading to colloidal stability are electrostatic, steric and depletion stabilization 











According to the DLVO theory two forces are acting on particles in aqueous medium: 
attractive forces (van der Waal) and repulsive forces (electrostatic) [10]. The repulsive forces 
originate from the overlapping of electrical double layers (EDL) surrounding the particles, and 
prevent agglomeration (Figure 1A). As adsorption of ions is reversible, charge stabilized NPs 
are sensitive to electrolyte addition and pH changes. 
Steric stabilization (Figure 1B) is achieved by attachment of polymers, e.g. polyethylene 
glycol (PEG), poloxamer, polyvinyl alcohol (PVA), or surfactants, e.g. polysorbate, sodium 
dodecyl sulfate, onto the particle surface. Thereby the attractive van der Waals forces 
become more reduced than the repulsive electrostatic forces [13]. This mechanism depends 
on the polymer affinity to the respective surface, the polymer concentration and average chain 
length. 
Depletion stabilization (Figure 1C) results from free non-adsorbing polymer in solution. The 
NPs may experience a depletion force originating from the excluded volume effect, for which 
no specific binding between the NP and polymer is required [12]. The depletion interaction is 
considered to have both, a short-range attractive minimum and a long-range repulsive barrier. 
Above a certain polymer concentration, the repulsive energy barrier becomes high enough to 
allow kinetical (i.e. thermodynamically metastable) stabilization [14,15]. Semenov et al. 
reported that the particle surface may exhibit strongly attractive sites at which polymer 
segments get trapped. This leads to adsorbed polymer layers which provide short-range 
steric repulsion. The interaction of free polymers with these fluffy layers gives rise to a 
depletion repulsion force between colloidal particles [16]. Still, the exact mechanism of 
depletion stabilization is a subject of debate.  
2.2 Stresses occurring during freezing 
Freezing is a widely used preservation technique to extend the shelf life of compounds 
suffering from poor stability. Moreover, it is the first step of freeze-drying and known to 
generate a variety of stresses which impact the stability of NPs, including crystal formation, 










Figure 2: Destabilization factors and consequences on colloidal NP stability during freezing. 
 
Crystal formation during freezing 
Ice and also excipient, e.g. mannitol, glycine, or NaCl-eutectic crystals, can exert mechanical 
stress on NPs. Especially mechanically fragile types, e.g. liposomes or enveloped viruses, 
may be damaged [17,18]. Furthermore, these NP qualities have a liquid inner core, hence 
external and internal ice crystal formation creates stress [17–19]. Additionally, shear stress 
potentially occurring as the ice crystal matrix forms can lead to deformation and drug leakage 
which was reported for liposomes [20]. 
The higher the degree of supercooling, the higher the number of small ice crystals and the 
larger the interfacial area [21]. The ice-liquid interface may lead to adsorption and damage of 
colloidal structures as shown for proteins [22]. Surfactants can compete for adsorption on 
denaturing interfaces [23] which could be beneficial for surfactant-based vesicles or viruses, 
especially if decorated with proteins which may be negatively affected [24]. 
Changes during freeze-concentration 
Freezing rapidly increases the concentration of all compounds in the remaining liquid fraction 
up to 50 times which may negatively impact particle stability [2,25]. The decreased particle 
distance facilitates particle-particle interactions as attractive forces can overcome repulsive 
forces resulting in particle aggregation. This process can be accelerated by the increased 
ionic strength in the freeze-concentrate shielding charges. With increasing ionic strength, the 





particle aggregation may occur due to hindered electrostatic repulsion and a higher particle 
concentration. 
Freeze-concentration also results in an increase of the osmotic pressure on particles 
possessing a lipid bilayer such as liposomes, extracellular vesicles and enveloped viruses. 
The water flux driven by the osmotic pressure gradient imparts physical force to the 
membrane which can cause membrane rupture [27]. The osmotic stability during freezing 
highly depends on the lipid membrane composition due to selective permeability towards 
solutes [28,29]. After shrinkage in size, the lipid layer adapts leading to deformation into 
lens-shaped vesicles [30] or invagination resulting in multilamellar structured liposomes [31]. 
These deformation processes may lead to leakage. The osmotic pressure further impacts the 
release kinetics of hydrophilic and, to a minor extent, lipophilic content [32]. 
Buffer pH change 
During freezing, buffers may undergo a significant pH change affecting the colloidal stability 
[33–36]. The pH shift arises from solubility limitations leading to eutectic crystallization, e.g. 
for sodium phosphate, succinate, and tartrate, and temperature-associated changes in the 
pKa values of the buffer components, e.g. for histidine, citrate, and malate [35,37–39]. Sodium 
phosphate buffer is the most prominent example for this phenomenon: disodium phosphate 
crystallizes earlier compared to the monosodium salt which can results in a pH drop by up to 
3 units [37,40]. The potassium salt of phosphate does not have this limitation [35]. 
Phase separation 
Freeze-concentration may also lead to liquid-liquid phase separation [41] and a destabilizing 
effect has to be expected if NP and stabilizer separate. A characteristic of phase-separated 
systems are two glass transition temperatures [25]. Some polymer-polymer and polymer-salt 
pairs are known to cause phase separation. Many of these polymers are of interest as 
cryoprotectants, e.g. PEG, and polyvinyl pyrrolidon (PVP), or collapse temperature modifiers, 
e.g. dextran, and ficoll. Heller et al. showed that phase separation between PEG and dextran 
resulted in structural damage of hemoglobin during freeze-drying even after addition of 5% 






2.3 Stresses occurring during drying 
The drying step in lyophilization is divided into primary and secondary drying. During primary 
drying frozen water sublimates and during secondary drying residual adsorbed water gets 
desorbed. Water is an integral part of electrostatically stabilized NPs. The EDL ensures 
stabilization through repulsive electrostatic forces. Dehydration leads to its disruption. 
Especially, the loosely associated diffuse layer is prone to external influences. As a result, 
NP interactions may increase causing particle aggregation. Steric and depletion stabilization 
of NPs can also be affected by the drying step since the mobility of polymers and surfactants 
may be hindered in the absence of water. Therefore, the substitution of water by excipients 
is necessary to maintain particle properties during and after the drying step. Depending on 
the individual particle properties, the loss of the hydration shell could result in NP damage 
and aggregation; an effect, that is well known for proteins [2]. Particles possessing a lipid 
bilayer are furthermore affected by a shift of the phase transition temperature Tm during the 
drying step as a consequence of dehydration. This behavior is explained in detail in 
section 3.3. 
2.4 Stability in the dried state 
Two different stabilization mechanisms are widely discussed to explain stabilization of 
proteins in the dried state [43,44]. These principles, the water replacement theory and the 
vitrification concept, may be transferred to other colloidal systems, such as NPs. 
2.4.1 Water replacement hypothesis 
The water replacement theory states that sugar molecules replace the hydrogen bonds of 
water at the surface of a colloid maintaining the molecular structure upon drying [45]. 
Hydrogen bonding is assumed to be most effective when sugar molecules tightly fit the 
irregular colloid surface thus be in the amorphous state and not crystalline [46]. The 
replacement theory is supported by the fact that an increasing sugar to particle ratio usually 
leads to increased particle stability which is beyond a simple spacing separation effect 
resulting from a lower particle fraction [47–49]. 
Stabilization of bilayer vesicles was mainly investigated for liposomes which have the simplest 
structure. Crowe et al. were the first group proposing the water replacement hypothesis for 
liposomes (Figure 3). In the dry state, water between the phospholipid head groups is 
replaced by sugar molecules. As a result, the head group spacing between phospholipids can 
be maintained leading to reduced van der Waals interactions among the acyl chains [50,51]. 





trehalose molecules supporting the water replacement hypothesis [52]. Moreover, 
preservation of lyophilized vesicles was improved when the cryoprotectant was also 
distributed inside the vesicles suggesting an additional stabilizing effect at the phospholipid 




Figure 3: Mechanism of water replacement during lyophilization and rehydration of lipid bilayers 
(adapted from [55]). 
 
2.4.2 Vitrification hypothesis 
The vitrification theory, also called particle isolation hypothesis, describes colloidal and 
chemical stabilization in the dried state from a kinetic point of view. Colloids are immobilized 
in a rigid, amorphous glassy sugar matrix which drastically slows down diffusion, aggregation, 
fusion, and other degradation processes [56]. Consequently, the glass transition temperature 
Tg is of importance. Above Tg, the amorphous matrix is in a rubbery state where kinetic 
immobilization is lost. Water replacement is the predominant mechanism of stabilization when 
there is sufficient vitrification, i.e. Tg is at least 10 to 20 °C above the storage temperature 
[46]. The lack of vitrification becomes critical for stability at storage temperatures closer to or 
above Tg [57]. However, vitrification itself is not sufficient to preserve NPs, especially bilayer 
vesicles, during freezing or freeze-drying. Dextran failed to stabilize egg 
phosphatidylcholine-based liposomes during lyophilization compared to trehalose indicating 
better interaction and water replacement of the smaller disaccharide with the lipid bilayer [58]. 
Thus, the vitrification and water replacement theory are not mutually exclusive; instead both 
are required for lyophilization [51]. Both theories have their explanatory power, but leave room 





discussed in literature. Specifically, for biological vesicles, the depression of normal 
metabolism, the inhibition of free radical- and enzyme-mediated membrane damage, and the 
accumulation of specific proteins and carbohydrates play a role in the overall stabilization 
[59]. 
3 Freeze-drying of different nanoparticle types 
The colloidal stability is influenced by the surface chemistry of the NPs and affected by pH, 
ionic strength, buffer type, and other excipients. Additionally, the mechanical resistance 
against deformation triggered by ice crystals during freezing and the affinity to the ice crystal 
surface affect the particle stability. Thus, the set of the NP properties relevant for their stability 
is specific for each type. It is crucial to evaluate formulation principles within a material 
category first and to subsequently derive general rules. Important aspects for lyophilization of 
pharmaceutically relevant NP types distinguished according to their physico-chemical 
properties are described in the following sections (see Table 1). 
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3.1 Lipophilic nanoparticles 
Stabilization of lipophilic NPs, a group that comprises drug nanosuspensions or nanocrystals, 
solid lipid nanoparticles (SLNs), as well as nanostructured lipophilic carriers (NLCs), is usually 
accomplished by surfactants and/or polymers. These stabilizers affect particle-liquid and 
particle-particle interactions. Only a limited number of surfactants is approved for parenteral 
products [60] and accordingly lipophilic NPs are usually stabilized with lecithin or the non-ionic 
surfactants polysorbate 20 or 80 (PS20, PS80) and poloxamer 188 (P188). Steric stabilization 
by non-ionic surfactants leads to particles without considerable surface charge which reduces 
a negative impact by salt or pH change on stability. Also, the number of polymers approved 
for parenteral use is restricted. Therefore, usually PVP, PEG, hydroxyethyl starch (HES), 





3.1.1 Drug nanosuspensions (= nanocrystals) 
Nanosuspensions of pure API are utilized to improve the bioavailability of poorly water-soluble 
compounds. The high specific surface area caused by nanonization results in an increased 
dissolution rate according to Noyes-Whitney and Nernst-Brunner equations [63]. However, 
physical stability can be problematic as small particles tend to form aggregates because of 
their thermodynamically unfavorable high total surface energy [3]. The aggregation tendency 
of a nanosuspension depends on many aspects including the stabilizers added, the API 
solubility, and the employed nanosizing method [64]. Freeze-drying of drug nanosuspensions 
is an important technique to generate a dry powder and thereby improve stability. A rapidly 
reconstituted lyophilizate may additionally provide more convenient handling compared to a 
suspension. The latter may require vigorous shaking for a longer time period to assure 
homogeneity which comes also with the risk of air entrapment or foaming. 
Fast freezing may result in less particle aggregation [65,66]. But the effect may be limited 
when considering the rates possible with commercial freeze-dryers [47]. Low molecular 
weight sugars like sucrose and trehalose led to better stabilization of freeze-dried 
indomethacin nanocrystals compared to a high molecular weight sugar like maltodextrin. This 
is potentially due to better hydrogen bonding also with the surfactant used [67]. Beirowski et 
al. showed that drug nanosuspensions do not require immobilization by glass-forming 
excipients to inhibit aggregation unless an appropriate type of steric stabilizer is present in a 
suitable concentration [68]. This is in line with studies showing successful lyophilization of 
nanocrystals using mannitol [69] which is known to crystallize upon drying. Furthermore, 
polymers such as Ficoll, high molecular weight PEG, carrageen, or gelatin were able to 
prevent aggregation of different nanocrystal types during lyophilization [67,70,71]. Whereas 
Cremophor EL was inappropriate as steric stabilizer of a model drug nanosuspension, 
poloxamer 338 substantially inhibited aggregation during freeze-drying and long-term 
storage [72]. 
3.1.2 Solid lipid nanoparticles/ Nanostructured lipid carriers 
SLNs are typically prepared by high pressure homogenization of triglycerides, 
monoglycerides, fatty acids, fatty alcohols, and waxes emulsified with 0.5 - 5.0% surfactant 
in water. SLNs have a good loading capacity for both hydrophilic and lipophilic 
compounds [73]. The incorporation can increase drug stability, provide controlled release, or 
improve bioavailability [73,74]. The focus currently shifts from small molecules to peptides, 
proteins, antibodies and DNA [75,76]. SLNs may suffer from a change in lipid modification 
upon storage. The resulting more stable modifications with less imperfections may lead to 





lipid and an oil were developed with more imperfections in the lipid matrix [77,78]. SLNs and 
NLCs show physical and chemical instability. Frequently, an increase in particle size will be 
observed within a few months [74]; lyophilization is a promising way to extend the shelf life. 
Heiati et al. investigated the influence of trehalose, glucose, mannitol and lactose as 
cryoprotectants on process stability of zidovudine-loaded glyceryl trilaurate SLNs with lecithin 
as surfactant [79]. Trehalose was most effective at a sugar to lipid weight ratio of 2.6 to 3.9; 
the ratio depending on the phospholipid composition. A sufficiently high concentration of 
cryoprotectant is crucial. Cavalli et al. observed pronounced particle aggregation after 
lyophilization of similar SLNs with 2% trehalose for cryoprotection [48]. Using 15% trehalose 
provided better stabilization with a particle size of around 100 nm after freeze-drying, 
compared to 56.5 nm before and to 240 nm after freeze-drying with 2% trehalose. Also 
Schwarz et al. identified 10 to 15% glucose, mannose, maltose, and trehalose as effective 
protectors during freezing and thawing of SLNs [49]. After freeze-drying, they found least 
aggregation using 15% trehalose, but still particle size increased by a factor of 3. Loading of 
the SLNs with 1% tetracaine or etomidate resulted in large aggregates presumably due to an 
effect of free drug on the zeta potential of the particles or a change in the lipid matrix 
properties. Recent studies on lyophilization of progesterone-loaded SLNs showed best 
preservation using 20% trehalose; still, this formulation suffered from low short-term storage 
stability at 25 °C [80]. Other authors also reported that trehalose is not a universal solution 
for lyophilization of SLNs [81] concluding that further formulation parameters such as pH, 
surfactant type, and concentration are very important. 
Ohshima et al. found that 5% glucose, fructose, maltose, or sucrose equally stabilized 
nifedipine-loaded SLNs during lyophilization [82]. Stabilization of SLNs can also be achieved 
by using mannitol which crystallizes upon lyophilization. Tiyaboonchai et al. found that 4% of 
mannitol is sufficient to preserve the particle size of freeze-dried curuminoids-loaded 
SLNs [83]. Thus, a glass forming sugar is not obligatory for freeze-drying of SLNs. Vighi et 
al. successfully freeze-dried cationic stearic acid SLNs without cryoprotectant [84]. However, 
they used a high surfactant concentration of 6%, and other lipid matrices showed irreversible 
particle aggregation suggesting lipid specific freeze-drying behavior. 
Furthermore, it appears to play a role, when the cryoprotectant is added. Siekmann et al. 
found that 20% sucrose better stabilized SLNs during lyophilization, when added already 
before as compared to after high pressure homogenization [85]. They hypothesize that the 
disaccharide molecules form hydrogen bonds with the phosphodiester group of the 






In none of the aforementioned publications, the surfactant/ cosurfactant composition was 
varied. Analogous to drug nanosuspensions, the surfactant type and concentration is 
assumed to be crucial for the freeze-drying success. However, in contrast to drug 
nanosuspensions, the surfactant/ cosurfactant types are key factors for the properties of the 
lipid matrices including drug loading capacity and release kinetics. Thus, interchangeability 
of surfactants is not straightforward in manufacturing of SLNs. 
3.2 Polymeric nanoparticles 
3.2.1 Nanospheres/-capsules & Polyelectrolyte complexes 
Nanospheres are matrix systems in which the drug is physically and uniformly dispersed, 
whereas nanocapsules are vesicular systems in which the drug is located in a cavity 
surrounded by a polymeric layer [86]. Both types are used as drug delivery systems, mainly 
for controlled drug release. Commonly used synthetic polymers are poly(lactic-co-glycolic) 
acid (PLGA), polylactide (PLA), and polycaprolactone (PCL), whereas saccharides such as 
chitosan, and alginate or proteins such as human serum albumin (HSA) and gelatin are typical 
natural polymers used to form these NPs. Nanospheres and nanocapsules are frequently 
lyophilized in order to preserve their physical and chemical stability and especially in order to 
block payload release that can occur if stored in liquid suspension. 
Disaccharides maintained the particle size of lyophilized PLGA and PCL NPs in several 
studies [87–91]. Additionally, release kinetics of testosterone-loaded PLGA NPs were not 
affected [88]. In contrast, mannitol failed to prevent aggregation concluding that vitrification is 
favorable. Excipients forming such an amorphous matrix are not interchangeable as shown 
for PLA NPs [92,93]; the smaller disaccharides were superior to the larger saccharides ficoll, 
and dextran as well as PVP [92]. Fonte et al. showed that co-encapsulation of lyoprotectants, 
e.g. trehalose, improves drug stability of insulin-loaded PLGA NPs during lyophilization [94]. 
Freeze-drying of cyclosporine-loaded PLGA and PCL NPs led to a 1.5-fold increase of particle 
size in presence of 20% sucrose as reported by Saez et al. [95] indicating further critical 
aspects than the choice of the cryoprotectant. 
Polymeric NPs are often stabilized by polymers or surfactants, such as PVA or P188 which 
can bind to the NP surface. Their concentration and type strongly affect the success of 
lyophilization. PVA itself exhibits a cryoprotective effect as shown after freeze-thawing of PCL 
NPs and freeze-drying of PLGA NPs [96,97]. De Chasteigner et al. found that sodium 
deoxycholate instead of P188 results in complete stabilization of itraconazole-loaded PCL 
nanospheres after freeze-drying in presence of 10% sucrose, speculating about P188 





PLA NPs, interestingly both when added to the formulation before or to the reconstitution 
medium after lyophilization [99]. Thus, reconstitution appears to be a further critical step 
fostering aggregation. De Jaeghere et al. found that both adsorbed and covalently bound 
polyethylene oxide (PEO) destabilized PLA NPs during freeze-drying, which might be due to 
PEO crystallization [100,101]. However, this effect was minimized by increasing the amount 
of trehalose as cryoprotectant. Interestingly, lyophilization of insulin-loaded PLGA NPs 
increased drug release due to increased pore formation on the NP surface [102]. Overall, an 
annealing step during freezing was suitable to accelerate sublimation without negative impact 
on the particle size of PCL NPs [103]. 
HSA NPs as protein-based drug delivery vehicles can be stabilized by trehalose and sucrose 
during lyophilization independent of drug loading or PEGylation. The disaccharides were 
superior to mannitol [104,105]. Self-assembly of charged polyelectrolytes (e.g. chitosan, 
gelatin) with substances of opposite charge can be defined as polyelectrolyte complexes. 
Depending on the counterparts of the complexes, there is a smooth transition to polyplexes 
which are described in section 3.2.2. Disaccharides are suitable to stabilize various types of 
chitosan complexes [106–108]. Insulin-chitosan NPs formulated with trehalose showed 
comparable particles sizes before and after lyophilization [109] while freeze-drying in 
presence of mannitol led to a slightly decreased size [106] indicating altered particle 
properties. Bromelain-chitosan NPs were better stabilized using the disaccharide maltose 
compared to glycine as cryoprotectant [110]. Lyophilization of poly(propylacrylic acid)-peptide 
complexes was recently studied by Mukalel et al.. They identified sucrose, trehalose and 
lactosucrose as efficient stabilizers [108]. Umerska et al. furthermore observed synergistic 
cryoprotection of trehalose/PEG mixtures for various polyelectrolyte complexes [111]. 
Zillies et al. successfully lyophilized oligonucleotide-loaded gelatin NPs using sucrose or 
trehalose [112]. Interestingly, mannitol also showed notable process stabilization despite its 
crystalline nature. Based on these findings, Geh et al. further developed lyophilization of 
oligodeoxynucleotide (ODN)-loaded gelatin NPs investigating histidine, arginine, and glycine 
as alternative cryoprotectants [113]. Histidine emerged as an excellent stabilizer in contrast 
to arginine and glycine. Furthermore, the controlled ice nucleation technique shortened drying 








Nonviral vectors are a rather new class of nucleic-acid-based biopharmaceuticals used for 
gene delivery. These delivery systems are based on cationic polymers (= polyplexes) or 
cationic lipids (= lipoplexes) which form condensed complexes with the negatively charged 
nucleic acids [114]. Ternary complexes of cationic liposomes, polycations (cationic polymers 
or peptides), and nucleic acids are called lipopolyplexes [115]. Synthetic polymers such as 
poly(L-lysine) and polyethylene imine (PEI) are widely used cationic polymers for polyplex 
formation. Lipo(poly)plexes are referred to lipid bilayer structured NPs and are therefore 
discussed in section 3.3. The size of the complexes affects cellular uptake and should be 
between 70 and 90 nm [116]. Hence, aggregation of particles in aqueous solutions correlates 
with a loss in transfection efficiency. 
Armstrong et al. observed time and temperature dependend aggregation of pDNA/PEI 
polyplexes in the frozen state which was inhibited at temperatures below Tg’ providing 
complete immobilization [117]. Kasper et al. further found the initial sample viscosity and the 
residence time in the low-viscosity state as very important factors in pDNA/LPEI 
stabilization [118]. At a certain temperature and degree of freeze-concentration, particle 
mobility can be inhibited due to high sample viscosity even above Tg’. It is very likely that 
these principles also apply to other colloidal systems which degrade by aggregation. 
Generally, cryoprotectants forming an amorphous matrix, preferably sucrose or trehalose, 
proved to successfully stabilize various polyplex types (Table 2). 
Table 2: Polyplexes stabilized in amorphous matrices. 
Polyplex type Reference 
pDNA/ PEI [117–119] 
pDNA/ transferrin-PEI [120] 
pDNA/ poly((2-dimethylamino) ethyl methacrylate) [121,122] 
pDNA/ iodoacetic acid alkylated Cys-Typ-Lys18 [123] 
pDNA/ oligopeptide end modified poly(β-aminoester) [124] 
pDNA/ chitosan [125] 
siRNA/ oligoamidoamide [126] 
siRNA/ PEG-PCL-PEI [127] 
siRNA/ chitosan [128] 
oligodeoxynucleotide/ PEI [129] 






Cross-linking of core-shell polyplexes improved freeze-drying process stability as shown for 
pDNA/PEG-poly(L-lysine) polyplexes [130]. Brus et al. found pronounced aggregation for 
pDNA/PEI polyplexes, while ODN/PEI polyplexes remained stable upon lyophilization 
independent of cryoprotectant type [129]. Similarly, the process stability of ODN/chitosan 
polyplexes was better compared to siRNA/chitosan polyplexes as reported by 
Veilleux et al. [128]. Thus, freeze-drying success does not only depend on the choice of 
cryoprotectant, but also on individual particle properties. Long-term stability studies of 
freeze-dried pDNA/LPEI polyplexes revealed successful particle size stabilization in 
lactosucrose, HP-β-CD/sucrose, or PVP/sucrose. However, PVP/sucrose led to a decreased 
metabolic activity which was already seen for freshly prepared samples and speculatively 
attributed to peroxide impurities [119]. Consequently, biological activity may not correlate with 
colloidal stability and should be assessed before lyophilization. 
Polyplexes are sensitive towards buffer type and pH; ODN/chitosan polyplexes formulated at 
pH 6.5 were stable in histidine, Tris-maleic acid, sodium phosphate, or maleic acid, but 
aggregated in Tris-HCl, already before freeze-drying [128]. After lyophilization in presence of 
trehalose, the polyplex size furthermore increased in maleic acid and sodium phosphate, but 
not in histidine buffer. The particle size of pDNA/peptide condensates remained stable after 
lyophilization in HEPES at pH 4 to 7, but drastically increased at pH 3 which was attributed 
to altered surface charges [123]. Interestingly, severe aggregation of lyophilized 
pDNA/chitosan particles was avoided by adding 3.5 mM histidine at pH 6.5 to either sucrose, 
dextran, or trehalose [125]. Furthermore, it appears to be important when the buffer and 
cryoprotectant are added [124]. Fornaguera et al. demonstrated that polyplex precipitation 
was hindered in presence of sucrose and HEPES, potentially due to inhibited electrostatic 
interactions [124]. Lyophilization can also be used for up-concentration. Reconstitution with 
less volume, however, comes with increased solutes concentrations. Veilleux et al. mimicked 
up-concentration in liquid state and found pronounced aggregation of ODN/chitosan 
polyplexes with increasing buffer concentration which was attributed to partial polymer 
deprotonation affecting electrostatic particle interaction [128]. The effect was observed for 
maleic acid and phosphate buffer, but nor for histidine buffer. 
3.3 Lipid bilayer vesicles: Liposomes and biological nanoparticles 
Liposomes (0.05-5.0 µm) serve as drug delivery systems by entrapping drugs into their cavity 
or bilayer structure and form spontaneously upon hydration of certain lipids in aqueous 
media [131]. In this review, the term ‘vesicles’ implies the presence of a lipid bilayer. Their 
main constituents are amphiphilic phospholipids. Most biological NPs, such as extracellular 





highly challenging as the lipid bilayer is both fragile and flexible. Still, it is a highly promising 
technique to extend storage stability of bilayer vesicles, e.g. novel liposomes tested as 
adjuvants, when compared to liquid formulations [132]. The complexity further increases for 
biological vesicles due to their heterogeneous composition. Thus, it is crucial to understand 
essential attributes and parameters affecting the bilayer stability. After general considerations 
which are applicable to most bilayer structured particles, lyophilization aspects of different 
types including lipoplexes, extracellular vesicles, and enveloped viruses are elucidated in 
more detail. 
3.3.1 Lipid bilayer: composition & phase transition Tm 
The lipid bilayer is a thin polar membrane composed of two layers of lipid molecules providing 
a barrier between intra- and extracellular components. Biological bilayers are mainly 
composed of amphiphilic phospholipids, but can also include cholesterol which alters 
properties as for example the width and packing density of the bilayer [133]. In fully hydrated 
state, the phospholipids are exposed to permanent fluctuations making the bilayer a fluid 
phase [134]. As a consequence, hydrocarbon chains of the lipid molecules are 
conformationally disordered. 
The lipid bilayer is temperature sensitive and can undergo a gel to liquid crystalline phase 
transition [135]. Below the transition temperature Tm, the hydrocarbon chains are in an 
ordered crystalline structure, considered as the gel phase. Above Tm, the ordered structure is 
lost resulting in the liquid crystalline phase, also called fluid phase. Depending on the amount 
of water present, phospholipids can exist in one or more intermediate or mesomorphic 
forms [136]. The Tm depends on the hydrocarbon chain length and the degree of saturation 
which impact the energy necessary to overcome van der Waals interactions (see Table 3). 
Mixtures of phospholipids, e.g. in biological membranes, melt over a broader temperature 
range compared to pure lipids [137]. Furthermore, incorporation of cholesterol into the lipid 
bilayer leads to a broadening of Tm, both by hindering crystallization into the gel phase and 
by hampering bilayer mobility in the liquid crystalline phase [136]. The lipid bilayer may also 
be affected by the presence of surfactants; Susa et al. observed a significant reduction in size 
after freeze-thawing liposomes in presence of PS80 which is attributed to intercalation of the 





Table 3: Bilayer phase transition temperatures of hydrated phospholipids. 
Phospholipid Acyl chains Tm [°C] Reference 
DLPC 12:0 −1 [139] 
DMPC 14:0 24 [139] 
DPPC 16:0 41 [136] 
POPC 16:0/18:1 cis −3 [139] 
SOPC 18:0/18:1 cis 6 [139] 
DSPC 18:0 58 [136] 
Egg PC Mixed chains −5 to −15 [136] 
Soy PC Mixed chains −20 to −30 [136] 
 
DLPC is dilauryl phosphatidylcholine, DMPC is dimyristoyl phosphatidylcholine, DPPC is dipalmitoyl 
phosphatidylcholine, POPC is 1-palmitoyl, 2-oleoyl phosphatidylcholine, SOPC is 1-steroyl, 2-oleoyl 
phosphatidylcholine, and DSPC is distearoyl phosphatidylcholine 
 
The Tm of the phospholipid determines the susceptibility of payload loss and is therefore a 
critical process parameter. Thus, in case of artificial vesicles, lyophilization success may 
depend on the phospholipid selection. The importance of Tm on cooling, freezing and 
reconstitution of lipid bilayer vesicles is thus explained in detail in the following section. 
3.3.2 Factors affecting leakage and release of vesicles 
Payload retention is an important parameter to assess damage caused by lyophilization. 
Phospholipid packing defects and phase separation between gel and liquid crystalline 
domains are widely discussed to transiently increase the bilayer permeability [139,140]. In 
addition, phase transition and fluidity of the bilayer affect the vesicle stability by determining 
properties such as permeability, fusion, and aggregation [141]. Avoiding a phase transition 
and thereby unintended leakage is therefore a major goal to increase the payload retention 
during freeze-drying, subsequent storage, and upon reconstitution. 
Dehydration leads to an increase in Tm of the main phase transition which is attributed to 
increased van der Waals forces between the phospholipids [136]. Koster et al. revealed that 
disaccharides diminish the increase in Tm upon dehydration [142]. They also found a 
relationship between Tm and the sugar glass transition temperature Tg: if Tg > Tm0 (Tm0 = Tm 
at full hydration), and vitrification occurs in the liquid crystalline phase, then Tm is depressed 
below Tm0; if Tg < Tm0, vitrification has no effect on Tm [143]. The Tm reduction is suggested to 
be driven by water replacement at the phospholipids [144]. Thus, cryoprotectant type and 
residual water content highly impact the bilayer phase transition during lyophilization and of 





Specifically during freezing, dehydration, and reconstitution of lyophilizates potential leakage 
due to a bilayer phase transition may occur [145]. In presence of sugars, Tm is not affected 
until the end of ice sublimation when all of the bulk water is removed. If phase transition 
occurs during the dehydration step, there is no bulk water left into which the vesicle contents 
could be leaked. Thus, Tm depression upon dehydration in presence of a sugar can be 
decisive. Vesicles exhibiting a high Tm value are expected to undergo bilayer phase transition 
neither during lyophilization nor upon reconstitution. Vesicles with low Tm are prone for 
destabilization by both events. E.g. trehalose depresses the Tm of POPC liposomes from 
about −1 °C to −20 °C after drying [145]. Thus, both freezing (liquid → gel) and  
drying (gel → liquid) induce phase transitions, however not the rehydration step since the lipid 
is in the liquid crystalline phase after drying. In comparison, the Tm of DMPC is depressed 
from 26 °C to 6 °C [143] so that phase transition does not occur during lyophilization 
(depending on the secondary drying temperature), but during reconstitution at  
RT (gel → liquid). Consequently, the Tm shift in presence of sugars is crucial for leakage. 
Cholesterol has a broadening effect on Tm and leads to multiple phase transitions upon 
dehydration [146]. Hence, longer residence in the phase transition period and thus increased 
drug leakage is expected. However, freeze-dried liposomes containing cholesterol showed 
higher retention upon rehydration [147]. Cholesterol reduces membrane fluidity by increasing 
membrane packing, stiffness, and thickness of the bilayer; as a result membrane permeability 
decreases [148]. In addition, cholesterol is able to depress Tm in the dried state [149] similarly 
to sugars. 
Content leakage further depends on the hydrophobicity of the encapsulated substance. 
Hydrophilic substances (logPoct < −0.3) are located inside of vesicles; lipophilic substances 
(logPoct > 5) are entrapped in the acyl chains of the lipid membrane, and amphiphilic cargos 
(1.7 < logPoct < 4) can be located at either site [150]. Hence, hydrophilic or amphiphilic 
molecules are more prone to leakage compared to lipophilic substances. Guimarães et al. 
revealed that a drug located in the lipid bilayer was less susceptible to leakage after 
lyophilization compared to a drug present in the aqueous core [151]. 
Hays et al. reported that increasing cooling rates lead to a decreased residence time in the 
phase transition period and thus decreased leakage of liposomes [139]. The addition of 
defect-forming additives such as a second phospholipid or small amounts of a surfactant 
increased leakage during the phase transition but not above or below Tm. Moreover, payload 
retention of lyophilized unilamellar vesicles in presence of trehalose was higher for medium 
sized vesicles (50-100 nm) compared to smaller or larger ones, indicating a preferred particle 
size for content retention [152,153]. The size affects the length of the diffusional pathway, the 





phospholipids [139]. However, these observations are not generally valid since 5 µm sized 
multilamellar liposomes containing 5-fluorouracil were successfully freeze-dried in presence 
of sucrose with 80% payload retention [154]. 
3.3.3 Strategies to avoid leakage & fusion of vesicles 
The addition of a sugar as a cryo- and lyoprotectant is considered as the most important 
parameter towards preservation of particle size and payload retention. Moreover, a phase 
transition after rehydration can be avoided by the addition of sugars since they reduce the Tm 
after drying. Disaccharides are preferred over monosaccharide due to higher glass transition 
temperatures. Polysaccharides such as HES exhibit even higher Tg values after lyophilization. 
However, HES did not prevent leakage from liposomes though inhibiting particle fusion which 
was attributed to weak interactions with the phospholipids [155]. When glucose was added to 
the HES matrix, the liposomes were well stabilized when kept below Tg. Thus, immobilization 
in an amorphous matrix and reduction of Tm may improve liposome preservation during 
lyophilization. Talsma et al. showed that freeze-thawing of liposomes to −50 °C in presence 
of trehalose (Tg’~−29 °C) resulted in carboxyfluorescein retention of 95%, while samples 
frozen to −25 °C lead to 50% marker retention [17] indicating leakage at temperatures 
above Tg’. 
Trehalose is often considered to be superior to sucrose regarding its protective effects, 
potentially due to stronger interactions with the bilayer [156]. Crowe et al. postulated that 
under ideal drying and storage conditions, trehalose should act comparably to other 
disaccharides [145]. However, under suboptimal conditions, such as high temperatures or 
humidity during storage, trehalose has unique properties; it may form a dihydrate thereby 
shielding the vitrified matrix from further water penetration. But trehalose may also destabilize 
colloids during freezing due to trehalose dihydrate crystallization above Tg’ [157,158]. During 
drying, the dihydrate dehydrates to amorphous anhydrate disguising potential previous 
crystallization.  
Tryptophan and phenylalanine were not able to stabilize liposomes during freezing resulting 
in leakage and membrane fusion, although the interactions with phospholipids were similar 
to sugars [159,160]. Lysine, however, showed cryoprotective effects comparable to 
trehalose [161]. Phenylalanine is known to crystallize upon lyophilization, while lysine 
remains amorphous [162]. Therefore, it appears that the potential for lyoprotection depends 
on the ability of the amino acid to form an amorphous matrix. Antifreeze glycoproteins, 
especially species >13 kDa, prevented leakage of liposomes while cooled through their phase 
transition [163,164]. Furthermore, the phytochemical arbutin was tested for lyophilization of 





desiccation-tolerant plants [165]. Arbutin inhibits phospholipase A2 under partially hydrated 
conditions and thereby prevents deesterification of membrane lipids [59]. Hincha et al. 
showed that the protective effect of arbutin depends on in the bilayer composition since it only 
prevented liposome leakage if a non-bilayer lipid such as monogalactosyldiacylglycerol was 
present in the membranes. Furthermore, arbutin can depress Tm upon dehydration [166]. 
In a recent study aiming for high-throughput screening protein-loaded liposomal formulations 
were successfully freeze-dried in 96 well plates [167]. Another interesting approach is the 
manipulation of the reconstitution medium. Zingel et al. found that rehydration of lyophilized 
liposomes with mannitol solution resulted in higher drug retention compared to rehydration 
with water or Tris buffer [168]. The rehydration step can also be used for loading as shown 
for reconstitution of naked liposome lyophilizates with siRNA solution [169,170]. 
The cryoprotectant can also affect lyophilization process stability when additionally distributed 
inside of vesicles. The presence of trehalose both inside and outside of vesicles decreases 
Tm in aqueous medium and may further maximize payload retention upon 
lyophilization [53,54,171]. This effect may depend on the applied freezing rate; higher 
freezing rates lead to higher retention during freeze-thawing of liposomes containing 
trehalose on both sides of the membrane [172]. In contrast, content retention was barely 
affected by the freezing rate when trehalose was distributed only outside the vesicles. 
Osmotic shrinkage during cryo-concentration is suggested to prevent mechanical damage 
resulting in high marker retention (see Figure 4). Formulations with cryoprotectant on both 
sides of the membrane do not undergo total osmotic shrinkage. Thus, the residual internal 
supercooled solution may either freeze or get damaged by ice penetration which depends on 
kinetic aspects. Van Winden et al. found that slow freezing results in higher retention rates 
after freeze-drying with trehalose (external) compared to fast freezing in liquid nitrogen [173]. 
This effect depended on the lipid composition and was observed for various DPPC liposomes, 







Figure 4: Schematic freezing behavior of vesicles. The physical state of internal and external water 
is denoted in the upper and lower rows respectively. Grey boxes indicate suggested 
physical states (adapted from [172]). 
 
3.3.4 Lipoplexes 
Lipoplexes are nonviral lipid-based vectors composed of cationic lipids, usually mixed with 
neutral co-lipids, and nucleic acids. Two types of structures were observed in plain lipoplexes: 
(1) a multilamellar vesicular structure, with DNA monolayers sandwiched between cationic 
membranes, and (2) an inverted hexagonal structure, with DNA encapsulated within cationic 
lipid monolayer tubes [174]. As most lipoplexes are of vesicular structure, the principles 
described for liposomes, should be applicable for most lipoplex types. In contrast to classical 
liposomes, lipoplexes are special due to their charged lipids and thus surface as well as their 
cargo. Therefore, the following section aims to outline studies which were conducted with 
lipoplexes in particular. 
Molina et al. showed that not only the preservation of lipoplex size is important, but that 
changes in particle properties as indicated by a change in surface charge upon freezing might 
result in reduced transfection activity [175]. Yavada et al. reported that an activity loss of 
lyophilized lipoplexes is not due to siRNA damage since lyophilized siRNA when rehydrated 
and complexed with liposomes was still active. Instead, the change in activity correlated to 
the change in lipoplex size [176]. Thus, both size and surface charge are essential 
parameters to evaluate lyophilization success. Recent studies further suggest using 
disaccharides as cryoprotectants, since certain mono- or trisaccharides may induce 





Sucrose or trehalose are suitable to protect particle size and transfection rates of lipid/DNA 
complexes during the lyophilization process [178,179]. More dilute samples required less 
excipient to prevent aggregation concluding that vitrification is not the only mechanism by 
which sugars protect lipoplexes during the freezing step. Instead, Allison et al. confirmed the 
particle isolation hypothesis by showing that the separation of individual particles within the 
unfrozen fraction prevents aggregation [179]. The authors also postulated that water 
replacement plays a significant role in lipoplex protection during lyophilization, similar as for 
liposomes [180]. Sucrose and trehalose are the cryoprotectants of choice as they inhibited 
aggregation and maintained high transfection rates of lipoplexes in several  
studies [178,181–191]. Sucrose was furthermore superior to other protectants including 
lactose, mannitol, isomaltose, isomaltotriose, and HES [179,192,193]. An appropriate amount 
of cryoprotectant has to be chosen as a high trehalose concentrations (>5%) can lead to 
slightly increased lipoplexes with decreased surface charge after freeze-drying [182]. 
Combinations of saccharides, such as sucrose/dextran, effectively inhibited particle 
aggregation upon freeze-drying [181]. Hinrichs et al. observed that both dextran and inulin 
were able to stabilize nonPEGylated lipoplexes while only inulin was able to protect 
PEGylated particles [194,195]. They hypothesized that aggregation of the PEGylated 
lipoplexes in dextran solutions is caused by the incompatibility between dextran and PEG. 
They further suggested that both oligosaccharides might be more versatile cryoprotectants 
than disaccharides because of their higher Tg’ and Tg values which enables freezing at higher 
temperatures and storage at higher relative humidities respectively. 
Hydroxypropyl-γ-cyclodextrin was furthermore superior to several cryoprotectants including 
trehalose in preservation of lyophilized DNA-loaded pegylated lipoplexes decorated with 
covalently linked monoclonal antibodies [196]. Yu et al. showed that the addition of PS80 
minimizes aggregation and loss of transfection of lyophilized lipoplexes indicating surface-
induced damage, especially caused by the freezing step of lyophilization [185]. Interestingly, 
recovery of lipoplexes was also improved when PS80 was added to the reconstitution medium 
indicating that severe aggregation can also occur during the rehydration step. 
The impact of the freezing rate on lipoplex stability is discussed intensively. On the one hand 
Li et al. reported that fast freezing caused less aggregation upon freeze-thawing [183]. On 
the other hand, Aso et al. observed that slow freezing led to better storage stability of lipoplex 
lyophilizates; they measured longer shear relaxation times for lyophilizates prepared by slow 
freezing indicating reduced matrix mobility [181]. The storage stability of lipoplexes is affected 
by multiple factors [184]. The formation of hexagonal lipid structures during storage of 
lyophilizates is proposed to reduce transfection efficiency over time. The rearrangement 
propensity depends on the lipid phase composition; hydrated lipoplexes rather adopt 





compared to cholesterol. Furthermore, a low Tg impairs long-term stability. But cake collapse 
and thus increased viscous flow is not solely responsible for decreased lipoplex stability since 
a loss of transfection efficiency was even observed after storage temperatures at −20 °C. 
Trace amounts of metal ions may induce the formation of reactive oxygen species affecting 
the stability of lipoplexes during lyophilization and storage [187,189]; especially unsaturated 
lipids are prone to oxidative damage.  The close proximity of DNA to the lipid component may 
facilitate interactions of DNA with oxidized species, e.g. peroxyl radicals and other 
by-products. The proceeding oxidative damage can be partly inhibited by the addition of a 
chelators and/or antioxidants [190]. The residual water content was elucidated as a further 
storage stability limiting factor [191]. Lyophilizates with a higher moisture content of 2%, 
demonstrated greater stability than dryer samples. 
3.3.5 Extracellular Vesicles 
Extracellular vesicles (EVs) are cell-derived NPs excreted by the conjugation of intermediate 
endocytic bodies to the plasma membrane [197,198]. EVs consist of a lipid bilayer membrane 
decorated with surface and membrane proteins and enable intercellular transfer of biological 
cargos [198,199]. Loading EVs with exogenous cargos opens up potential for controlled drug 
delivery [200]. However, the scope of therapeutic application is limited by effective 
preservation and storage which is usually accomplished by freezing EVs in phosphate 
buffered saline to −80 °C [201,202]. Thus, lyophilization would facilitate storage and handling 
and offers new possibilities for application, e.g. pulmonary drug delivery. 
Trehalose improved preservation of EV size and concentration upon several freeze-thaw 
cycles [203]. Interestingly, EVs were able to resist one freeze-thaw cycle in absence of 
cryoprotectants. Lyophilization of EVs without cryoprotectant leads to marked 
aggregation [204,205]. Frank et al. found improved freeze-drying process stability of EVs after 
addition of trehalose, which was more efficient than the addition of mannitol and PEG 400. 
Still, a decreased particle number and activity of encapsulated enzyme after lyophilization 
indicated particle aggregation and cargo loss or degradation [204]. Lyophilization success 
also depended on the EV type; EVs derived from A549 cells were less stable compared to 
EVs from MSC or HUVEC cells. A recent study by Charoenviriyakul et al. revealed that the 
biological activity of protein and DNA-loaded EVs was preserved after lyophilization with 





3.3.6 Enveloped Viruses 
Attenuated or inactivated viruses are vaccine types which can be assigned as NPs. Their size 
is heterogeneous and ranges from approximately 40 to 500 nm or even 1.2 µm [206]. Most 
viruses exhibit a lipid bilayer as viral envelope which is decorated with proteins which enable 
to identify and infect host cells. Enveloped viruses can also have a protein shell between the 
envelope and their nucleic acid, the capsid, to further protect the viral genome. New 
approaches focused on the preparation of the less pathogenetic virosomes; i.e. virus-like 
particles, consisting of the viral envelope without encapsulated genetic material [207]. 
Storage and transportation at 2-8 °C is typical for stabilization. Furthermore, cold-chain is a 
major hurdle for supply in developing countries. But inadvertent freezing during cold-chain 
might also lead to a loss of efficacy. Therefore, stabilization by freeze-drying is of great 
interest. 
A historical formulation often used for lyophilization of viruses is SPGA (sucrose, potassium 
phosphate, potassium glutamate, bovine albumin) or variations thereof. SPGA was first 
mentioned by Bovarnick et al. in 1950 and favored survival of rickettsiae (bacteria) after 
freeze-thawing [208]. A second prominent stabilizer mixture is BUGS (buffered gelatin, 
sorbitol). In 1989, De Rizzo et al. found that a sorbitol/gelatin mixture is suitable to stabilize 
freeze-dried measles virus [209]. Both formulations SPGA and BUGS successfully stabilized 
different enveloped viruses during lyophilization and are used in many marketed products 
(see the comprehensive review by Hansen et al. [5]). Furthermore, sucrose and trehalose, 
also in combination with lactalbumin, showed good stabilization of pox virus [210], ovine 
rinderpest vaccine [211], ebola virus [212], herpes simplex virus [213], and parainfluenza 
virus [214]. Further stabilizers, such as P188 as surfactant, may additionally add to the 
stability of lyophilized viruses [214]. 
The pH and osmolarity are formulation key factors for virus stabilization in liquid state and 
should therefore also be considered for lyophilization. Measles virus revealed a loss of viral 
protein secondary structure and aggregation at acidic pH [215]. Yannarell et al. found better 
lyophilization process stability when influenza virus was formulated at pH 7 compared to pH 6 
and pH 8 [216]. The importance of osmolarity in liquid state was described by Colwell et al.; 
1000 mOsm/kg (NaCl) led to a decreased stability of marek’s disease herpes virus while 
osmolarity below the physiological osmotic pressure merely affected stability up to 
90 mOsm/kg [217]. In contrast, liquid formulations of herpes simplex virus revealed higher 
stability after 20 h storage in presence of 840 mOsm trehalose or Tris-HCl compared to 
50 mOsm and lyophilization stability was drastically improved by increasing the amount of 
trehalose or sucrose up to 27% [213]. The authors hypothesized that virus shrinkage in 





between bilayer and capsid, which lowers the ice nucleation temperature inside the virus 
membrane and prevents large ice crystal growth [213]. For additional information on 
lyophilization of various vaccines including case studies, the authors refer to a review recently 
published by Preston et al. [218]. 
3.4 Other nanoparticles 
3.4.1 Lipid nanoparticles 
mRNA lipid NPs (LNPs) are a new particle type which got attention as COVID-19 vaccines. 
A key aspect of LNPs and the main difference from liposomes is the presence of lipids in the 
core [219]. Zhao et al. showed that both trehalose and sucrose were able to protect novel 
phospholipid-mRNA NPs only when stored in liquid nitrogen, but not during lyophilization 
[220]. As this particle type is a quite new modality, no comprehensive study on lyophilization 
is published yet. 
3.4.2 Non-enveloped Viruses 
Analogous to enveloped viruses, non-enveloped viruses shielded by the capsid, but no 
phospholipid bilayer, show a pH dependent stability profile in liquid state; enteroviruses 
(poliovirus, coxsackievirus) are instable at acidic pH (< 4.5) [221]. In this case, a buffer pH 
shift during freezing should be avoided. Sucrose was suitable to stabilize adenovirus upon 
freeze-drying [120]. Qi et al. showed that urea improves process and storage stability of 
lyophilized inactivated poliovirus vaccine (IPV) in presence of sucrose [222]. Addition of 0.4 M 
urea inhibited capsid denaturation during lyophilization. Potassium phosphate instead of 
sodium phosphate buffer better stabilized adenovirus and adeno-associated virus (AAV) after 
storage at −20 °C and 4 °C [223]. AAVs formulated with sucrose, mannitol and protamine 
showed significantly improved storage stability at −80 °C or −20 °C after addition of 
Span 20™ instead of P188 as surfactant. However, upon freeze-drying, titer loss was less 
using sucrose as cryoprotectant without further additives. Adenovirus lyophilizates revealed 
a narrow moisture level window of 1.5% in which viral titer was maintained. The 
non-enveloped infectious pancreatic necrosis virus was successfully freeze-dried using 
lactalbumin hydrolysate, lactose or skim milk [224], while potato virus X could be stabilized 
using dextran as cryoprotectant [225]. Furthermore, modified SPGA, with sorbitol and gelatine 
instead of sucrose and albumin, significantly improved the lyophilization process stability of 





3.4.3 Inorganic nanoparticles 
Inorganic NPs, specifically functionalized silica material, gain more and more attention as 
mesoporous drug delivery carries [227]. But, only little literature is available on lyophilization 
of this NP type. Sameti et al. showed that trehalose is suitable to stabilize cationically modified 
silica NPs with simultaneous preservation of their DNA-binding and transfection activity [228]. 
Recent studies further confirmed that antibody-conjugated PEI-PEG coated mesoporous 
silica NPs are well stabilized by trehalose [229]. Moreover, trehalose and sucrose were 
superior to mannitol to stabilize freeze-dried antibody-conjugated gold nanorods [230]. 
Au NPs were furthermore successfully lyophilized using sucrose combined with sucrose 
monopalmitate as surfactant [231]. Overall, these studies highlight the prerequisite of an 
amorphous stabilizing matrix. 
 
4 Summary and practical advices 
The success of NP lyophilization mainly depends on the type of NP and formulation factors; 
nonetheless process factors should not be neglected. This review aims to summarize the 
current knowledge on the colloidal stability of NPs in this regard to give practical advice. In 
general, formulations of lyophilized NP products should include one or more of the following 
formulation excipients: a cryo-/ lyoprotectant, a bulking agent, a buffering agent, a surfactant. 





Table 4: Commonly used excipients in lyophilization classified according to their function (modified 
from [232]). 
Stabilizers Function Examples 
Cryoprotectant Protection during freezing Sugars (e.g. sucrose, trehalose) 
Amino acids (e.g. arginine) 
Lyoprotectant Protection during drying and/or storage Sugars (e.g. sucrose, trehalose) 
Polymers (e.g. PVP, HES) 
Amino acids (e.g. proline, 
arginine) 
Bulking agent Provide cake stability (amorphous) Sugars (e.g. sucrose, trehalose) 
Provide elegant cake structure (crystalline) Sugar alcohol (mannitol) 
Amino acids (e.g. glycine, 
phenylalanine) 
Buffering agent pH stabilization Histidine, citrate, phosphate, Tris 
Surfactant Prevention of adsorption and aggregation 
at surfaces and the liquid–ice interface 
PS20, PS80, P188 
Tonicity agent Providing isotonicity for tolerability of 
injectables; often the cryo-/lyoprotectant, 
bulking agent 
Sugars/ polyols (sucrose, 
trehalose, mannitol) 
Amino acids (glycine) 
Caution: salts, e.g. NaCl, are not 
recommended due to potential 
interference with charge 
interactions and poor freeze-
drying performance 
 
4.1 Selection of cryo-/ lyoprotectant 
The selection of a suitable cryo- and lyoprotectant is highly important since it affects i) the NP 
process stability, ii) the specific process parameters, i.e. the critical temperature Tg’ that the 
product temperature shall not exceed during primary drying, and iii) storage conditions since 
the storage temperature should be 10-20 °C above Tg. Table 5 provides information about Tg’ 
and Tg of commonly used sugars for lyophilization of NPs. 
Sucrose and trehalose proved to stabilize various NP types and they are the cryoprotectants 
of choice. Their stabilization mechanisms are well described by the water replacement and 
vitrification/ particle isolation theories [45–58]. Furthermore, it was demonstrated that 
disaccharides better stabilize lyophilized colloids compared to polysaccharides (e.g. 
dextran) [233]. Smaller and molecularly more flexible sugars are less affected by steric 
hindrance and thus better cover colloidal surface. However, at same osmolarity, oligo- and 





isolation. Mixtures of a disaccharide and an oligo-/polysaccharide might benefit from good 
cryoprotection and water replacement as well as high Tg and particle isolation. 
Table 5: Glass transition temperatures of commonly used sugars for lyophilization. 
Sugar Tg’ [°C] Tg [°C] Reference 
Glucose −43 39 [2] 
Sucrose −31 77 [194] 
Trehalose −29 121 [194] 
HES −12 >110 [2] 
Dextran 5 kDa −17 175 [194] 
Dextran 40 kDa −12 227 [194] 
HP-β-CD −11 201 [234] 
 
4.2 Selection of bulking agents 
Bulking agents are added to provide mechanical strength and an attractive product 
appearance of the final cake [235]. Usually crystallizing agents are used for this purpose as 
they are also able to prevent macroscopic product collapse. Mannitol and glycine are the 
most frequently used bulking agents. Crystallizing agents do not contribute to vitrification and 
water replacement, but are able to provide particle isolation within the lyophilizate. 
4.3 Selection of buffer agent 
The colloidal stability of NPs is particularly sensitive to the zeta-potential, especially if strong 
charge-based repulsion is necessary for colloidal stabilization or if the NPs are assembled 
due to electrostatic interactions. Therefore, the buffer selection has to consider pH shifts upon 
cooling and freezing as known for sodium phosphate. Buffers without considerable pH shift 
are potassium phosphate, citrate and Tris buffers. In general, high buffer concentrations 
should be avoided since an increased ionic strength in the cryo-concentrate may destabilize 
NPs due to charge shielding. Furthermore, buffers may impact Tg’ during freezing, and Tg of 
the dried formulation [236]. 
4.4 Selection of surfactant 
Surfactants are essential for colloidal stability of lipophilic NPs, i.e. drug nanosuspensions 
and SLNs. The type of surfactant highly impacts their lyophilization process stability [47]. The 
selection of surfactant type and concentration is at present an empirical process. Surfactants 





added to the reconstitution medium [99,185]. Most commonly, lecithin and the non-ionic 
surfactant PS20, PS80, and P188 are utilized; all approved for parenteral use [60]. 
Nonetheless surfactants may come with the risk of lipid bilayer disruption and lysis. 
Furthermore, high surfactant concentrations may lower the Tg of lyophilizates due to a 
plasticizing effect which impairs storage stability. 
4.5 Osmolarity 
Osmolarity is an important aspect for bilayer structured NPs, including viruses. Due to 
freeze-concentration, vesicles are prone to damage caused by the increased osmotic 
pressure. Rapid water flux through the bilayer can be responsible for physical forces leading 
to ruptures [27]. A high osmotic pressure during cryo-concentration may also lead to osmotic 
shrinkage which decreases mechanical damage caused by ice crystals [172]. Overall, the 
osmotic stability and payload retention highly depends on the lipid membrane composition 
and selective permeability towards solutes [28,29]. The osmotic agent should be selected 
cautiously; e.g. NaCl is known to destabilize colloids during freezing and shows a poor 
freeze-drying performance due to its eutectic crystallization at −21 °C and low Tg at < 60 °C 
[2,237]. Furthermore, an increased ionic strength may shield particle surface charges and 
thus destabilize NPs. 
4.6 The process 
The lyophilization process is overall less important compared to formulation aspects, but 
should not be neglected during development. For basic principles, the readers are referred to 
a comprehensive review on the freeze-drying process itself (see [4]). It is important that the 
product temperature is kept below Tg’ during primary drying. The secondary drying step can 
be used to adjust the residual moisture which was a critical process stability factor for 
lipoplex [191] and adenovirus [223] lyophilizates. The liquid crystalline to gel phase transition 
temperature Tm is a further critical parameter affecting the payload retention of lipid bilayer 
NPs. In addition, the freezing rate determines the ice crystal size, i.e. fast freezing leads to 
smaller ice crystals thereby affecting the extent of mechanical stress and the residence time 
in the cryo-concentrated phase. Large ice crystals may also be generated by applying 
controlled ice nucleation or by adding an annealing step to the freezing protocol. But all these 
variations should be applied with the limitations of the capacities of large-scale freeze-dryers 





4.7 Particle properties affecting process and storage stability 
Depending on their stabilization mechanism, surface charge, ability to encapsulate drugs, or 
other properties, the described NP types are affected to a different degree. Mechanical stress 
caused by ice or excipient crystals is particularly relevant for lipid bilayer vesicles such as 
liposomes, lipoplexes and viruses. Moreover, most of the described NP types are sensitive 
to pH and/or electrolyte changes leading to altered release kinetics, surface charges, or 
osmotic pressure; especially SLNs, polymeric NPs, lipid bilayer vesicles, and inorganic NPs. 
NP types exhibiting low surface charges, e.g. lipophilic NPs stabilized with non-ionic 
surfactants or polymers, are expected to be less susceptible to charge shielding caused by 
pH or electrolyte changes. In general, the amount of added surfactant is high in case of 
lipophilic NPs and should be chosen carefully due to the Tg lowering effect in sugar matrices. 
Finally, Figure 5 summarizes the aforementioned essential formulation parameters and 










This review gives an overview of parameters affecting NP colloidal stability in the liquid state, 
the dried state, and during lyophilization. We further provide individual information on 
lyophilization of different NP types. The differentiation of NPs according to their material 
category brings chaos to order and allows to derive general rules; e.g. embedding NP in an 
amorphous matrix better stabilizes NPs compared to a crystalline matrix. The selection of 
appropriate excipients before freeze-drying is of vital importance as formulations factors are 
expected to play a key role for stabilization. Therefore, we provided practical advices 







[1] D. Bobo, K.J. Robinson, J. Islam, K.J. Thurecht, S.R. Corrie, Nanoparticle-Based Medicines: A Review 
of FDA-Approved Materials and Clinical Trials to Date, Pharm. Res. 33 (2016) 2373–2387. 
[2] W. Wang, Lyophilization and development of solid protein pharmaceuticals, Int. J. Pharm. 203 (2000) 1–
60. 
[3] L. Wu, J. Zhang, W. Watanabe, Physical and chemical stability of drug nanoparticles, Adv. Drug Deliv. 
Rev. 63 (2011) 456–469. 
[4] X. Tang, M.J. Pikal, Design of freeze-drying processes for pharmaceuticals: practical advice, Pharm. 
Res. 21 (2004) 191–200. 
[5] L.J.J. Hansen, R. Daoussi, C. Vervaet, J.-P. Remon, T.R.M. de Beer, Freeze-drying of live virus vaccines: 
A review, Vaccine 33 (2015) 5507–5519. 
[6] P. Fonte, S. Reis, B. Sarmento, Facts and evidences on the lyophilization of polymeric nanoparticles for 
drug delivery, J. Control. Release 225 (2016) 75–86. 
[7] K. Park, Prevention of nanoparticle aggregation during freeze-drying, J. Control. Release 248 (2017) 153. 
[8] W. de Jong, J. Bridges, K. Dawson, T. Jung, A. Proykova, Scientific Basis for the Definition of the Term 
“nanomaterial”, European Commission, Brussels, 2010. pp. 1–43. 
[9] Food and Drug Administration, Guidance for Industry: Considering Whether an FDA-Regulated Product 
Involves the Application of Nanotechnology, 2014. pp. 1–14 
[10] T. Tadros, Colloid stability: The role of surface forces, Wiley-VCH, Weinheim, 2007. pp. 1–22. 
[11] A.R. Studart, E. Amstad, L.J. Gauckler, Colloidal stabilization of nanoparticles in concentrated 
suspensions, Langmuir 23 (2007) 1081–1090. 
[12] X. Zhang, M.R. Servos, J. Liu, Ultrahigh nanoparticle stability against salt, pH, and solvent with retained 
surface accessibility via depletion stabilization, J. Am. Chem. Soc. 134 (2012) 9910–9913. 
[13] D. Napper, Steric stabilization, J. Colloid Interface Sci. 58 (1977) 390–407. 
[14] R.I. Feigin, D.H. Napper, Depletion stabilization and depletion flocculation, J. Colloid Interface Sci. 75 
(1980) 525–541. 
[15] S. Kim, K. Hyun, J.Y. Moon, C. Clasen, K.H. Ahn, Depletion stabilization in nanoparticle-polymer 
suspensions: multi-length-scale analysis of microstructure, Langmuir 31 (2015) 1892–1900. 
[16] A.N. Semenov, A.A. Shvets, Theory of colloid depletion stabilization by unattached and adsorbed 
polymers, Soft Matter 11 (2015) 8863–8878. 
[17] H. Talsma, M.J. van Steenbergen, D. Crommelin, The cryopreservation of liposomes: 3. Almost complete 
retention of a water-soluble marker in small liposomes in a cryoprotectant containing dispersion after a 
freezing/thawing cycle, Int. J. Pharm. 77 (1991) 119–126. 
[18] J. Kristiansen, Leakage of a trapped fluorescent marker from liposomes: Effects of eutectic crystallization 
of NaCl and internal freezing, Cryobiology 29 (1992) 575–584. 
[19] M. Kobayashi, K. Nemoto, G. Tanaka, M. Hishida, Study of the Freezing Behavior of Liposomes, J. 
Therm. Sci. Technol. 6 (2011) 57–68. 
[20] Z. Shen, H. Ye, M. Kröger, Y. Li, Self-assembled core-polyethylene glycol-lipid shell nanoparticles 
demonstrate high stability in shear flow, Phys. Chem. Chem. Phys. 19 (2017) 13294–13306. 
[21] J.C. Kasper, W. Friess, The freezing step in lyophilization: physico-chemical fundamentals, freezing 
methods and consequences on process performance and quality attributes of biopharmaceuticals, Eur. 
J. Pharm. Biopharm. 78 (2011) 248–263. 
[22] B.S. Chang, B.S. Kendrick, J.F. Carpenter, Surface-induced denaturation of proteins during freezing and 





[23] L. Krielgaard, L.S. Jones, T.W. Randolph, S. Frokjaer, J.M. Flink, M.C. Manning, J.F. Carpenter, Effect 
of tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII, J. 
Pharm. Sci. 87 (1998) 1597–1603. 
[24] L. Shi, G. Sanyal, A. Ni, Z. Luo, S. Doshna, B. Wang, T.L. Graham, N. Wang, D.B. Volkin, Stabilization 
of human papillomavirus virus-like particles by non-ionic surfactants, J. Pharm. Sci. 94 (2005) 1538–
1551. 
[25] T.W. Randolph, Phase separation of excipients during lyophilization: effects on protein stability, J. Pharm. 
Sci. 86 (1997) 1198–1203. 
[26] S. Bhattacharjee, DLS and zeta potential - What they are and what they are not?, J. Control. Release 
235 (2016) 337–351. 
[27] K. Muldrew, L.E. McGann, The osmotic rupture hypothesis of intracellular freezing injury, Biophys. J. 66 
(1994) 532–541. 
[28] E. Nagamachi, Y. Hirai, K. Tomochika, Y. Kanemasa, Studies on osmotic stability of liposomes prepared 
with bacterial membrane lipids by carboxyfluorescein release, Microbiol. Immunol. 36 (1992) 231–234. 
[29] J. de Gier, Osmotic behaviour and permeability properties of liposomes, Chem. Phys. Lipids 64 (1993) 
187–196. 
[30] Z. Varga, A. Wacha, A. Bóta, Osmotic shrinkage of sterically stabilized liposomes as revealed by time-
resolved small-angle X-ray scattering, J. Appl. Crystallogr. 47 (2014) 35–40. 
[31] P. Wessman, K. Edwards, D. Mahlin, Structural effects caused by spray- and freeze-drying of liposomes 
and bilayer disks, J. Pharm. Sci. 99 (2010) 2032–2048. 
[32] I.Y. Wu, N. Škalko-Basnet, M.P. Di Cagno, Influence of the environmental tonicity perturbations on the 
release of model compounds from large unilamellar vesicles (LUVs): A mechanistic investigation, 
Colloids Surf. B 157 (2017) 65–71. 
[33] K.A. Pikal-Cleland, J.L. Cleland, T.J. Anchordoquy, J.F. Carpenter, Effect of glycine on pH changes and 
protein stability during freeze-thawing in phosphate buffer systems, J. Pharm. Sci. 91 (2002) 1969–1979. 
[34] K.A. Pikal-Cleland, N. Rodríguez-Hornedo, G.L. Amidon, J.F. Carpenter, Protein denaturation during 
freezing and thawing in phosphate buffer systems: monomeric and tetrameric beta-galactosidase, Arch. 
Biochem. Biophys. 384 (2000) 398–406. 
[35] P. Kolhe, E. Amend, S.K. Singh, Impact of freezing on pH of buffered solutions and consequences for 
monoclonal antibody aggregation, Biotechnol. Prog. 26 (2010) 727–733. 
[36] M.S. Salnikova, H. Davis, C. Mensch, L. Celano, D.S. Thiriot, Influence of formulation pH and suspension 
state on freezing-induced agglomeration of aluminum adjuvants, J. Pharm. Sci. 101 (2012) 1050–1062. 
[37] N. Murase, F. Franks, Salt precipitation during the freeze-concentration of phosphate buffer solutions, 
Biophys. Chem. 34 (1989) 293–300. 
[38] E.Y. Shalaev, T.D. Johnson-Elton, L. Chang, M.J. Pikal, Thermophysical properties of pharmaceutically 
compatible buffers at sub-zero temperatures: implications for freeze-drying, Pharm. Res. 19 (2002) 195–
201. 
[39] P. Sundaramurthi, R. Suryanarayanan, The effect of crystallizing and non-crystallizing cosolutes on 
succinate buffer crystallization and the consequent pH shift in frozen solutions, Pharm. Res. 28 (2011) 
374–385. 
[40] L. van den Berg, D. Rose, Effect of freezing on the pH and composition of sodium and potassium 
phosphate solutions: the reciprocal system KH2PO4 Na2HPO4 H2O, Arch. Biochem. Biophys. 81 
(1959) 319–329. 
[41] B.S. Bhatnagar, R.H. Bogner, M.J. Pikal, Protein stability during freezing: separation of stresses and 





[42] M.C. Heller, J.F. Carpenter, T.W. Randolph, Protein formulation and lyophilization cycle design: 
Prevention of damage due to freeze-concentration induced phase separation, Biotechnol. Bioeng. 63 
(1999) 166–174. 
[43] L.L. Chang, D. Shepherd, J. Sun, D. Ouellette, K.L. Grant, X.C. Tang, M.J. Pikal, Mechanism of protein 
stabilization by sugars during freeze-drying and storage: native structure preservation, specific 
interaction, and/or immobilization in a glassy matrix?, J. Pharm. Sci. 94 (2005) 1427–1444. 
[44] M.T. Cicerone, M.J. Pikal, K.K. Qian, Stabilization of proteins in solid form, Adv. Drug. Deliv. Rev. 93 
(2015) 14–24. 
[45] J.F. Carpenter, J.H. Crowe, An infrared spectroscopic study of the interactions of carbohydrates with 
dried proteins, Biochemistry 28 (1989) 3916–3922. 
[46] N. Grasmeijer, M. Stankovic, H. de Waard, H.W. Frijlink, W.L.J. Hinrichs, Unraveling protein stabilization 
mechanisms: vitrification and water replacement in a glass transition temperature controlled system, 
Biochim. Biophys. Acta Proteins Proteomics. 1834 (2013) 763–769. 
[47] J. Beirowski, S. Inghelbrecht, A. Arien, H. Gieseler, Freeze-drying of nanosuspensions, 1: freezing rate 
versus formulation design as critical factors to preserve the original particle size distribution, J. Pharm. 
Sci. 100 (2011) 1958–1968. 
[48] R. Cavalli, Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles, Int. J. 
Pharm. 148 (1997) 47–54. 
[49] C. Schwarz, W. Mehnert, Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN), Int. 
J. Pharm. 157 (1997) 171–179. 
[50] L.M. Crowe, J.H. Crowe, Trehalose and dry dipalmitoylphosphatidylcholine revisited, Biochim. Biophys. 
Acta Biomembr. 946 (1988) 193–201. 
[51] J.H. Crowe, F.A. Hoekstra, K.H. Nguyen, L.M. Crowe, Is vitrification involved in depression of the phase 
transition temperature in dry phospholipids?, Biochim. Biophys. Acta Biomembr. 1280 (1996) 187–196. 
[52] C.S. Pereira, R.D. Lins, I. Chandrasekhar, L.C.G. Freitas, P.H. Hünenberger, Interaction of the 
Disaccharide Trehalose with a Phospholipid Bilayer: A Molecular Dynamics Study, Biophys. J. 86 (2004) 
2273–2285. 
[53] L.M. Crowe, J.H. Crowe, A. Rudolph, C. Womersley, L. Appel, Preservation of freeze-dried liposomes by 
trehalose, Arch. Biochem. Biophys. 242 (1985) 240–247. 
[54] R.D. Jangle, B.N. Thorat, Effect of Freeze-Thawing Study on Curcumin Liposome for Obtaining Better 
Freeze-Dried Product, Dry. Technol. 31 (2013) 966–974. 
[55] C. Chen, D. Han, C. Cai, X. Tang, An overview of liposome lyophilization and its future potential, J. 
Control. Release 142 (2010) 299–311. 
[56] M.A. Mensink, H.W. Frijlink, K. van der Voort Maarschalk, W.L.J. Hinrichs, How sugars protect proteins 
in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions, 
Eur. J. Pharm. Biopharm. 114 (2017) 288–295. 
[57] W.Q. Sun, A.C. Leopold, L.M. Crowe, J.H. Crowe, Stability of dry liposomes in sugar glasses, Biophys. 
J. 70 (1996) 1769–1776. 
[58] J.H. Crowe, S.B. Leslie, L.M. Crowe, Is vitrification sufficient to preserve liposomes during freeze-drying?, 
Cryobiology 31 (1994) 355–366. 
[59] A.E. Oliver, O. Leprince, W.F. Wolkers, D.K. Hincha, A.G. Heyer, J.H. Crowe, Non-disaccharide-based 
mechanisms of protection during drying, Cryobiology 43 (2001) 151–167. 
[60] V. Gervasi, R. Dall Agnol, S. Cullen, T. McCoy, S. Vucen, A. Crean, Parenteral protein formulations: An 





[61] M. Bjelošević, A. Zvonar Pobirk, O. Planinšek, P. Ahlin Grabnar, Excipients in freeze-dried 
biopharmaceuticals: Contributions toward formulation stability and lyophilisation cycle optimisation, Int. 
J. Pharm. 576 (2020) 119029. 
[62] B.M. Rayaprolu, J.J. Strawser, G. Anyarambhatla, Excipients in parenteral formulations: selection 
considerations and effective utilization with small molecules and biologics, Drug Dev. Ind. Pharm. 44 
(2018) 1565–1571. 
[63] K. Göke, T. Lorenz, A. Repanas, F. Schneider, D. Steiner, K. Baumann, H. Bunjes, A. Dietzel, J.H. Finke, 
B. Glasmacher, A. Kwade, Novel strategies for the formulation and processing of poorly water-soluble 
drugs, Eur. J. Pharm. Biopharm. 126 (2018) 40–56. 
[64] J.P. Möschwitzer, Drug nanocrystals in the commercial pharmaceutical development process, Int. J. 
Pharm. 453 (2013) 142–156. 
[65] J. Lee, Y. Cheng, Critical freezing rate in freeze drying nanocrystal dispersions, J. Control. Release 111 
(2006) 185–192. 
[66] M.K. Lee, M.Y. Kim, S. Kim, J. Lee, Cryoprotectants for freeze drying of drug nano-suspensions: effect 
of freezing rate, J. Pharm. Sci. 98 (2009) 4808–4817. 
[67] S. Kumar, R. Gokhale, D.J. Burgess, Sugars as bulking agents to prevent nano-crystal aggregation 
during spray or freeze-drying, Int. J. Pharm. 471 (2014) 303–311. 
[68] J. Beirowski, S. Inghelbrecht, A. Arien, H. Gieseler, Freeze drying of nanosuspensions, 2: the role of the 
critical formulation temperature on stability of drug nanosuspensions and its practical implication on 
process design, J. Pharm. Sci. 100 (2011) 4471–4481. 
[69] L. Wang, Y. Ma, Y. Gu, Y. Liu, J. Zhao, B. Yan, Y. Wang, Cryoprotectant choice and analyses of freeze-
drying drug suspension of nanoparticles with functional stabilisers, J. Microencapsul. 35 (2018) 241–248. 
[70] N.-O. Chung, M.K. Lee, J. Lee, Mechanism of freeze-drying drug nanosuspensions, Int. J. Pharm. 437 
(2012) 42–50. 
[71] S. Kim, J. Lee, Effective polymeric dispersants for vacuum, convection and freeze drying of drug 
nanosuspensions, Int. J. Pharm. 397 (2010) 218–224. 
[72] J. Beirowski, S. Inghelbrecht, A. Arien, H. Gieseler, Freeze-drying of nanosuspensions, part 3: 
investigation of factors compromising storage stability of highly concentrated drug nanosuspensions, J. 
Pharm. Sci. 101 (2012) 354–362. 
[73] A. Gordillo-Galeano, C.E. Mora-Huertas, Solid lipid nanoparticles and nanostructured lipid carriers: A 
review emphasizing on particle structure and drug release, Eur. J. Pharm. Biopharm. 133 (2018) 285–
308. 
[74] W. Mehnert, K. Mäder, Solid lipid nanoparticles, Adv. Drug. Deliv. Rev. 64 (2012) 83–101. 
[75] N. Kathe, B. Henriksen, H. Chauhan, Physicochemical characterization techniques for solid lipid 
nanoparticles: principles and limitations, Drug Dev. Ind. Pharm. 40 (2014) 1565–1575. 
[76] A. del Pozo-Rodríguez, M.A. Solinís, A.R. Gascón, J.L. Pedraz, Short- and long-term stability study of 
lyophilized solid lipid nanoparticles for gene therapy, Eur. J. Pharm. Biopharm. 71 (2009) 181–189. 
[77] S. Weber, A. Zimmer, J. Pardeike, Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers 
(NLC) for pulmonary application: a review of the state of the art, Eur. J. Pharm. Biopharm. 86 (2014) 7–
22. 
[78] S. Das, W.K. Ng, R.B.H. Tan, Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles 
(SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and 





[79] H. Heiati, R. Tawashi, N.C. Phillips, Drug retention and stability of solid lipid nanoparticles containing 
azidothymidine palmitate after autoclaving, storage and lyophilization, J. Microencapsul. 15 (1998) 173–
184. 
[80] T.M. Amis, J. Renukuntla, P.K. Bolla, B.A. Clark, Selection of Cryoprotectant in Lyophilization of 
Progesterone-Loaded Stearic Acid Solid Lipid Nanoparticles, Pharmaceutics 12 (2020). 
[81] S. Doktorovova, R. Shegokar, L. Fernandes, P. Martins-Lopes, A.M. Silva, R.H. Müller, E.B. Souto, 
Trehalose is not a universal solution for solid lipid nanoparticles freeze-drying, Pharm. Dev. Technol. 19 
(2014) 922–929. 
[82] H. Ohshima, A. Miyagishima, T. Kurita, Y. Makino, Y. Iwao, T. Sonobe, S. Itai, Freeze-dried nifedipine-
lipid nanoparticles with long-term nano-dispersion stability after reconstitution, Int. J. Pharm. 377 (2009) 
180–184. 
[83] W. Tiyaboonchai, W. Tungpradit, P. Plianbangchang, Formulation and characterization of curcuminoids 
loaded solid lipid nanoparticles, Int. J. Pharm. 337 (2007) 299–306. 
[84] E. Vighi, B. Ruozi, M. Montanari, R. Battini, E. Leo, Re-dispersible cationic solid lipid nanoparticles (SLNs) 
freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid, Eur. J. 
Pharm. Biopharm. 67 (2007) 320–328. 
[85] B. Siekmann, Westesen K., Melt-homogenized solid lipid nanoparticles stabilized by the nonionic 
surfactant tyloxapol, Pharm. Pharmacol. Lett (1994) 225–228. 
[86] K.S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, W.E. Rudzinski, Biodegradable polymeric 
nanoparticles as drug delivery devices, J. Control. Release 70 (2001) 1–20. 
[87] M. Holzer, V. Vogel, W. Mäntele, D. Schwartz, W. Haase, K. Langer, Physico-chemical characterisation 
of PLGA nanoparticles after freeze-drying and storage, Eur. J. Pharm. Biopharm. 72 (2009) 428–437. 
[88] Y.-I. Jeong, Y.-H. Shim, C. Kim, G.-T. Lim, K.-C. Choi, C. Yoon, Effect of cryoprotectants on the 
reconstitution of surfactant-free nanoparticles of poly(DL-lactide-co-glycolide), J. Microencapsul. 22 
(2005) 593–601. 
[89] W. Abdelwahed, G. Degobert, H. Fessi, Investigation of nanocapsules stabilization by amorphous 
excipients during freeze-drying and storage, Eur. J. Pharm. Biopharm. 63 (2006) 87–94. 
[90] W.S. Cheow, M.L.L. Ng, K. Kho, K. Hadinoto, Spray-freeze-drying production of thermally sensitive 
polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants, Int. J. 
Pharm. 404 (2011) 289–300. 
[91] T. Zelenková, D. Fissore, D.L. Marchisio, A.A. Barresi, Size control in production and freeze-drying of 
poly-ε-caprolactone nanoparticles, J. Pharm. Sci. 103 (2014) 1839–1850. 
[92] D. Quintanar-Guerrero, A. Ganem-Quintanar, E. Allémann, H. Fessi, E. Doelker, Influence of the 
stabilizer coating layer on the purification and freeze-drying of poly(D,L-lactic acid) nanoparticles 
prepared by an emulsion-diffusion technique, J. Microencapsul. 15 (1998) 107–119. 
[93] S. Hirsjärvi, L. Peltonen, J. Hirvonen, Effect of sugars, surfactant, and tangential flow filtration on the 
freeze-drying of poly(lactic acid) nanoparticles, AAPS PharmSciTech 10 (2009) 488–494. 
[94] P. Fonte, F. Araújo, V. Seabra, S. Reis, M. van de Weert, B. Sarmento, Co-encapsulation of 
lyoprotectants improves the stability of protein-loaded PLGA nanoparticles upon lyophilization, Int. J. 
Pharm. 496 (2015) 850–862. 
[95] A. Saez, M. Guzmán, J. Molpeceres, M. Aberturas, Freeze-drying of polycaprolactone and poly(d,l -lactic-
glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded 





[96] W. Abdelwahed, G. Degobert, H. Fessi, A pilot study of freeze drying of poly(epsilon-caprolactone) 
nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization, Int. J. Pharm. 309 
(2006) 178–188. 
[97] J. Wendorf, M. Singh, J. Chesko, J. Kazzaz, E. Soewanan, M. Ugozzoli, D. O’Hagan, A practical 
approach to the use of nanoparticles for vaccine delivery, J. Pharm. Sci. 95 (2006) 2738–2750. 
[98] S. de Chasteigner, G. Cav, H. Fessi, J.-P. Devissaguet, F. Puisieux, Freeze-drying of itraconazole-loaded 
nanosphere suspensions: a feasibility study, Drug Dev. Res. 38 (1996) 116–124. 
[99] S. Hirsjärvi, L. Peltonen, L. Kainu, J. Hirvonen, Freeze-drying of low molecular weight poly(L-lactic acid) 
nanoparticles: effect of cryo- and lyoprotectants, J. Nanosci. Nanotechnol. 6 (2006) 3110–3117. 
[100] F. de Jaeghere, E. Allémann, J. Feijen, T. Kissel, E. Doelker, R. Gurny, Freeze-drying and 
lyopreservation of diblock and triblock poly(lactic acid)-poly(ethylene oxide) (PLA-PEO) copolymer 
nanoparticles, Pharm. Dev. Technol. 5 (2000) 473–483. 
[101] F. de Jaeghere, E. Allémann, J.C. Leroux, W. Stevels, J. Feijen, E. Doelker, R. Gurny, Formulation and 
lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in 
vitro cell uptake, Pharm. Res. 16 (1999) 859–866. 
[102] P. Fonte, S. Soares, A. Costa, J.C. Andrade, V. Seabra, S. Reis, B. Sarmento, Effect of cryoprotectants 
on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying, Biomatter 2 (2012) 
329–339. 
[103] W. Abdelwahed, G. Degobert, H. Fessi, Freeze-drying of nanocapsules: impact of annealing on the 
drying process, Int. J. Pharm. 324 (2006) 74–82. 
[104] M.G. Anhorn, H.-C. Mahler, K. Langer, Freeze drying of human serum albumin (HSA) nanoparticles with 
different excipients, Int. J. Pharm. 363 (2008) 162–169. 
[105] M. Dadparvar, S. Wagner, S. Wien, F. Worek, H. von Briesen, J. Kreuter, Freeze-drying of HI-6-loaded 
recombinant human serum albumin nanoparticles for improved storage stability, Eur. J. Pharm. 
Biopharm. 88 (2014) 510–517. 
[106] M. Diop, N. Auberval, A. Viciglio, A. Langlois, W. Bietiger, C. Mura, C. Peronet, A. Bekel, D. Julien David, 
M. Zhao, M. Pinget, N. Jeandidier, C. Vauthier, E. Marchioni, Y. Frere, S. Sigrist, Design, characterisation, 
and bioefficiency of insulin-chitosan nanoparticles after stabilisation by freeze-drying or cross-linking, Int. 
J. Pharm. 491 (2015) 402–408. 
[107] M.V. Lozano, H. Esteban, J. Brea, M.I. Loza, D. Torres, M.J. Alonso, Intracellular delivery of docetaxel 
using freeze-dried polysaccharide nanocapsules, J. Microencapsul. 30 (2013) 181–188. 
[108] S. Eliyahu, A. Almeida, M.H. Macedo, J. das Neves, B. Sarmento, H. Bianco-Peled, The effect of freeze-
drying on mucoadhesion and transport of acrylated chitosan nanoparticles, Int. J. Pharm. 573 (2020) 
118739. 
[109] K. Sonaje, Y.-J. Chen, H.-L. Chen, S.-P. Wey, J.-H. Juang, H.-N. Nguyen, C.-W. Hsu, K.-J. Lin, H.-W. 
Sung, Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles 
for oral insulin delivery, Biomaterials 31 (2010) 3384–3394. 
[110] J.A. Ataide, D.C. Geraldes, E.F. Gérios, F.M. Bissaco, L.C. Cefali, L. Oliveira-Nascimento, P.G. Mazzola, 
Freeze-dried chitosan nanoparticles to stabilize and deliver bromelain, J. Drug Deliv. Sci. Techn. 61 
(2021) 102225. 
[111] A. Umerska, K.J. Paluch, M.J. Santos-Martinez, O.I. Corrigan, C. Medina, L. Tajber, Freeze drying of 
polyelectrolyte complex nanoparticles: Effect of nanoparticle composition and cryoprotectant selection, 





[112] J.C. Zillies, K. Zwiorek, F. Hoffmann, A. Vollmar, T.J. Anchordoquy, G. Winter, C. Coester, Formulation 
development of freeze-dried oligonucleotide-loaded gelatin nanoparticles, Eur. J. Pharm. Biopharm. 70 
(2008) 514–521. 
[113] K.J. Geh, M. Hubert, G. Winter, Progress in formulation development and sterilisation of freeze-dried 
oligodeoxynucleotide-loaded gelatine nanoparticles, Eur. J. Pharm. Biopharm. 129 (2018) 10–20. 
[114] A. Pathak, S. Patnaik, K.C. Gupta, Recent trends in non-viral vector-mediated gene delivery, Biotechnol. 
J 4 (2009) 1559–1572. 
[115] M. Rezaee, R.K. Oskuee, H. Nassirli, B. Malaekeh-Nikouei, Progress in the development of 
lipopolyplexes as efficient non-viral gene delivery systems, J. Control. Release 236 (2016) 1–14. 
[116] M.A. Mintzer, E.E. Simanek, Nonviral vectors for gene delivery, Chem. Rev. 109 (2009) 259–302. 
[117] T.K. Armstrong, T.J. Anchordoquy, Immobilization of nonviral vectors during the freezing step of 
lyophilization, J. Pharm. Sci. 93 (2004) 2698–2709. 
[118] J.C. Kasper, M.J. Pikal, W. Friess, Investigations on polyplex stability during the freezing step of 
lyophilization using controlled ice nucleation—the importance of residence time in the low-viscosity fluid 
state, J. Pharm. Sci. 102 (2013) 929–946. 
[119] J.C. Kasper, D. Schaffert, M. Ogris, E. Wagner, W. Friess, Development of a lyophilized plasmid/LPEI 
polyplex formulation with long-term stability—A step closer from promising technology to application, J. 
Control. Release 151 (2011) 246–255.  
[120] H. Talsma, J.-Y. Cherng, H. Lehrmann, M. Kursa, M. Ogris, W.E. Hennink, M. Cotten, E. Wagner, 
Stabilization of gene delivery systems by freeze-drying, Int. J. Pharm. 157 (1997) 233–238. 
[121] J.Y. Cherng, H. Talsma, D.J. Crommelin, W.E. Hennink, Long term stability of poly((2-
dimethylamino)ethyl methacrylate)-based gene delivery systems, Pharm. Res. 16 (1999) 1417–1423. 
[122] J.-Y. Cherng, P. Wetering, H. Talsma, D. Crommelin, W. Hennink, Stabilization of polymer-based gene 
delivery systems, Int. J. Pharm. 183 (1999) 25–28. 
[123] K.Y. Kwok, R.C. Adami, K.C. Hester, Y. Park, S. Thomas, K.G. Rice, Strategies for maintaining the 
particle size of peptide DNA condensates following freeze-drying, Int. J. Pharm. 203 (2000) 81–88. 
[124] C. Fornaguera, C. Castells-Sala, M.A. Lázaro, A. Cascante, S. Borrós, Development of an optimized 
freeze-drying protocol for OM-PBAE nucleic acid polyplexes, Int. J. Pharm. 569 (2019) 118612. 
[125] D. Veilleux, M. Nelea, K. Biniecki, M. Lavertu, M.D. Buschmann, Preparation of Concentrated 
Chitosan/DNA Nanoparticle Formulations by Lyophilization for Gene Delivery at Clinically Relevant 
Dosages, J. Pharm. Sci. 105 (2016) 88–96. 
[126] J.C. Kasper, C. Troiber, S. Küchler, E. Wagner, W. Friess, Formulation development of lyophilized, long-
term stable siRNA/oligoaminoamide polyplexes, Eur. J. Pharm. Biopharm. 85 (2013) 294–305. 
[127] T. Endres, M. Zheng, M. Beck-Broichsitter, T. Kissel, Lyophilised ready-to-use formulations of PEG-PCL-
PEI nano-carriers for siRNA delivery, Int. J. Pharm. 428 (2012) 121–124. 
[128] D. Veilleux, R.K. Gopalakrishna Panicker, A. Chevrier, K. Biniecki, M. Lavertu, M.D. Buschmann, 
Lyophilisation and concentration of chitosan/siRNA polyplexes: Influence of buffer composition, 
oligonucleotide sequence, and hyaluronic acid coating, J. Colloid Interface Sci. 512 (2018) 335–345. 
[129] C. Brus, E. Kleemann, A. Aigner, F. Czubayko, T. Kissel, Stabilization of oligonucleotide-polyethylenimine 
complexes by freeze-drying: physicochemical and biological characterization, J. Control. Release 95 
(2004) 119–131. 
[130] K. Miyata, Y. Kakizawa, N. Nishiyama, Y. Yamasaki, T. Watanabe, M. Kohara, K. Kataoka, Freeze-dried 
formulations for in vivo gene delivery of PEGylated polyplex micelles with disulfide crosslinked cores to 
the liver, J. Control. Release 109 (2005) 15–23. 





[132] M.T. Mabrouk, W.-C. Huang, B. Deng, N. Li-Purcell, A. Seffouh, J. Ortega, G. Ekin Atilla-Gokcumen, C.A. 
Long, K. Miura, J.F. Lovell, Lyophilized, antigen-bound liposomes with reduced MPLA and enhanced 
thermostability, Int J Pharm 589 (2020) 119843. 
[133] T.J. McIntosh, The effect of cholesterol on the structure of phosphatidylcholine bilayers, Biochim. 
Biophys. Acta Biomembr. 513 (1978) 43–58. 
[134] J.F. Nagle, S. Tristram-Nagle, Structure of lipid bilayers, Biochim. Biophys. Acta Biomembr. 1469 (2000) 
159–195. 
[135] J.F. Nagle, Theory of the Main Lipid Bilayer Phase Transition, Annu. Rev. Phys. Chem. 31 (1980) 157–
196. 
[136] K.M. Taylor, R.M. Morris, Thermal analysis of phase transition behaviour in liposomes, Thermochim. Acta 
248 (1995) 289–301. 
[137] S. Mabrey, J.M. Sturtevant, Investigation of phase transitions of lipids and lipid mixtures by sensitivity 
differential scanning calorimetry, Proc. Natl. Acad. Sci. U.S.A. 73 (1976) 3862–3866. 
[138] F. Susa, G. Bucca, T. Limongi, V. Cauda, R. Pisano, Enhancing the preservation of liposomes: The role 
of cryoprotectants, lipid formulations and freezing approaches, Cryobiology 98 (2021) 46–56. 
[139] L.M. Hays, J.H. Crowe, W. Wolkers, S. Rudenko, Factors affecting leakage of trapped solutes from 
phospholipid vesicles during thermotropic phase transitions, Cryobiology 42 (2001) 88–102. 
[140] J.H. Crowe, L.M. Crowe, F.A. Hoekstra, Phase transitions and permeability changes in dry membranes 
during rehydration, J. Bioenerg. Biomembr. 21 (1989) 77–91. 
[141] B. Maherani, E. Arab-Tehrany, M. R. Mozafari, C. Gaiani, M. Linder, Liposomes: A Review of 
Manufacturing Techniques and Targeting Strategies, Curr. Nanosci. 7 (2011) 436–452. 
[142] K.L. Koster, M.S. Webb, G. Bryant, D.V. Lynch, Interactions between soluble sugars and POPC (1-
palmitoyl-2-oleoylphosphatidylcholine) during dehydration: vitrification of sugars alters the phase 
behavior of the phospholipid, Biochim. Biophys. Acta Biomembr. 1193 (1994) 143–150. 
[143] K.L. Koster, Y.P. Lei, M. Anderson, S. Martin, G. Bryant, Effects of Vitrified and Nonvitrified Sugars on 
Phosphatidylcholine Fluid-to-Gel Phase Transitions, Biophys. J. 78 (2000) 1932–1946. 
[144] C. Cacela, D.K. Hincha, Low amounts of sucrose are sufficient to depress the phase transition 
temperature of dry phosphatidylcholine, but not for lyoprotection of liposomes, Biophys. J. 90 (2006) 
2831–2842. 
[145] J.H. Crowe, L.M. Crowe, A.E. Oliver, N. Tsvetkova, W. Wolkers, F. Tablin, The trehalose myth revisited: 
introduction to a symposium on stabilization of cells in the dry state, Cryobiology 43 (2001) 89–105. 
[146] S. Ohtake, C. Schebor, S.P. Palecek, J.J. de Pablo, Phase behavior of freeze-dried phospholipid-
cholesterol mixtures stabilized with trehalose, Biochim. Biophys. Acta Biomembr. 1713 (2005) 57–64. 
[147] E.C. van Winden, D.J. Crommelin, Short term stability of freeze-dried, lyoprotected liposomes, J. Control. 
Release 58 (1999) 69–86. https://doi.org/10.1016/S0168-3659(98)00130-8. 
[148] W. Shinoda, Permeability across lipid membranes, Biochim. Biophys. Acta Biomembr. 1858 (2016) 
2254–2265. https://doi.org/10.1016/j.bbamem.2016.03.032. 
[149] A.V. Popova, D.K. Hincha, Effects of cholesterol on dry bilayers: interactions between 
phosphatidylcholine unsaturation and glycolipid or free sugar, Biophys. J. 93 (2007) 1204–1214. 
https://doi.org/10.1529/biophysj.107.108886. 
[150] M. Gulati, M. Grover, S. Singh, M. Singh, Lipophilic drug derivatives in liposomes, Int. J. Pharm. 165 
(1998) 129–168. https://doi.org/10.1016/S0378-5173(98)00006-4. 
[151] D. Guimarães, J. Noro, C. Silva, A. Cavaco-Paulo, E. Nogueira, Protective Effect of Saccharides on 






[152] E.C. van Winden, Freeze-Drying of Liposomes: Theory and Practice, Methods Enzymol. 367 (2003) 99–
110. https://doi.org/10.1016/S0076-6879(03)67008-4. 
[153] J.H. Crowe, L.M. Crowe, Factors affecting the stability of dry liposomes, Biochim. Biophys. Acta 
Biomembr. 939 (1988) 327–334. https://doi.org/10.1016/0005-2736(88)90077-6. 
[154] M. Glavas-Dodov, E. Fredro-Kumbaradzi, K. Goracinova, M. Simonoska, S. Calis, S. Trajkovic-Jolevska, 
A.A. Hincal, The effects of lyophilization on the stability of liposomes containing 5-FU, Int. J. Pharm. 291 
(2005) 79–86. https://doi.org/10.1016/j.ijpharm.2004.07.045. 
[155] J.H. Crowe, A.E. Oliver, F.A. Hoekstra, L.M. Crowe, Stabilization of dry membranes by mixtures of 
hydroxyethyl starch and glucose: the role of vitrification, Cryobiology 35 (1997) 20–30. 
https://doi.org/10.1006/cryo.1997.2020. 
[156] S. Franzè, F. Selmin, P. Rocco, G. Colombo, A. Casiraghi, F. Cilurzo, Preserving the Integrity of 
Liposomes Prepared by Ethanol Injection upon Freeze-Drying: Insights from Combined Molecular 
Dynamics Simulations and Experimental Data, Pharmaceutics 12 (2020). 
https://doi.org/10.3390/pharmaceutics12060530. 
[157] P. Sundaramurthi, R. Suryanarayanan, Trehalose Crystallization During Freeze-Drying: Implications On 
Lyoprotection, J. Phys. Chem. Lett. 1 (2010) 510–514. https://doi.org/10.1021/jz900338m. 
[158] S.K. Singh, P. Kolhe, A.P. Mehta, S.C. Chico, A.L. Lary, M. Huang, Frozen state storage instability of a 
monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding, 
Pharm. Res. 28 (2011) 873–885. https://doi.org/10.1007/s11095-010-0343-z. 
[159] A.V. Popova, A.G. Heyer, D.K. Hincha, Differential destabilization of membranes by tryptophan and 
phenylalanine during freezing: the roles of lipid composition and membrane fusion, Biochim. Biophys. 
Acta Biomembr. 1561 (2002) 109–118. https://doi.org/10.1016/S0005-2736(01)00462-X. 
[160] A.V. Popova, D.K. Hincha, Specific interactions of tryptophan with phosphatidylcholine and 
digalactosyldiacylglycerol in pure and mixed bilayers in the dry and hydrated state, Chem. Phys. Lipids 
132 (2004) 171–184. https://doi.org/10.1016/j.chemphyslip.2004.06.003. 
[161] A.R. Mohammed, A.G.A. Coombes, Y. Perrie, Amino acids as cryoprotectants for liposomal delivery 
systems, Eur. J. Pharm. Sci 30 (2007) 406–413. https://doi.org/10.1016/j.ejps.2007.01.001. 
[162] M. Mattern, G. Winter, U. Kohnert, G. Lee, Formulation of proteins in vacuum-dried glasses. II. Process 
and storage stability in sugar-free amino acid systems, Pharm. Dev. Technol. 4 (1999) 199–208. 
https://doi.org/10.1081/pdt-100101354. 
[163] Y. Wu, Efficacy of antifreeze protein types in protecting liposome membrane integrity depends on 
phospholipid class, Biochim. Biophys. Acta Gen. Subj. 1524 (2000) 11–16. 
https://doi.org/10.1016/s0304-4165(00)00134-3. 
[164] Y. Wu, J. Banoub, S.V. Goddard, M.H. Kao, G.L. Fletcher, Antifreeze glycoproteins: relationship between 
molecular weight, thermal hysteresis and the inhibition of leakage from liposomes during thermotropic 
phase transition, Comp. Biochem. Physiol. B Biochem. Mol. Biol. 128 (2001) 265–273. 
https://doi.org/10.1016/s1096-4959(00)00323-7. 
[165] D.K. Hincha, A.E. Oliver, J.H. Crowe, Lipid Composition Determines the Effects of Arbutin on the Stability 
of Membranes, Biophys. J. 77 (1999) 2024–2034. 
[166] A.V. Popova, D.K. Hincha, Interactions of the amphiphiles arbutin and tryptophan with 
phosphatidylcholine and phosphatidylethanolamine bilayers in the dry state, BMC Biophys. 6 (2013) 9. 
[167] M.T. Hussain, N. Forbes, Y. Perrie, K.P. Malik, C. Duru, P. Matejtschuk, Freeze-drying cycle optimization 
for the rapid preservation of protein-loaded liposomal formulations, Int. J. Pharm. 573 (2020) 118722. 
[168] C. Zingel, A. Sachse, G.L. Röβling, R.H. Müller, Lyophilization and rehydration of iopromide-carrying 





[169] J. Gao, J. Sun, H. Li, W. Liu, Y. Zhang, B. Li, W. Qian, H. Wang, J. Chen, Y. Guo, Lyophilized HER2-
specific PEGylated immunoliposomes for active siRNA gene silencing, Biomaterials 31 (2010) 2655–
2664. 
[170] D. Peer, E.J. Park, Y. Morishita, C.V. Carman, M. Shimaoka, Systemic leukocyte-directed siRNA delivery 
revealing cyclin D1 as an anti-inflammatory target, Science 319 (2008) 627–630. 
[171] S. Ohtake, C. Schebor, J.J. de Pablo, Effects of trehalose on the phase behavior of DPPC-cholesterol 
unilamellar vesicles, Biochim. Biophys. Acta Biomembr. 1758 (2006) 65–73. 
[172] K. Izutsu, C. Yomota, T. Kawanishi, Stabilization of liposomes in frozen solutions through control of 
osmotic flow and internal solution freezing by trehalose, J. Pharm. Sci. 100 (2011) 2935–2944. 
[173] E.C. van Winden, W. Zhang, D.J. Crommelin, Effect of freezing rate on the stability of liposomes during 
freeze-drying and rehydration, Pharm. Res. 14 (1997) 1151–1160. 
[174] C. Tros de Ilarduya, Y. Sun, N. Düzgüneş, Gene delivery by lipoplexes and polyplexes, Eur. J. Pharm. 
Sci. 40 (2010) 159–170. 
[175] M.C. Molina, S.D. Allison, T.J. Anchordoquy, Maintenance of nonviral vector particle size during the 
freezing step of the lyophilization process is insufficient for preservation of activity: insight from other 
structural indicators, J. Pharm. Sci. 90 (2001) 1445–1455. 
[176] P. Yadava, M. Gibbs, C. Castro, J.A. Hughes, Effect of lyophilization and freeze-thawing on the stability 
of siRNA-liposome complexes, AAPS PharmSciTech 9 (2008) 335–341. 
[177] M. Tang, S. Hu, Y. Hattori, Effect of pre‑freezing and saccharide types in freeze‑drying of siRNA 
lipoplexes on gene‑silencing effects in the cells by reverse transfection, Mol. Med. Rep. 22 (2020) 3233–
3244. 
[178] T.J. Anchordoquy, J.F. Carpenter, D.J. Kroll, Maintenance of transfection rates and physical 
characterization of lipid/DNA complexes after freeze-drying and rehydration, Arch. Biochem. Biophys. 
348 (1997) 199–206. 
[179] S. Allison, M.d. Molina, T.J. Anchordoquy, Stabilization of lipid/DNA complexes during the freezing step 
of the lyophilization process: the particle isolation hypothesis, Biochim. Biophys. Acta Biomembr. 1468 
(2000) 127–138. 
[180] S.D. Allison, T.J. Anchordoquy, Mechanisms of Protection of Cationic Lipid‑DNA Complexes During 
Lyophilization, J. Pharm. Sci. 89 (2000) 682–691. 
[181] Y. Aso, S. Yoshioka, Effect of freezing rate on physical stability of lyophilized cationic liposomes, Chem. 
Pharm. Bull. 53 (2005) 301–304. 
[182] T. Furst, G.R. Dakwar, E. Zagato, A. Lechanteur, K. Remaut, B. Evrard, K. Braeckmans, G. Piel, Freeze-
dried mucoadhesive polymeric system containing pegylated lipoplexes: Towards a vaginal sustained 
released system for siRNA, J. Control. Release 236 (2016) 68–78. 
[183] B. Li, S. Li, Y. Tan, D.B. Stolz, S.C. Watkins, L.H. Block, L. Huang, Lyophilization of Cationic Lipid–
protamine–DNA (LPD) Complexes, J. Pharm. Sci. 89 (2000) 355–364. 
[184] M.d.C. Molina, T.K. Armstrong, Y. Zhang, M.M. Patel, Y.K. Lentz, T.J. Anchordoquy, The stability of 
lyophilized lipid/DNA complexes during prolonged storage, J. Pharm. Sci. 93 (2004) 2259–2273. 
[185] J. Yu, T.J. Anchordoquy, Synergistic effects of surfactants and sugars on lipoplex stability during freeze-
drying and rehydration, J. Pharm. Sci. 98 (2009) 3319–3328. 
[186] Y. Hattori, S. Hu, H. Onishi, Effects of cationic lipids in cationic liposomes and disaccharides in the freeze-
drying of siRNA lipoplexes on gene silencing in cells by reverse transfection, J. Liposome Res. (2019) 1–
11. 
[187] M.d.C. Molina, T.J. Anchordoquy, Metal contaminants promote degradation of lipid/DNA complexes 





[188] T.K.C. Armstrong, L.G. Girouard, T.J. Anchordoquy, Effects of PEGylation on the preservation of cationic 
lipid/DNA complexes during freeze-thawing and lyophilization, J. Pharm. Sci. 91 (2002) 2549–2558. 
[189] M.d.C. Molina, T.J. Anchordoquy, Degradation of lyophilized lipid/DNA complexes during storage: the 
role of lipid and reactive oxygen species, Biochim. Biophys. Acta Biomembr. 1778 (2008) 2119–2126. 
[190] M.d.C. Molina, T.J. Anchordoquy, Formulation strategies to minimize oxidative damage in lyophilized 
lipid/DNA complexes during storage, J. Pharm. Sci. 97 (2008) 5089–5105. 
[191] J. Yu, T.J. Anchordoquy, Effects of moisture content on the storage stability of dried lipoplex formulations, 
J. Pharm. Sci. 98 (2009) 3278–3289. 
[192] N. Khatri, D. Baradia, I. Vhora, M. Rathi, A. Misra, Development and characterization of siRNA lipoplexes: 
Effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study, AAPS 
PharmSciTech 15 (2014) 1630–1643. 
[193] Y. Maitani, Y. Aso, A. Yamada, S. Yoshioka, Effect of sugars on storage stability of lyophilized 
liposome/DNA complexes with high transfection efficiency, Int. J. Pharm. 356 (2008) 69–75. 
[194] W.L.J. Hinrichs, N.N. Sanders, S.C. de Smedt, J. Demeester, H.W. Frijlink, Inulin is a promising cryo- 
and lyoprotectant for PEGylated lipoplexes, J. Control. Release 103 (2005) 465–479. 
[195] W.L.J. Hinrichs, F.A. Manceñido, N.N. Sanders, K. Braeckmans, S.C. de Smedt, J. Demeester, H.W. 
Frijlink, The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles 
during freeze thawing and freeze drying, Int. J. Pharm. 311 (2006) 237–244. 
[196] H. Lee, D. Jiang, W.M. Pardridge, Lyoprotectant Optimization for the Freeze-Drying of Receptor-Targeted 
Trojan Horse Liposomes for Plasmid DNA Delivery, Mol. Pharm. 17 (2020) 2165–2174. 
[197] S.G. Darband, M. Mirza-Aghazadeh-Attari, M. Kaviani, A. Mihanfar, S. Sadighparvar, B. Yousefi, M. 
Majidinia, Exosomes: natural nanoparticles as bio shuttles for RNAi delivery, J. Control. Release 289 
(2018) 158–170. 
[198] P. Vader, E.A. Mol, G. Pasterkamp, R.M. Schiffelers, Extracellular vesicles for drug delivery, Adv. Drug. 
Deliv. Rev. 106 (2016) 148–156. 
[199] G. Fuhrmann, A.L. Neuer, I.K. Herrmann, Extracellular vesicles - A promising avenue for the detection 
and treatment of infectious diseases?, Eur. J. Pharm. Biopharm. 118 (2017) 56–61. 
[200] M. Lu, H. Xing, Z. Yang, Y. Sun, T. Yang, X. Zhao, C. Cai, D. Wang, P. Ding, Recent advances on 
extracellular vesicles in therapeutic delivery: Challenges, solutions, and opportunities, Eur. J. Pharm. 
Biopharm. 119 (2017) 381–395. 
[201] A. Jeyaram, S.M. Jay, Preservation and Storage Stability of Extracellular Vesicles for Therapeutic 
Applications, AAPS J. 20 (2017) 1. 
[202] K.W. Witwer, E.I. Buzás, L.T. Bemis, A. Bora, C. Lässer, J. Lötvall, E.N. Nolte-‘t Hoen, M.G. Piper, S. 
Sivaraman, J. Skog, C. Théry, M.H. Wauben, F. Hochberg, Standardization of sample collection, isolation 
and analysis methods in extracellular vesicle research, J. Extracell. Vesicles 2 (2013). 
[203] S. Bosch, L. de Beaurepaire, M. Allard, M. Mosser, C. Heichette, D. Chrétien, D. Jegou, J.-M. Bach, 
Trehalose prevents aggregation of exosomes and cryodamage, Sci. Rep. 6 (2016) 36162. 
[204] J. Frank, M. Richter, C. de Rossi, C.-M. Lehr, K. Fuhrmann, G. Fuhrmann, Extracellular vesicles protect 
glucuronidase model enzymes during freeze-drying, Sci. Rep. 8 (2018) 12377. 
[205] C. Charoenviriyakul, Y. Takahashi, M. Nishikawa, Y. Takakura, Preservation of exosomes at room 
temperature using lyophilization, Int. J. Pharm. 553 (2018) 1–7. 
[206] R. Lippé, Flow Virometry: a Powerful Tool To Functionally Characterize Viruses, J. Virol. 92 (2018). 
[207] J.-P. Amorij, A. Huckriede, J. Wilschut, H.W. Frijlink, W.L.J. Hinrichs, Development of stable influenza 





[208] M.R. Bovarnick, J.C. Miller, J.C. Snyder, The influence of certain salts, amino acids, sugars, and proteins 
on the stability of rickettsiae, J. Bacteriol. 59 (1950) 509–522. 
[209] E. de Rizzo, E.C. Tenório, I.F. Mendes, F.L. Fang, M.M. Pral, C.S. Takata, C. Miyaki, N.M. Gallina, H.N. 
Tuchiya, O.K. Akimura, Sorbitol-gelatin and glutamic acid-lactose solutions for stabilization of reference 
preparations of measles virus, Bull. Pan Am. Health Organ. 23 (1989) 299–305. 
[210] M. Prabhu, V. Bhanuprakash, G. Venkatesan, R. Yogisharadhya, D.P. Bora, V. Balamurugan, Evaluation 
of stability of live attenuated camelpox vaccine stabilized with different stabilizers and reconstituted with 
various diluents, Biologicals 42 (2014) 169–175. 
[211] J. Sarkar, B.P. Sreenivasa, R.P. Singh, P. Dhar, S.K. Bandyopadhyay, Comparative efficacy of various 
chemical stabilizers on the thermostability of a live-attenuated peste des petits ruminants (PPR) vaccine, 
Vaccine 21 (2003) 4728–4735. 
[212] C.F. Chisholm, T.J. Kang, M. Dong, K. Lewis, M. Namekar, A.T. Lehrer, T.W. Randolph, Thermostable 
Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide, Eur. J. Pharm. 
Biopharm. 136 (2019) 213–220. 
[213] S. Zhai, R.K. Hansen, R. Taylor, J.N. Skepper, R. Sanches, N.K.H. Slater, Effect of freezing rates and 
excipients on the infectivity of a live viral vaccine during lyophilization, Biotechnol. Prog. 20 (2004) 1113–
1120. 
[214] A.M. Abdul-Fattah, V. Truong-Le, L. Yee, E. Pan, Y. Ao, D.S. Kalonia, M.J. Pikal, Drying-induced 
variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: 
stability of a vaccine, Pharm. Res. 24 (2007) 715–727. 
[215] J. Kissmann, S.F. Ausar, A. Rudolph, C. Braun, S.P. Cape, R.E. Sievers, M.J. Federspiel, S.B. Joshi, 
C.R. Middaugh, Stabilization of measles virus for vaccine formulation, Hum. Vaccin 4 (2008) 350–359. 
[216] D.A. Yannarell, K.M. Goldberg, R.N. Hjorth, Stabilizing cold-adapted influenza virus vaccine under 
various storage conditions, J. Virol. Methods 102 (2002) 15–25. 
[217] W.M. Colwell, D.G. Simmons, J.R. Harris, T.G. Fulp, J.H. Carrozza, T.A. Maag, Influence of some 
physical factors on survival of Marek’s disease vaccine virus, Avian Dis. 19 (1975) 781–790. 
[218] K.B. Preston, T.W. Randolph, Stability of lyophilized and spray dried vaccine formulations, Adv. Drug 
Deliv. Rev. 171 (2021) 50–61. 
[219] L. Schoenmaker, D. Witzigmann, J.A. Kulkarni, R. Verbeke, G. Kersten, W. Jiskoot, D.J.A. Crommelin, 
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability, Int. J. Pharm. 601 (2021) 120586. 
[220] P. Zhao, X. Hou, J. Yan, S. Du, Y. Xue, W. Li, G. Xiang, Y. Dong, Long-term storage of lipid-like 
nanoparticles for mRNA delivery, Bioact. Mater. 5 (2020) 358–363. 
[221] R.J. Salo, D.O. Cliver, Effect of acid pH, salts, and temperature on the infectivity and physical integrity of 
enteroviruses, Arch. Virol. 52 (1976) 269–282. 
[222] W. Qi, S. Orgel, A. Francon, T.W. Randolph, J.F. Carpenter, Urea Improves Stability of Inactivated Polio 
Vaccine Serotype 3 During Lyophilization and Storage in Dried Formulations, J. Pharm. Sci. 107 (2018) 
2070–2078. 
[223] M.A. Croyle, X. Cheng, J.M. Wilson, Development of formulations that enhance physical stability of viral 
vectors for gene therapy, Gene Ther. 8 (2001) 1281–1290. 
[224] K. Wolf, M.C. Quimby, C.P. Carlson, Infectious Pancreatic Necrosis Virus: Lyophilization and Subsequent 
Stability in Storage at 4 C, Appl. Microbiol. 17 (1969) 623–624. 
[225] E. Jermoljev, L. Albrechtová, Stabilization of purified potato virus X by dextran T-10 during lyophilization, 
Biol. Plant. 11 (1969) 375–380. 
[226] M.S. Kang, H. Jang, M.C. Kim, M.J. Kim, S.J. Joh, J.H. Kwon, Y.K. Kwon, Development of a stabilizer 





[227] I.I. Slowing, J.L. Vivero-Escoto, C.-W. Wu, V.S.-Y. Lin, Mesoporous silica nanoparticles as controlled 
release drug delivery and gene transfection carriers, Adv. Drug Deliv. Rev. 60 (2008) 1278–1288. 
[228] M. Sameti, G. Bohr, M. Ravi Kumar, C. Kneuer, U. Bakowsky, M. Nacken, H. Schmidt, C.-M. Lehr, 
Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery, Int. J. Pharm. 
266 (2003) 51–60. 
[229] W. Ngamcherdtrakul, T. Sangvanich, M. Reda, S. Gu, D. Bejan, W. Yantasee, Lyophilization and stability 
of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery, 
Int. J. Nanomedicine 13 (2018) 4015–4027. 
[230] M.A. Hamaly, S.R. Abulateefeh, K.M. Al-Qaoud, A.M. Alkilany, Freeze-drying of monoclonal antibody-
conjugated gold nanorods: Colloidal stability and biological activity, Int. J. Pharm. 550 (2018) 269–277. 
[231] H. Yokota, M. Kadowaki, T. Matsuura, H. Imanaka, N. Ishida, K. Imamura, The Use of a Combination of 
a Sugar and Surfactant to Stabilize Au Nanoparticle Dispersion against Aggregation during Freeze-
Drying, Langmuir 36 (2020) 6698–6705. 
[232] J.C. Kasper, S. Hedtrich, W. Friess, Lyophilization of Synthetic Gene Carriers, Methods Mol. Biol. 1943 
(2019) 211–225. 
[233] W.F. Tonnis, M.A. Mensink, A. de Jager, K. van der Voort Maarschalk, H.W. Frijlink, W.L.J. Hinrichs, Size 
and molecular flexibility of sugars determine the storage stability of freeze-dried proteins, Mol. Pharm. 12 
(2015) 684–694. 
[234] C. Haeuser, P. Goldbach, J. Huwyler, W. Friess, A. Allmendinger, Excipients for Room Temperature 
Stable Freeze-Dried Monoclonal Antibody Formulations, J. Pharm. Sci. 109 (2020) 807–817. 
[235] F. Franks, Freeze-drying of bioproducts: putting principles into practice, Eur. J. Pharm. Biopharm. 45 
(1998) 221–229. 
[236] C. Wu, S. Shamblin, D. Varshney, E. Shalaev, Advance Understanding of Buffer Behavior during 
Lyophilization, in: D. Varshney, M. Singh (Eds.), Lyophilized Biologics and Vaccines, Springer New York, 
New York, NY, 2015, pp. 25–41. 
[237] K. Izutsu, S. Yoshioka, S. Kojima, Effect of Cryoprotectants on the Eutectic Crystallization of NaCl in 
Frozen Solutions Studied by Differential Scanning Calorimetry (DSC) and Broad-Line Pulsed NMR, 






Chapter 2  
 
Objectives of the Thesis 
Stabilization of pharmaceutical NPs by freeze-drying has to consider both chemical and 
physical stability. Specifically, little is known about fundamental principles of colloidal stability 
of NP lyophilizates providing purposeful guidance for future development. This is due to the 
heterogeneity of NPs in their physico-chemical properties. But investigations on lyophilization 
of NPs are typically carried out focusing on one NP type. 
The present thesis aims to provide a deeper understanding on the mutual dependency of 
particle properties, formulation composition and process parameters on the colloidal stability 
of NPs during lyophilization and upon storage of lyophilizates. Different NP types were 
investigated, including inorganic NPs, drug nanosuspensions, SLNs, and extracellular 
vesicles. Basic formulation aspects such as buffer type and pH were studied for all NP types 
for a good fundamental understanding. 
At first, a comprehensive summary on parameters affecting colloidal stability of NPs in the 
liquid state, the dried state, and during lyophilization is required which is summarized in 
Chapter 1. Current knowledge on lyophilization of NPs is differentiated according to specific 
material categories bringing order to rather unstructured literature. 
Subsequently, in Chapter 3, we describe studies on the impact of the buffer type, pH and 
further additives on initial colloidal stabilization and stability upon freeze-thawing of α-Al2O3 
NPs. These inorganic NPs serve as a non-hydrophobic, mechanically and thermally stable 
model. Moreover, the pH changes of buffered solutions upon freezing and thawing are 
described. 
As a next step, Chapter 4 summarizes investigations on lipophilic drug nanosuspensions and 
SLNs with respect to their lyophilization behavior. Crucial formulation, process, and storage 
aspects are evaluated. Specifically, the freezing step is investigated as a potentially critical 
process parameter considering conventional ramp freezing, including an annealing step as 
well as controlled nucleation. Results of subsequent storage stability studies provide further 






Finally, in Chapter 5, a development study for a lyophilized formulation of extracellular 
vesicles (EVs) with long-term stability regarding both colloidal stability and biological activity 
of an encapsulated protein is described. Freeze-thaw stability of EVs derived from bacterial 
and mammalian cells is studied and a fundamental understanding of the impact of the 
formulation on the critical freezing step generated. Additionally, formulation effects on EV size 
and concentration are analyzed. A 6 months storage stability study elucidates changes in the 
colloidal properties of lyophilized mammalian EV formulations as well as the stability of 
incorporated protein. 
Chapter 6 summarizes this thesis and gives an outlook and suggestions for future attempts 
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The use of inorganic nanoparticles (NPs) gains interest for pharmaceutical applications, e.g. 
as adjuvants or drug delivery vehicles. Colloidal stability of NPs in aqueous suspensions is a 
major development challenge. Both frozen and lyophilized liquids are alternative 
presentations to liquid dispersion. To improve the basic understanding, we investigated the 
freeze-thawing stability of model α-Al2O3 NPs. Freeze-thawing was conducted in three 
different buffer types at pH 5 and 8 without and with additives to determine fundamental 
formulation principles. Before freeze-thawing, α-Al2O3 NPs could be stabilized in sodium 
citrate buffer at pH 5 and 8, and in sodium or potassium phosphate at pH 8. Particles revealed 
low zeta potential values in phosphate buffers at pH 5 indicating insufficient electrostatic 
stabilization. After freeze-thawing, an increase in NP size was strongly reduced in potassium 
phosphate and sodium citrate buffers. Subsequent pH measurements upon freezing revealed 
a drastic acidic pH shift in sodium phosphate which was further demonstrated to destabilize 
NPs. The ionic stabilizers gelatin A/B, Na-CMC, and SDS, were suitable to improve colloidal 
stability in phosphate buffers at pH 5 highlighting the importance of charge stabilization. 
Freeze-thawing stability was best in presence of gelatin A/B, followed by PVA, mannitol, or 
sucrose. Depletion and steric stabilization were insufficient using PEG and surfactants 
respectively. Thus, we could identify the fundamental formulation principles to preserve 
inorganic NPs upon freezing: i) sufficient charge stabilization, ii) a maintained pH during 
freezing, and iii) the addition of a suitable stabilizer, preferably gelatin, not necessarily 











Al2O3 Aluminum oxide 
Na-CMC Sodium carboxymethyl cellulose 
DLS Dynamic light scattering 
DSC Differential scanning calorimetry 
FT Freeze-thawing 
LO Light obscuration 
Man Mannitol 
MW Molecular weight 
NP Nanoparticle 
PDI Polydispersity index 
PEG Polyethylene glycol 
PS20 Polysorbate 20 
PVA Polyvinyl alcohol 
RT Room temperature 
SDS Sodium dodecyl sulfate 
Suc Sucrose 
Tc Crystallization temperature 
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1 Introduction  
Inorganic nanoparticles (NPs) are utilized for a number of biomedical applications, including 
cancer therapy, imaging, and drug delivery [1–4]. Specifically, aluminum containing adjuvants 
are used for decades in vaccines for human or veterinary immunizations [5,6]. In order to 
improve the colloidal and chemical stability of the aqueous dispersions they can be stored at 
low temperatures. Additionally, freezing and freeze-drying are widely used to overcome the 
limited stability of colloidal systems [7,8]. However, these processes are also known to cause 
stress which might lead to NP aggregation and size increase. During freezing, particle 
aggregation can be triggered by increased particle-particle interaction in the cryo-
concentrated phase [9], by pH changes arising from crystallization of buffer salts [10], by 
surface induced destabilization at the ice-liquid interfaces [11], or by mechanical stress due 
to formation of ice crystals [7]. Braun et al. prevented freezing of vaccines containing alum by 
adding substantial amounts of propylene glycol, polyethylene glycol 300, and glycerol which 
lead to a freezing point depression [12]. Although this attempt prevents damage during 
freezing, it does not overcome the predominant problem of physical instability in aqueous 
media and is not in line with isotonicity requirements. Drying is further accompanied by the 
loss of the hydration shell leading to particle destabilization. NP aggregation can result in 
reduced therapeutic efficacy and embolism [13] and has to be avoided by adequate 
formulation and process design. 
While fundamental concepts for freeze-drying of protein drugs have been a research focus in 
recent years, there is a lack of knowledge about freezing and lyophilization of inorganic NPs. 
Beirowski et al. emphasized the higher importance of formulation design over the freezing 
rate for drug nanosuspensions [8]. Yet, the formulation design depends on specific NP 
properties. For example, the physico-chemical properties and stability of alum NPs depends 
on the amount and type of bound antigen as well as the binding mechanism [14]. Nature and 
concentration of excipients like cryoprotectants, lyoprotectants, surfactants, and polymers will 
have substantial impact on the NP stability during freezing. Salnikova et al. found that the pH 
strongly affects the electrostatic charges and by that the extent of freeze-thaw aggregation of 
alum adjuvant [15]. But a systematic evaluation of e.g. the impact of buffer species and ionic 
strength in presence of different stabilizing excipients is still lacking. 
The objective of this study was to close this gap investigating the impact of different buffer 
types in combination with various excipients on the stability of α-Al2O3 NPs during freezing. 
Freezing is considered to be the key stress for products stored as frozen liquids or 
lyophilizates [16]. Freeze-thaw (FT) experiments were conducted using sodium phosphate, 
potassium phosphate, and sodium citrate buffer at pH 5 and 8. We analyzed the pH during 





investigated the potential of different additives, including surfactants, polymers, and 
cryoprotectants, to preserve colloidal stability upon FT. This study illustrates the importance 
of sufficient charge stabilization, maintained pH during freezing, and the addition of a suitable 
stabilizer on particle size preservation of freeze-thawed α-Al2O3 NPs serving as a model for 
charge stabilized inorganic NPs. 
 
2 Material and methods 
2.1 Materials 
α-Al2O3 NPs were obtained from IoLiTec Nanomaterials (Heilbronn, Germany). Sucrose, 
mannitol, sodium dodecylsulfate (SDS), gelatin type A 175, gelatin type B 225, polyvinyl 
alcohol (PVA; MW ~31.000-50.000 Da) (all Sigma-Aldrich, Steinheim, Germany), 
polyethylene glycol (PEG; MW ~20.000 Da), polysorbate 20 (PS20) (all Merck KGaA, 
Darmstadt, Germany), and sodium carboxymethyl cellulose (Na-CMC) (Tylopur C 300 P2, 
Clariant, Wiesbaden, Germany) were used without further purification. Na-, K-phosphate (all 
VWR International, Ismaning, Germany), and Na-citrate buffer (Merck, Darmstadt, Germany) 
were used to prepare 10 mM buffers at pH 5 and 8. Highly purified water (HPW) was used 
for the preparation of buffer and stabilizer stock solutions. 10R glass vials (Schott, Müllheim, 
Germany) with rubber stoppers (West, Eschweiler, Germany) were used throughout the 
studies. 
2.2 Methods 
2.2.1 Sample preparation 
10 mM Na-citrate, Na phosphate, or K phosphate buffer at pH 5 or 8 without and with one of 
the stabilizers (Na-CMC, gelatin A, gelatin B, PVA, PEG 20.000, SDS, PS20, sucrose and 
mannitol [each at two concentrations]) were prepared by manual mixing with HPW and 
subsequent 0.2 µm filtration. 1 mg/mL α-Al2O3 NP suspension was obtained after addition of 
the respective solution to the NPs, 10 s ultrasonic homogenization (Bandelin Sonoplus 
HD 3100, Berlin, Germany), and filtration through a 1.2 μm cellulose acetate filter (Sartorius, 





2.2.2 Freeze-thaw cycles 
The different formulations (3 mL in 10R vials) were freeze-thawed three times on a pilot scale 
freeze-drier (FTS LyoStarTM 3, SP Scientific, Stone Ridge, New York). Samples were frozen 
at –1 °C/min to –50 °C. After 90 min at –50 °C, the samples were thawed at 1 °C/min to 10 °C 
with a 90 min hold. 
2.2.3 Dynamic light scattering (DLS) 
Particle size and polydispersity index (PDI) were analyzed on a DLS platereader DynaPro II 
(Wyatt Technology, Dernbach, Germany) using 96 UV-well plates (CostarTM, Corning, 
Glendale, Arizona). 100 μL sample (n=3) per well was measured at RT (10 acquisitions with 
5 s each). DYNAMICS software (Version 7.8.0.26) was used for data evaluation. 
Corresponding preset refractive index parameters were used for all samples. Sample 
viscosities were determined on an AMVn Automated Micro Viscometer (Anton Paar, Graz, 
Austria). 
2.2.4 Zeta potential measurement 
Zeta potential measurements were conducted by electrophoretic light scattering on a 
Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany). Undiluted samples were 
analyzed in a disposable capillary cell (DTS1070). NP titration was performed in combination 
with a Malvern MPT-2 Autotitrator. 12 mL sample was transferred into a stirred polypropylene 
tube and titrated from pH 8 to pH 2 in increments of 0.5 pH units (± 0.2 U) using 0.1 M HCl 
and 0.1 M NaOH. Zeta potential and z-average size were measured in a disposable zeta cell 
(DTS1070) with three measurements per pH value. Analysis was performed at 25 °C and at 
a voltage of 50 V in ‘monomodal mode’ with automatic attenuation selection. 
2.2.5 Analysis of pH during freezing and thawing 
Pure buffer solutions were analyzed for pH shifts during freezing. A low temperature pH 
electrode (Inlab®cool, Mettler Toledo GmbH, Giessen, Germany) was equipped with a 
thermocouple and placed in the center of the sample vial (6 mL in 10R vials). Shelves were 
cooled at –1 °C/min to –35 °C. After 90 min at –35 °C, the samples were thawed at 1 °C/min 
to RT. 
2.2.6 Subvisible particle analysis by light obscuration (LO) 
Subvisible particles (SVPs) were analyzed using a PAMAS SVSS-35 particle counter with a 





Selected samples were measured in triplicates before and after freeze-thawing. After sample 
pre-rinse with 0.4 mL, each sample was analyzed three times with 0.3 mL. Data evaluation 
was carried out using the PAMAS PMA software. 
2.2.7 Differential scanning calorimetry (DSC) 
DSC measurements were performed using a Mettler Toledo DSC 822e (Mettler Toledo 
GmbH, Giessen, Germany) in order to determine the glass transition temperature of the 
maximally freeze-concentrated solution (Tg’) or crystallization events (Tc). 20 µL sample was 
filled and sealed in 40 µL aluminum crucibles. The samples were cooled at 10 °C/min from 
25 °C to –60 °C, held at –60 °C for 1 min, and reheated at 10 °C/min to 25 °C. Tg’ were 
defined as the inflection point of the glass transition in the heating scan of the DSC 
experiment. 
 
3 Results and discussion 
3.1 Impact of buffer type and pH 
α-Al2O3 NPs were formulated in 10 mM Na-citrate, Na-phosphate, or K-phosphate buffer in 
order to evaluate the impact of buffer type and pH on zeta potential and particle stability upon 
FT. The buffers were not in the center but still within their effective buffering range. pH 5 and 8 
were chosen to obtain differently charged particles and thus investigate the impact of 
electrostatic stabilization. Particle size, PDI and zeta potential measurements were 
conducted before and after FT providing insight into colloidal stability. DLS measurements 
revealing particles >1 µm show a distinct qualitative information for insufficient NP 
stabilization and were thus not further investigated, e.g. by laser diffraction. 
Before FT, α-Al2O3 NPs exhibited a mean particle size of 240 nm and a mean PDI below 0.4 
in Na-citrate buffer at both pH values as well as in phosphate buffers at pH 8 (Figure 1). In 
contrast, the larger particle size of approximately 480 nm and PDI values >0.56 in Na- and 
K-phosphate buffer at pH 5 revealed a pronounced impact of buffer type and pH on initial 
colloidal particle stability. After three times FT, the DLS results did not change in Na-citrate 
buffer at pH 5 and 8. Particle size was markedly increased in phosphate buffer, except in 
K-phosphate at pH 8. Overall, all formulations showed a multimodal size distribution, as also 
indicated by the high PDI, independent of buffer type and pH, indicating a strong tendency of 
the NPs to aggregate. Crystal growth of NPs due to irreversible Ostwald ripening may be an 





high performance ceramics, packing materials, paints, and catalysts and with its poor water 
solubility and stability it is not expected to show Ostwald ripening in the aqueous media within 




Figure 1: DLS results of α-Al2O3 NPs formulated in 10 mM Na-citrate, Na-phosphate, and 
K-phosphate buffer at pH 5 or 8 before and after 3xFT (mean ± SD; n=3). PDI values >0.56 
represent a multimodal size distribution and are therefore stated as ‘1.0’. 
 
The NPs showed a strong negative surface charge of ~–42 mV and ~–48 mV in Na-citrate 
buffer at pH 5 and 8 (Table 1). The zeta potential was significantly lower in phosphate buffers 
at pH 5, whereas values of ~–39 mV and ~–60 mV were obtained at pH 8 in Na- and 
K-phosphate buffer respectively. The NP surface charge did not change upon FT. 
 
Table 1: ζ-Potential values of α-Al2O3 NPs formulated in 10 mM Na-citrate, Na-phosphate, and 
K-phosphate buffer at pH 5 or 8 before and after 3xFT (mean ± SD; n=3). 
ζ-Potential [mV]   
Buffer pH before FT after FT 
Na-citrate 5 –42.1 ± 2.1 –40.2 ± 2.1 
 8 –47.6 ± 3.3 –48.3 ± 3.7 
Na-phosphate 5 –19.0 ± 0.1 –19.3 ± 0.6 
 8 –38.6 ± 1.9 –34.8 ± 0.9 
K-phosphate 5 –25.2 ± 1.3 –21.5 ± 0.7 
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Salnikova et al. showed that FT induced aggregation of aluminum hydroxide and aluminum 
phosphate microparticles (AlhydrogelTM and AdjuphosTM) can be significantly reduced at a pH 
far away from the point of zero charge indicating an electrostatically driven effect [15]. Thus, 
we assume that electrostatic particle stabilization by the polyanions citrate and phosphate is 
the underlying cause for α-Al2O3 stabilization in aqueous suspension. Adsorbed multiply 
charged ions and polymer coatings on NP surfaces can suppress NP agglomeration [18]. 
With a lower degree of protonation and consequently a higher amount of charges at higher 
pH an increased stabilizing effect can be seen. Two negative charges in hydrogen citrate 
(> 50% at pH > 4.8) and hydrogen phosphate (> 50% at pH > 7.1) and three negative charges 
in citrate (> 50% at pH > 6.4) appear to be preferred underlining the importance of the buffer 
pH and type (citric acid: pKa1 = 3.1, pKa2 = 4.8, pKa3 = 6.4; phosphoric acid: pKa1 = 2.2, 
pKa2 = 7.1, pKa3 = 12.3 [19]). 
3.2 The pH shift during freezing and its impact on particle stability 
FT of α-Al2O3 NPs in phosphate buffer pH 8 resulted in a smaller increase of particle size with 
K+ as compared to Na+ as counter ion (see 3.1). Since it is known that buffers might undergo 
a pH shift during freezing, we examined the change in pH upon freezing to –30 °C and 
subsequent thawing. 
The pH of Na-citrate buffer slightly decreased from pH 5 to 4 and from pH 8 to 6 during 
freezing to approximately –30 °C (Figure 2). In contrast, a pH of 3 was measured at the lowest 
temperature in Na-phosphate buffer adjusted to pH 5 or 8 and in K-phosphate buffer adjusted 
to pH 5. The pH value of K-phosphate buffer pH 8 did not change upon freezing. In general, 
all buffer solutions maintained their pH until freezing started. The gradual pH shift started with 
ice crystallization which caused a temporarily increased solution temperature. The changes 
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Figure 2: Change in pH as a function of temperature for 10 mM Na-citrate, Na-phosphate, and 
K-phosphate buffer at pH 5 or 8 during freezing to –30 °C and subsequent thawing 
(mean ± SD; n=3). 
 


























































































Our observations are in accordance to previous publications [20–22]. The pH shift during 
freezing of buffers depends on the (cryo-)concentration and the eutectic temperatures of the 
salt components relative to their solubilities [22]. The eutectic point of the acidic monosodium 
phosphate (Teut = −9.7 °C) is lower compared to the basic disodium salt (Teut = −0.5 °C) 
resulting in a pH decrease upon freezing. In the potassium phosphate system, the 
dipotassium phosphate (Teut = −13.7 °C) is more soluble in water than the monopotassium 
salt (Teut = −2.7 °C) preventing an acidic pH shift in the buffer formulated at pH 8 [20,21]. 
Thus, in case of phosphate buffers, the mono to di ratio of the buffer salts is crucial for the 
occurrence and extent of pH shift. Na-citrate buffers show only a minimal change upon 
freezing potentially due to partial precipitation of disodium and trisodium citrate at pH 5 and 8 
respectively [22]. 
Additionally, we performed a pH titration to elucidate the impact of an acidic pH shift on zeta 
potential, particle size and PDI of α-Al2O3 NPs in Na-phosphate buffer pH 8. The acidic pH 
shift upon freezing leads to a decreasing surface charge which comes with pronounced 
aggregation as indicated by the increase in particle size and PDI value (Figure 3). An 
increased particle aggregation of α-Al2O3 NPs occurs as the pH approaches the point of zero 
charge, where van der Waals attraction forces dominate over electrostatic repulsion [23]. To 
the best of our knowledge, the destabilizing effect of an acidic pH shift on FT stability of 
inorganic NPs has not been reported yet. In contrast, it is well-known that proteins formulated 




Figure 3: Change in zeta potential, particle size, and PDI of α-Al2O3 NPs in 10 mM Na-phosphate as 
a function of pH (mean ± SD; n=3).  































































3.3 Impact of various stabilizers 
After understanding the effect of buffer and pH on the growth of α-Al2O3 NPs upon FT, we 
tested the potential of different additives to further improve FT stability as well as colloidal 
stability at pH 5 before FT. Na-CMC and gelatin A and B were chosen as electrostatic 
stabilizers and viscosity enhancers, SDS and PS20 were selected as ionic and non-ionic 
surfactants, and PVA and PEG 20.000 were used to test stabilization via depletion. 
Furthermore, mannitol and sucrose were tested as cryoprotective stabilizers and bulking 
agents. 
3.3.1 Colloidal stability before FT 
Before FT, α-Al2O3 NPs were well stabilized in Na-citrate independent of the buffer pH and 
excipient addition revealing a particle size of ~240 nm and a low PDI (Figure 4). Similarly, 
NPs exhibited a good colloidal stability in all samples formulated in phosphate buffer at pH 8. 
NP stability was critical in phosphate buffers pH 5 without the addition of further stabilizers as 
indicated by a large particle size and a multimodal size distribution. The uncharged stabilizers 
PS20, PVA, PEG 20.000, mannitol, and sucrose did not improve the initial particle stability 
thereby making the assessment of the FT stability obsolete. In contrast, NPs revealed a high 
colloidal stability in presence of gelatin independent of buffer type and pH. Additionally, 
Na-CMC and SDS containing formulations were able to stabilize NPs in phosphate buffers 
pH 5, still showing larger particle sizes compared to formulations at pH 8. The improved 
colloidal stability in presence of gelatin, Na-CMC, or SDS is attributed to electrostatic 
interactions. Likos et al. reported that gelatin adsorbs to the particle surfaces thereby 
providing both electrostatic and steric stabilization [25]. This effect was also described for 
negatively charged Na-CMC (pKa = 4.3 [19]) and SDS [26,27]. The stabilization by gelatin 
appears to be independent of the net electrical charge, since gelatin exhibits an isoelectric 
point at pH 7.0 – 9.0 (type A) or 4.7 – 5.4 (type B) [19]. Gelatin molecules might adsorb 
through attractive interactions of some amino acid segments, regardless of its overall charge 
[28]. Interestingly, Na-CMC and SDS failed to stabilize α-Al2O3 NPs in K-phosphate buffer at 
both investigated additive concentrations. The presence of potassium ions seems to impair 
electrostatic interactions although sodium ions are added by Na-CMC (0.1%: 3.8 mM Na+, 
0.5%: 19.0 mM Na+) and SDS (0.1%: 3.47 mM Na+, 1%: 34.7 mM Na+). We speculate that 






















Figure 4: DLS results of α-Al2O3 NPs in 10 mM Na-citrate, Na phosphate, and K-phosphate buffer at 
pH 5 or 8 in presence of different excipients before and after 3xFT (mean ± SD; n=3). PDI 
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The zeta potential of α-Al2O3 NPs was mainly determined by the buffer type and pH (Figure 5). 
Zeta potential measurements generally showed higher surface charges for particles prepared 
at pH 8 independent of the added excipient. The highest surface charge values resulted in 
K-phosphate pH 8. At pH 5, Na-citrate led to higher zeta potential values compared to 
phosphate buffers, except in Na-CMC containing samples. SDS increased while PVA and 
1% PS20 decreased the surface potentials in all buffer types. Interestingly, gelatin containing 
formulations revealed NPs with approximately neutral surface charge independent of buffer 
type and pH. 
 
 
Figure 5: ζ-Potential of α-Al2O3 NPs in 10 mM Na-citrate, Na-phosphate, and K-phosphate at pH 5 or 
8 in presence of different excipients before and after 3x FT (mean ± SD; n=3). 
 
3.3.2 FT stability 
The surface charge did not change with FT (Figure 5). In general, citrate buffer provided better 
stabilization than phosphate buffer highlighting the importance of electrostatic stabilization 
(Figure 4). The FT stability in presence of additives is discussed in more detail in the following 
along the line of the proposed stabilization mechanisms. Additionally, DSC measurements of 
aqueous excipient solutions were performed in order to assess potential glass transitions of 
the freeze-concentrate or solute crystallization. No thermal events were detected in samples 
























































Na-CMC was not able to stabilize α-Al2O3 NPs except in Na-citrate pH 5. Thus, an increased 
initial viscosity (~7.5 mPas) is insufficient without further stabilization. In contrast, gelatin A 
was able to preserve NPs independent of the buffer composition. Gelatin B was beneficial at 
pH 8 but not around its isoelectric point of 4.7 to 5.4. The favorable cryoprotective effect of 
gelatin is reported for several different NP types, such as nanocapsules, viruses, and 
bacteriophages [29–31].  
PS20 containing formulations only improved FT stability at pH 8; the pH shift in Na-phosphate 
seems to be critical. Furthermore, SDS only improved FT stability in K-phosphate at pH 8. 
During the heating scan of DSC measurements, 1% SDS revealed a thermal event in 
phosphate buffers at pH 8 at about –18 °C which is attributed to SDS crystallization 
(Figure 6). SDS crystallization is usually observed at temperatures below RT depending on 
its concentration [32,33]. Interestingly, in our study no crystallization event was detected in 
phosphate buffers at pH 5 or in Na-citrate buffer. The (partial) crystallization of SDS in 
K-phosphate pH 8 appears to have a cryoprotective effect upon FT speculatively by providing 
enhanced particle isolation during thawing. 
 
 
Figure 6: DSC profiles of 1% SDS in 10 mM Na-citrate, Na-phosphate, and K-phosphate buffer at 
pH 5 or 8. 
 
The two polymers PVA and PEG 20.000 improved the FT stability of the NPs in Na-citrate 
buffer pH 5 and 8 as well as in K-phosphate at pH 8. Overall, the lowest PDI values after FT 
were detected in Na-citrate buffers containing PVA or PEG 20.000. PVA further improved FT 
stability in Na phosphate at pH 8, whereas pronounced aggregation was found in formulations 
containing PEG 20.000. The stabilizing effect of PVA and PEG 20.000 is related to depletion 
by the free polymers in solution separating particles from each other [34,35]. Furthermore, 
PVA is a known as an ice recrystallization inhibitor due to adsorption to the ice surface thereby 
































avoiding the formation of large ice crystals [36]. The anti-freezing effect of PVA was further 
demonstrated to slow the rate of ice crystal growth during thawing [37]. Thus, the absence of 
large ice crystals and recrystallization processes may reduce the mechanical stress on NPs 
during FT. Furthermore, lower ice nucleation temperatures might attenuate the pH shift in 
Na-phosphate buffer. 
The small polyol mannitol and the cryoprotectant sucrose were suitable to protect α-Al2O3 
NPs in Na-citrate at pH 5 and in all formulations prepared at pH 8 against FT stress with only 
a slight increase in PDI. In line with literature DSC measurements showed a Tg’ of about  
–32 °C for sucrose in all formulations [7]. Mannitol revealed two glass transition events at  
~–32 °C and ~–25 °C and an exothermic crystallization at ~–20 °C (Figure S-1) [7,38]. Thus, 
both excipients formed an amorphous matrix during FT which is able to stabilize the NPs. 
Mannitol is known to form an amorphous matrix and may crystallize upon FT depending on 
freezing protocol and other excipients [38,39]. Upon mannitol crystallization its beneficial 
effect can be lost [39]. Particle isolation, vitrification, and increased solution viscosity are used 
in literature to explain the cryoprotective effect of amorphous sugars and polyols on various 
NP types (i.e. polyplexes, lipoplexes, liposomes) during freezing [41–43]. Clausi et al. 
demonstrated that aggregation of aluminum hydroxide microparticles (AlhydrogelTM) particles 
can be minimized through proper choice of buffer ions, or kinetically inhibited by rapidly 
forming a glassy state during freezing [44]. Furthermore, successful lyophilization of 
mesoporous silica and gold nanorods was reported using trehalose and sucrose [45–47]. 
Mannitol and sucrose furthermore successfully stabilized α-Al2O3 NPs in Na-phosphate buffer 
in spite of the earlier discussed pH shift. The amorphous sugar may completely inhibit buffer 
salt crystallization during freezing of phosphate buffered saline, while mannitol can at least 
partially suppress the crystallization thereby attenuating the pH shift [48]. Higher 
concentrations of stabilizers did not further substantially improve the FT stability at the 
investigated NP concentration. In contrast, Clausi et al. showed that high concentrations of 
trehalose (up to 15%) are necessary to completely prevent aggregation of aluminum 
hydroxide microparticles upon FT and lyophilization [44]. Our study generally shows that 
particle preservation of α-Al2O3 is more successful in formulations prepared at pH 8 
highlighting the importance of electrostatic stabilization which is considered to be the 
predominant stabilization mechanism. 
Overall, DLS measurements revealed best FT stability of α-Al2O3 NPs in (i) Na-citrate, (ii) at 
pH 8, and (iii) in presence of a suitable additive. Since DLS gives no information on the 
number of large particles formed after FT, we additionally performed SVP analysis. α-Al2O3 
NPs were formulated in Na-citrate pH 8 with 0.1% gelatin A, 5% Suc, or 5% Man. Gelatin A 





type and pH while Suc and Man might serve as potential bulking agents for lyophilization. All 
formulations exhibited ~10,000 particles/mL before FT (Figure 7). After three times FT, the 
number of SVP was increased only slightly to values between 17,000 and 
~26,000 particles/mL. Surprisingly, 0.1% gelatin A showed a similar cryoprotective effect as 
the two matrix formers at 5%. Again, electrostatic and steric stabilization are at least as 
important as the formation of a glassy matrix. 
 
 
Figure 7: SVP concentrations of α-Al2O3 NPs in 10 mM Na-citrate pH 8 stabilized with 0.1% gelatin, 
5% Suc, and 5% Man before and after 3xFT (mean ± SD; n=3). 
 
4 Conclusion 
The poor colloidal stability of inorganic NPs in aqueous suspension limits their application 
and is an important hurdle in development. Frozen storage and lyophilization are technologies 
to overcome this challenge. But a detailed and systematic investigation of the effect of pH, 
buffer type, and stabilizing excipients on colloidal stability is a prerequisite. We used α-Al2O3 
NPs as a model and investigated the FT stability in presence of different buffers at pH 5 and 
8, and of various excipients covering different stabilization mechanisms. 
Before FT, Na- and K-phosphate buffer only provided colloidal stability at pH 8, whereas the 
NPs size increased at pH 5 due to the lower surface charge indicating insufficient electrostatic 
stabilization. Na-citrate stabilized NPs at both pH 5 and 8. The aggregation propensity upon 
FT was pronounced in Na-phosphate buffer at both pH 5 and 8. This is caused by the acidic 
pH shift in the buffers during freezing which results in a drastic decrease of the zeta potential. 
The colloidal stability in Na- and K-phosphate buffer pH 5 was improved by gelatin, Na-CMC, 
















































were not able to increase the initial particle stability. After FT, NPs were best preserved in 
Na-citrate buffer pH 5 and 8 or K-phosphate buffer pH 8, still revealing larger particles in 
absence of further additives. The addition of gelatin, PVA, mannitol and sucrose drastically 
improved FT stability most likely due to enhanced particle isolation and/or the formation of a 
stabilizing matrix. Most remarkably, gelatin A was able to provide both colloidal and FT 
stability in all buffer types. 
Overall, electrostatic stabilization was vital for the stabilization of α-Al2O3 NPs before and after 
FT as shown by the importance of buffer type and pH; citrate was in general superior to 
phosphate buffer. The addition of mannitol, sucrose and gelatin further improved FT stability 
and offer great potential for future studies on lyophilization which additionally involves 
potential stresses during drying. 
 




























5% Man pH 5
5% Man pH 8
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Lyophilization formulation and process development for lipophilic nanoparticle (NPs) 
products is highly challenging as the NPs have a low colloidal stability. We compared two 
different NP types, pure paliperidone palmitate nanocrystals and trimyristin solid lipid 
nanoparticles regarding formulation, process, and storage stability aspects. Freeze-thaw 
studies were conducted to investigate the basic formulation aspects such as buffer type, pH, 
and ionic strength as well as different cryoprotectants. In freeze-drying conventional ramp 
freezing was performed and compared to freezing with an annealing step added or with 
controlled ice nucleation. Different formulations were lyophilized and tested for short-term 
storage stability up to 6 weeks. Samples were analyzed for particle size, subvisible particle 
number, specific surface area, residual moisture, crystallinity, and glass transition 
temperature. Sucrose significantly better stabilized both NP types against freeze-thaw stress 
compared to mannitol demonstrating the importance of a fully amorphous matrix. While the 
impact of buffer type and pH was negligible, the aggregation propensity of NPs was reduced 
in presence of NaCl. The freezing step also impacted NP aggregation but the effect was less 
important than the formulation design. Surfactants did not necessarily improve the colloidal 
stability but resulted in a lower glass transition temperature of the lyophilizates and may 
cause phase separation which limits storage stability. This hurdle can be overcome by using 
a hydroxypropyl-β-cyclodextrin/ sucrose mixture as cryoprotectant. In general, we could 
show a similar freeze-drying behavior of the two NP types. Thus, we established a 
formulation and process approach to achieve stable lyophilizates of lipophilic NPs based on 








Drug nanosuspension, Solid lipid nanoparticles, Freeze-thaw, Freeze-drying, Buffer type, 
Ionic strength, Process stability, Stability testing 
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AN Annealing step 
CN Controlled nucleation 
DLS Dynamic light scattering 
DSC Differential scanning calorimetry 
FT Freeze-thaw 
LO Light obscuration 
Man Mannitol 
NP Nanoparticle 
PDI Polydispersity index 
P407 Poloxamer 407 
PS20 Polysorbate 20 
PP Paliperidone palmitate 
RM Residual moisture 
RN Random nucleation 
RT Room temperature 
SSA Specific surface area 
SLN Solid lipid nanoparticle 
Suc Sucrose 
SVP Subvisible particle 
Tc Crystallization temperature 
Tg Glass transition temperature of the freeze-dried cake 
Tg’ Glass transition temperature of the freeze-concentrated solution 
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The emerging field of nanomedicine combines nanotechnology with pharmaceutical and 
biomedical sciences and aims to develop drugs with higher efficacy and improved safety [1]. 
However, the development of nanoparticulate systems is challenging. Most nanoparticles 
(NPs) are produced and suspended in aqueous medium. They are known to have poor 
storage stability due to particle aggregation or other physical and chemical degradation 
processes. In many cases NPs can only be used for several hours or a few days. Hence, 
the vast majority of studies work with freshly prepared NPs [2]. This poor stability limits the 
experimental use and the development of drug products. 
Removal of water by freeze-drying is an important technique to stabilize colloidally instable 
systems. The solid matrix permits long-term storage and easy transportation. Yet, freeze-
drying is also known to induce NP aggregation due to freezing and drying stress. During 
freezing, particle aggregation can be triggered by increased particle-particle interaction in 
the cryo-concentrated phase [3], by pH changes arising from a temperature dependent 
dissociation behavior or crystallization of buffer salts [4,5], by surface induced destabilization 
at the ice-liquid interfaces [6] or by mechanical stress due to formation of ice crystals [7]. 
Consequently, stress during freezing is assumed to be a key factor during lyophilization. 
During drying, the removal of unfrozen water can lead to destabilization due to a loss of the 
stabilizing hydration shell at the NP surface [8]. These main drawbacks of lyophilization can 
be prevented by the addition of cryoprotectants and adjusting the lyophilization cycle. 
Unfortunately, except of empirical principles, there is little known about purposeful 
formulation and process design when freeze-drying NPs. The precise mechanisms 
underlying the effects of lyophilization-induced stress on nanoparticulate formulations and 
protection afforded by cryoprotectants are not well understood [2]. 
NPs can be differentiated into several material categories, e.g. polymeric NPs, crystalline 
NPs, and liposomal NPs. Their surface characteristics including charge, hydrophobicity, and 
functional groups are important for NP stability [9]. The three main mechanisms leading to 
colloidal stability are electrostatic, steric and depletion stabilization. A depletion force 
originates from the excluded volume effect in presence of free non-adsorbing polymers 
leading to a kinetic NP stabilization [10–12]. Consequently, during lyophilization, the diverse 
NP types show different colloidal instability, on top of potential chemical or other physical 
instability. This leads to complex formulation and process considerations due to the lack of 
universal rules. 
Nanosized drug and solid lipid nanoparticle (SLNs) nanosuspensions are essentially 





and the bulking agent is crucial for NP preservation during freeze-drying [13]. In most 
studies, freeze-drying of NPs is conducted with one single NP type which gives limited 
information about general rules for lyophilization of NPs. Furthermore, variations almost 
exclusively focus on the freezing rate when it comes to the process or changing the 
cryoprotectant type or concentration with respect to the formulation. Beirowski et al. showed 
that the freezing rate is of minor importance compared to formulation composition when 
freeze-drying drug nanosuspensions [14]. Similar results were found for SLNs; type and 
concentration of stabilizers play a vital role for lyophilization success [15,16]. 
However, it is not clear, if drug nanosuspensions and SLNs can be considered as one NP 
type, i.e. lipophilic NPs, having fundamental lyophilization principles in common. 
Furthermore, formulation aspects such as buffer type and ionic strength or other 
modifications of the freezing step are not reported in literature. Therefore, this study aims to 
clarify four different aspects when freeze-drying lipophilic NPs: 
1) Drug nanosuspensions are solid crystals, while SLNs are solid lipids. Although 
physically different, the lipophilic character and their identical stabilization 
mechanism in aqueous medium point to similar behavior upon freeze-drying. To the 
best of our knowledge, they have never been compared according to their 
freeze-drying behavior. Finding similarities would facilitate formulation and process 
development since findings from one type can be transferred to the other. 
 
2) Buffer type and pH are known to play an important role for stabilization and 
freeze-drying of therapeutic proteins. For example, histidine and sodium phosphate 
buffers are known to cause a pH shift upon freezing affecting stability. Furthermore, 
the ionic strength can have a detrimental effect on freeze-thaw (FT) or freeze-drying 
stability due to charge shielding. However, there is a lack of experimental data in 
case of NPs. Therefore, we evaluated the impact of buffer type, pH, and sodium 
chloride (NaCl) on NP stability during freezing. 
 
3) Besides changing the freezing rate, the freezing step can also be modified by adding 
an annealing step or inducing ice nucleation in a controlled fashion. These 
modifications have a great influence on ice crystal formation. It has been shown that 
the ice-liquid interfacial area leads to enrichment, association and surface-induced 
denaturation of colloids during lyophilization. This obstacle can be addressed by the 
addition of a surfactant [6]. However, to date, the impact of interfacial stress on 





formation on particle aggregation and solid-state properties, freeze-drying was 
performed under three different freezing conditions. 
 
4) Formulations of lipophilic NP formulations are characterized by their high steric 
stabilizer concentration; usually surfactants are used. However, surfactants can have 
a plasticizing effect on amorphous matrices which might impair the storage stability 
of lyophilizates. Thus, we investigated the impact of the surfactants polysorbate 20 
and poloxamer 407 on the glass transition temperature of different formulations. 
Subsequently, selected samples were tested for their storage stability. 
NPs were analyzed with respect to their particle size and number of subvisible particles. 
Lyophilizates were further characterized by Karl-Fischer titration, differential scanning 
calorimetry (DSC), X-ray diffraction (XRD), and BET measurements and were checked for 
macroscopic appearance and reconstitution time. 
 
2 Material and methods 
2.1 Materials 
Sucrose (Sigma-Aldrich, Steinheim, D), D-mannitol (VWR International, Ismaning, D), 
hydroxypropyl-beta-cyclodextrin (Cavasol™ W7 HP, Wacker, Munich, D), poloxamer 407 
(Kolliphor® P 407, BASF, Ludwigshafen am Rhein, D), polysorbate 20 (Tween 20™, Merck, 
Darmstadt, D), and NaCl (Merck, Darmstadt, D) were used to prepare excipient formulations 
at various concentrations. Na-, K-phosphate (all VWR International, Ismaning, D), and Na-
citrate buffers (Merck, Darmstadt, D) were prepared at pH 5 and 8. Paliperidone palmitate 
(Crystal Pharma, Boecillo, Valladolid, E) and trimyristin (Dynasan® 114, Cremer Oleo, 
Witten, D) were used as received. Highly purified water (HPW) was used for the preparation 
of excipient stock solutions and buffers. Solutions were filtered using 0.2 µm 
polyethersulfone membrane syringe filters (VWR International, Ismaning, D). All excipients 
were of analytical or higher grade and were used without further purification. 2R glass vials 
(Schott, Müllheim, D) with according rubber stoppers (igloo, B2–TR coating, West 






2.2.1 Sample preparation 
Paliperidone palmitate nanosuspension 
100 mg/mL of the poorly water-soluble drug paliperidone palmitate (PP) were dispersed in 
with 1% polysorbate 20 (PS20) or poloxamer 407 (P407). The suspensions were sonicated 
for 10 min at 25 °C (Ultrasonic cleaning bath, VWR International, Radnor, PA). After 
sonication the suspensions were comminuted using a high-pressure homogenizer (APV 
Micro Lab 40, Luebeck, D). Two cycles at 500 bar were applied as presteps followed by 
40 cycles at 1,500 bar to obtain a nanosuspension. After homogenization, the drug 
nanosuspension was centrifuged at 10,000 xg on a Heraeus™ Megafuge™ 16R Centrifuge 
(Thermo Fisher Scientific, Waltham, MA) and filtrated with 1.2 μm filter (Minisart®, Sartorius, 
Goettingen, D). Centrifugation was conducted for 1 min for experiments comparing different 
buffer compositions while all other samples were centrifuged for 2 min. The concentration of 
PP was measured according to Trivedi et al. [17] using a spectrophotometer (UV-1600PC, 
VWR International, PA). Briefly, PP was solved after addition of THF, diluted with 
acetonitrile/water (60:40 v/v) and detected at 278 nm. 
Solid lipid nanoparticles (SLNs) 
Dynasan® 114 and 1% PS20 or P407 were separately heated in a water bath at 70 °C. After 
unifying the two phases, the obtained emulsion was mixed using a high-speed homogenizer 
at 17,000 rpm for 1 min (Euro Turrax T20b, IKA Labortechnik, Staufen im Breisgau, D). The 
pre-emulsion was subsequently homogenized in a 70 °C pre-heated high-pressure 
homogenizer (APV Micro Lab 40, Luebeck, D) conducting three cycles at 500 bar. After 
cooling at RT, the resulting SLNs were filtered through a 1.2 µm filter (Minisart®, Sartorius, 
Goettingen, D). 
PP nanosuspensions and SLNs were formulated at 10 mg/mL final particle concentration 
and 0.5% final surfactant concentration. 
2.2.2 Freeze-thaw cycle 
Freeze-thaw (FT) was conducted three times using an FTS LyoStarTM 3 (SP Scientific, Stone 
Ridge, NY). Samples (1 mL in 2 R vials) were frozen at –1 °C/min to –50 °C followed by a 






Lyophilization was performed on an FTS LyoStarTM 3 (SP Scientific, Stone Ridge, NY). 1 mL 
sample in 2R vials was frozen at –1 °C/min to –50 °C and held for 2 h. Primary drying was 
conducted at 0.08 mbar and –35 °C. The endpoint of primary drying was controlled by 
comparative pressure measurement between Pirani gauge and capacity manometer. 
Secondary drying was performed for 8 h at 25 °C and 0.08 mbar. Samples were stoppered 
at 600 mbar nitrogen and sealed with crimp caps. Conventional ramp freezing (RN) was 
modified by adding an annealing step (AN) at –15 °C for 2 h; ramp rates were set to 1 °C/min. 
Controlled nucleation (CN) was performed at –5 °C using an ice fog and subsequent freezing 
at 1 °C/min [18]. 
2.2.4 Dynamic light scattering 
Particle size and polydispersity index (PDI) were measured using a dynamic light scattering 
(DLS) platereader DynaPro II (Wyatt Technology, Dernbach, D). The samples were diluted 
1:1000 in corresponding formulations. 100 μL sample (n=3) per well of a 96 UV-well plate 
(CostarTM, Corning, Glendale, AZ) was analyzed at RT using 10 acquisitions with 5 s each. 
DYNAMICS software (Version 7.8.0.26) was used for data evaluation. The corresponding 
preset refractive index parameters were used for all samples. Viscosities required for DLS 
measurements were determined via an AMVn Automated Micro Viscometer (Anton Paar, 
Graz, A). 
2.2.5 Zeta potential 
Zeta potential measurements were carried out by electrophoretic light scattering using a 
Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Samples without NaCl were 
spiked with 1M NaCl solution to obtain a 10 mM NaCl containing test sample. 
2.2.6 Light obscuration 
Subvisible particles (SVPs) were analyzed by light obscuration (LO) with a PAMAS SVSS-35 
particle counter equipped with a HCB-LD-25/25 sensor (PAMAS - Partikelmess- und 
Analysesysteme, Rutesheim, D). Samples were diluted 1:1000 in the corresponding 
formulation and measured in triplicates. The system was cleaned with 10 mL HPW between 
each analysis. The rinse volume was 0.4 mL, followed by three measurements of 0.3 mL. 





2.2.7 Specific surface area 
The specific surface area (SSA) analysis of freeze-dried samples was determined using 
Brunauer-Emmet-Teller (BET) krypton gas adsorption in a liquid nitrogen bath at 77.3 K 
(Autosorb 1 Quantachrome, Odelzhausen, D). Crushed lyophilizates of 80-100 mg were 
weighed into glass tubes and degassed under vacuum for at least 2 h at RT. An 11-point 
gas adsorption curve was measured from 0.05 to 0.30 relative pressure. Data evaluation 
was performed according to the multi-point BET method fit of the Autosorb 1 software. 
2.2.8 Residual moisture analysis 
The residual moisture (RM) of the lyophilizates was determined by Karl-Fischer titration. 
Measurements were performed using an Aqua 40.00 titrator (Analytik Jena AG, Halle, D) 
equipped with a headspace oven set at 100 °C. Samples of 10-20 mg crushed lyophilizates 
were analyzed in stoppered 2R vials. 
2.2.9 Differential scanning calorimetry 
The lyophilizates were analyzed using a Mettler Toledo differential scanning calorimeter 
(DSC) 822e (Mettler-Toledo GmbH, Giessen, D). Approximately 10 mg of the lyophilized 
samples was analyzed in sealed aluminum crucibles. Samples were heated from 0 to 150 °C 
using a scanning rate of 10 °C/min. Formulation screening studies included modulated DSC 
(mDSC) from 0 °C to 200 °C at 2 °C/min with an amplitude of ± 1 °C every 120 s. The glass 
transition of the maximally freeze-concentrated solution (Tg’) up to –60 °C was measured on 
the Mettler instrument while freezing up to –100 °C was conducted on a Netzsch DSC 204 
Phoenix (Netzsch, Selb, D). Therefore, 20 µL of the liquid samples were cooled at  
–10 °C/min from 20 °C to –60 °C or –100 °C, including a 1 min holding step, and reheated 
at 10 °C/min to 20 °C. The inflection point of the glass transition in the heat heating scan 
was defined as Tg and Tg’. 
2.2.10 X-ray powder diffraction 
The morphology of lyophilizates was measured using X-ray powder diffractometry (XRD). 
Analysis was carried out on an XRD 3000 TT diffractometer (Rich. Seifert & Co. GmbH & 
Co. KG, Ahrensburg, D). The instrument was equipped with a copper anode (40 kV, 30 mA, 
λ=0.154178 nm) and a scintillation detector at 1000 V. Crushed freeze-dried samples were 
smoothened homogenously on copper sample holders at 0.2 mm height. Samples were 





2.2.11 Cake appearance 
Images of representative lyophilizates were taken with a Nikon D5300 camera (Nikon 
GmbH, Düsseldorf, D) in front of a black background. 
2.2.12 Reconstitution time 
The lyophilizates were dissolved by adding the required volume of HPW. The reconstitution 
volume was calculated based on the formulation density and solid content. The time from 
adding HPW to complete disappearance of a solid cake was considered as reconstitution 
time and visually determined. During reconstitution, the vials were gently swirled to ensure 
wetting of the complete lyophilizate. 
2.2.13 Stability studies of lyophilized samples 




3.1 Impact of buffer type, pH, and ionic strength on freeze-thaw stability 
Prior to lyophilization, FT studies were performed to investigate the effect of the formulation 
parameters buffer type, pH, cryoprotectant type, and ionic strength on the colloidal stability 
of PP NPs and SLNs during this initial step of freeze-drying. DLS, LO and zeta potential 
measurements were performed before and after FT. 10 mg/mL Nanosuspensions in 0.5% 
P407 were freeze-thawed three times in 10 mM Na-phosphate, K-phosphate or Na-citrate 
buffer at pH 5 and 8 in combination with 10% mannitol (Man) or 10% sucrose (Suc) or 
















   
Figure 1: DLS and LO measurements of three times freeze-thawed PP NPs and SLNs stabilized 
with 0.5% P407 in 10 mM Na-phosphate, K-phosphate or Na-citrate buffer at pH 5 or 8 
without cryoprotectant or in presence of 10% Man or 10% Suc (n=3). PDI values >0.56 
represent a multimodal size distribution and are therefore stated as ‘1.0’. 
 
After three times FT without a cryoprotectant and in presence of 10% Man particle size and 
PDI of PP NPs drastically increased up to 714 ± 156 nm and 1.0 respectively (Figure 1). A 
PDI of 1.0 indicates a multimodal particle size distribution and thus marked NP aggregation. 
In contrast, particle size and PDI remained stable in presence of 10% Suc. Similar trends 
were observed for SLNs. Without cryoprotectant and in presence of 10% Man the PDI 
increased whereas the mean particle size was not affected by freezing and thawing. SLNs 
formulated with 10% Suc showed comparable size and PDI before and after FT. Buffer type 
and pH did not impact the colloidal stability of PP NPs and SLNs. 
The number of SVPs ≥1 µm was dramatically increased in samples without cryoprotectant 
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compared to SLNs. SVP numbers of PP NPs increased from ~4,000 up to 
~140,000 particles/µL in 10% Man, while SLNs exhibited most SVPs when no 
cryoprotectant was used. In contrast, the number of SVP ≥1 µm did not increase with FT in 
presence of 10% Suc for all investigated buffer types. Additionally, Zeta potential 
measurements revealed surface charges close to neutral independent of the buffer type, 
pH, and cryoprotectant composition (Table 1). 
Table 1: ζ-Potential values of three times freeze-thawed PP NPs and SLNs (n=3). 
ζ-Potential [mV]    
  PP NPs SLNs 
Cryoprotectant Buffer pH before FT after FT before FT after FT 
w/o Na-phos 5 0.6 ± 0.2 0.2 ± 0.1 0.8 ± 0.2 0.3 ± 0.1 
  8 0.7 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 1.5 ± 0.6 
 K-phos 5 0.4 ± 0.1 0.8 ± 0.0 0.8 ± 0.3 0.7 ± 0.4 
  8 1.0 ± 0.0 1.0 ± 0.1 1.5 ± 0.4 1.1 ± 0.4 
 Na-citr 5 0.6 ± 0.1 0.2 ± 0.1 0.8 ± 0.2 1.0 ± 0.2 
  8 1.7 ± 0.1 1.2 ± 0.2 1.7 ± 0.5 1.1 ± 0.3 
10% Man Na-phos 5 0.6 ± 0.1 0.6 ± 0.0 0.3 ± 0.1 0.2 ± 0.1 
  8 0.9 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 1.1 ± 0.2 
 K-phos 5 0.8 ± 0.0 0.8 ± 0.1 0.4 ± 0.0 0.5 ± 0.1 
  8 1.1 ± 0.0 1.0 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 
 Na-citr 5 0.4 ± 0.1 0.4 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 
  8 1.7 ± 0.2 1.3 ± 0.2 1.4 ± 0.0 1.6 ± 0.2 
10% Suc Na-phos 5 0.1 ± 0.0 0.4 ± 0.1 0.2 ± 0.1 0.3 ± 0.2 
  8 0.8 ± 0.0 0.6 ± 0.0 0.9 ± 0.2 1.1 ± 0.2 
 K-phos 5 0.3 ± 0.0 0.2 ± 0.0 0.5 ± 0.2 0.5 ± 0.1 
  8 0.9 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.2 ± 0.2 
 Na-citr 5 0.4 ± 0.0 0.6 ± 0.1 0.7 ± 0.2 0.5 ± 0.0 
  8 1.1 ± 0.2 1.2 ± 0.2 1.5 ± 0.1 1.5 ± 0.1 
 
The impact of ionic strength was investigated by adding 70 or 140 mM NaCl to NPs 
formulated with 0, 2.5, 5 or 10% Suc in combination with 0.5% P407 or PS20. None of the 
PS20 containing formulations of PP NPs was negatively impacted by FT, independent of 
further excipient addition (Figure 2). Also P407 containing formulations showed high 
stability; only when no NaCl and sucrose was added the particle size slightly increased from 
200.6 ± 5.1 nm to 257.1 ± 1.8 nm and the effect was less pronounced in presence of 70 or 
140 mM NaCl whereas particle size and PDI were well preserved by addition of sucrose. In 
contrast, SLNs were less stable compared to PP NPs. Without addition of further excipients, 





formulations. SLNs stabilized by PS20 exhibited a particle size of 595.6 ± 84.6 nm without 
the addition of NaCl and of 464.5 ± 42.1 nm and 302.2 ± 35.4 nm with addition of 70 and 
140 mM NaCl respectively. The SLN size was maintained in formulations containing 
sucrose. Furthermore, higher sucrose concentrations led to less pronounced increase in the 
PDI values for SLNs stabilized by P407; the PDI did not change in PS20 based formulations 











Figure 2: DLS and LO measurements of three times freeze-thawed PP NPs and SLNs stabilized 
with 0.5% PS20 or P407. NPs were formulated with 0, 70 or 140 mM NaCl, without 
cryoprotectant or in presence of 2.5, 5 or 10% Suc (n=3). PDI values >0.56 represent a 
multimodal size distribution and are therefore stated as ‘1.0’. 
 
The formation of larger SVPs was substantially reduced in presence of NaCl and sucrose. 
The PP NPs were in generally less affected by FT than the SLNs. PP NPs did show SVP 
formation in presence of sucrose in PS20 containing formulations; only without sucrose the 
























































































































































































































































































































































800 particles/mL (70 mM NaCl). In P407 containing PP NPs formulations SVPs formed upon 
FT with clear reduction by addition of sucrose or NaCl. SLNs similarly exhibited least SVP 
formation at the highest NaCl and sucrose concentrations. Overall, salt had less positive 
impact on SVP formation than Suc for both NP types. 
Interestingly, PP NPs stabilized by PS20 did not show SVP formation at 140 mM NaCl even 
without a cryoprotectant. DSC measurements showed crystallization of the NaCl-water 
eutectic as indicated by a eutectic melting endotherm upon heating of the frozen solution 
(Figure S-1). This effect was not observed in presence of Suc. Moreover, increasing NaCl 
concentrations led to decreasing Tg’ values in Suc formulations. Similar to the 
aforementioned buffer experiments, the NPs exhibited surface charges of ~0 mV 
independent of the formulation composition (Table S-1). 
3.2 Variation of the freezing step 
3.2.1 Impact on process stability 
In the next step we evaluated the impact of the freezing process itself on NP stability. Three 
different freezing protocols were applied. Conventional ramp freezing (RN) was further 
modified by adding an annealing step at –15 °C (AN) or freezing was performed with 
controlled nucleation at –5 °C (CN). The NPs were lyophilized using a conservative 
freeze-drying cycle. Before primary drying samples were frozen to –50 °C well below Tg’ in 
order to ensure vitrification of the sucrose matrix. Two different surfactant stabilizers (PS20, 
P407) in combination with three different sucrose concentrations (2.5, 5 and 10%) were 
evaluated. 
Before freeze-drying, both NP types exhibited a particle size of approximately 200-250 nm 
and a PDI of ~0.2 (Figure 3). An increasing sucrose concentration led to better NP 
stabilization upon freeze-drying; particle size and PDI of both NP types were best preserved 
in presence of 10% Suc. Additionally, the type of surfactant used for initial particle 
stabilization had a great impact. In 2.5% Suc, PP NPs revealed a PDI < 0.5 in PS20 
formulations as compared to 1.0 in P407 samples. The impact of the surfactant type became 
less pronounced in presence of 5% and 10% Suc. Nevertheless, a lower number of SVPs 
after lyophilization (RN) was achieved by using 1.0% P407 as compared to 0.5% 
(Figure S-2). SLNs stabilized with P407 exhibited less aggregation and a lower PDI 
compared to PS20 formulations at all sucrose levels. Overall, the freezing condition did not 















   
Figure 3: DLS and LO measurements of lyophilized PP NPs and SLNs stabilized with 0.5% PS20 
or P407 in presence of 2.5, 5 or 10% Suc (n=3). Conventional ramp freezing (RN), 
including an annealing step (AN), or under controlled nucleation (CN) was applied. PDI 
values >0.56 represent a multimodal size distribution and are therefore stated as ‘1.0’. 
 
The number of SVPs, reflecting larger NP agglomerates, increased slightly from 
~250 particles/mL up to ~390 particles/mL after freeze-drying in presence of PS20 for PP. 
Surprisingly, the aggregation propensity was not affected by the sucrose concentration. In 
contrast, the number of SVPs drastically increased from ~400 particle/mL up to 
~40,000 particles/mL in P407 formulations with 2.5% Suc. In contrast, SLNs showed higher 
SVP numbers in PS20 containing formulations compared to P407 formulations. In general, 
an increasing sucrose concentration led to decreasing SVP formation except for PP NPs 
stabilized with PS20. The SVP number was furthermore affected by the applied freezing 
condition. Generally, CN led to a lower number of SVPs compared to RN, while AN showed 














































































































































































































































































The SSA of NP lyophilizates formulated with 10% Suc was analyzed in order to investigate 
the impact of the freezing step on the interfacial surface area which is potentially the site of 
NP agglomeration (Table 2). The lyophilizates produced via RN showed the highest, while 
CN samples revealed the smallest SSA. The SSA was slightly higher for PS20 compared to 
P407 containing samples. 
Table 2: SSA of NP lyophilizates in presence of 10% Suc (n=3). 
SSA [m2/g]    
Formulation Freezing step PP NPs SLNs 
PS20 RN 0.97 ± 0.03 0.84 ± 0.04 
 AN 0.78 ± 0.02 0.76 ± 0.05 
 CN 0.50 ± 0.02 0.66 ± 0.04 
P407 RN 0.88 ± 0.04 0.87 ± 0.03 
 AN 0.67 ± 0.04 0.73 ± 0.03 
 CN 0.47 ± 0.01 0.57 ± 0.02 
 
For all freeze-dried samples the RM levels were low (≤0.6%; Figure S-3). In general, CN 
resulted in higher residual moisture contents compared to RN and AN. Furthermore, the 
higher the sugar concentration the higher were the RM levels of the lyophilizates. All 
samples were amorphous according to DSC and XRD measurements independent of the 
freezing condition. 
3.2.2 Impact on macroscopic appearance and reconstitution time 
Cake appearance is an important attribute of freeze-dried products [19]. The lyophilizates of 
both NP types showed a pharmaceutically acceptable cake appearance without 
macroscopic cake collapse at all Suc concentrations. Thus, the cake appearance was not 
affected by the investigated type and concentration of NPs and surfactant. However, CN 
samples showed substantial fogging which is only minor for RN and AN samples (Figure 4). 







 PP NPs SLNs 
 PS20 P407 PS20 P407 
RN 
    
AN 
    
CN 
    
     
Figure 4: Macroscopic appearance of lyophilized NPs in presence of 10% Suc. 
 
All PP lyophilizates instantly dissolved upon reconstitution. As shown in Figure 5, 
reconstitution of lyophilized SLNs was fast in presence of 5% (< 11 s) and 10% Suc (< 6 s). 
The reconstitution time was about 60 s for RN 2.5% Suc samples. Furthermore, the 
reconstitution time could be reduced by applying AN or CN. 
 
 
Figure 5: Reconstitution times of lyophilized SLNs stabilized with PS20 or P407 in presence of 2.5, 
5 or 10% Suc (n=3). Conventional ramp freezing (RN), including an annealing step (AN), 
























































3.3 Thermal properties of lyophilizates 
Prior to stability studies, the Tg of the lyophilizates which is an important parameter limiting 
the storage stability was assessed by DSC. Exemplarily, DSC thermograms of 10% Suc 
lyophilizates are presented in Figure 6. Two glass transition events (Tg1~50 °C, Tg2~60 °C) 
were detected in all formulations, except in SLNs stabilized with PS20. Tg1 was more distinct 
in P407 samples compared to PS20 samples. Furthermore, an exothermic crystallization 
peak (Tc) was found at ~86 °C in PS20 and at ~92 °C in P407 verum and placebo samples. 
In contrast to placebo, SLN and PP lyophilizates exhibited a broad endothermic melting 
event at ~57 °C and ~110 °C respectively. The calorimetric events of the lyophilizates 
formulated with 2.5, 5 or 10% Suc are summarized in Table S-2. Most notably, the lower the 
Suc concentration and thus Suc/surfactant ratio the lower the Tg and Tc values of the 
lyophilizates; e.g. 2.5 and 5% Suc formulations revealed a Tg1 at ~40-45 °C. 




   
Figure 6: Representative DSC profiles of lyophilized SLNs, PP NPs, and placebo formulations in 
presence of 10% Suc and 0.5% PS20 (A) or P407 (B). 
 
Additional DSC measurements of both PS20 and P407 solutions with 10% Suc revealed 
also two Tg’ events at approximately −50 °C and −32 °C, whereas a pure PS20 solution 
showed one broad step in the heat capacity curve at ca. –72 °C (Figure S-4). In comparison, 
a pure P407 solution exhibited one Tg’ at ~–68 °C followed by an exothermic crystallization 
at ~–44 °C and an endothermic melting event at ~–14 °C. 
Since both surfactants contributed to a second glass transition event in both frozen solutions 
and in the lyophilizates, a more detailed screening of freeze-dried placebos by mDSC was 
performed. Pure sucrose lyophilizates revealed one Tg at ~66 °C followed by crystallization 
at ~108 °C independent of the sugar concentration (Figure 7). PS20 containing sucrose 
formulations showed one glass transition at 0.1% PS20 and two glass transitions at 




























































0.5% PS20; Tg values were slightly higher in presence of 10% Suc. 1% PS20 lyophilized 
with 5% Suc resulted in collapsed cakes without detectable thermal events while with 
10% Suc one glass transition at ~47 °C could be detected. P407 formulations revealed two 
glass transitions at all surfactant concentrations in presence of 10% Suc and at 0.1% P407 
in 5% Suc (Tg1~50 °C, Tg2~62 °C). Interestingly, both Tg values were independent of the 
sucrose and surfactant concentration. An endothermic melting peak and one glass transition 
were detected at 0.5% P407 while no glass transition was identified at 1% P407 in 5% Suc. 
All products, except the collapsed 1% PS20 in 5% Suc formulations, exhibited an 
exothermic crystallization event. In general, an increasing sucrose concentration led to an 
increasing Tc value while an increasing surfactant concentration resulted in decreasing 
crystallization temperatures. 




   
Figure 7: Glass transition temperatures (Tg, Tg1, Tg2), crystallization temperatures (Tc), and melting 
temperatures (Tm) of lyophilized placebo formulations in presence of 5 or 10% Suc and 0, 
0.1, 0.5 or 1% PS20 (A) or P407 (B) (n=3). n.d. = not detectable (collapsed cake). 
 
The glass transition at about 50 °C may be critical during storage, especially at elevated 
storage temperatures (e.g. 40 °C) when intending storage at room temperature. Therefore, 
we tested Suc/HP-β-CD mixtures with different surfactant concentrations to obtain 
lyophilizates with higher glass transition temperatures. Residual moisture levels were below 
0.8% in all lyophilizates. The Tg values of lyophilized 1:3 and 1:2 Suc/HP-β-CD samples 
were substantially higher above 100 °C (Figure 8). At a 1:1 Suc/HP-β-CD ratio, the Tg values 
were similar to the pure Suc based formulations. With higher surfactant concentration and 
lower Suc/HP-β-CD ratio the tendency to two glass transition events substantiated and was 
more pronounced with P407 as compared to PS20. Overall, various combinations with Tg 
values above 100 °C and high surfactant concentration could be realized. 
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Figure 8: Glass transition temperatures (Tg, Tg1, Tg2) of lyophilized placebo formulations in presence 
of 5% Suc and 5, 10 or 15% HP-β-CD and 0, 0.5, 1 or 2% PS20 (A) or P407 (B) (n=3). 
 
3.4 Storage stability study 
PP NPs and SLNs formulated with 0.5% PS20 or P407 and 10% Suc, 10% HP-β-CD or 
‘5% Suc + 10% HP-β-CD’ were selected for a storage stability test at 2-8 °C, 25 °C or 40 °C 
for 6 weeks. After reconstitution, samples were analyzed for particle size and particles; solid 
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Figure 9: DLS and LO measurements of lyophilized PP NPs and SLNs stabilized with 0.5% PS20 
or P407 in presence of 10% Suc, 10% HP-β-CD or ‘5% Suc + 10% HP-β-CD’ (n=3). 
Samples were stored for 6 weeks at 2-8 °C, 25 °C or 40 °C. PDI values >0.56 represent 
a multimodal size distribution and are therefore stated as ‘1.0’. n.d. = not detectable 
(reconstitution not possible). 
 
All lyophilizates, except PS20 containing SLNs formulated with 10% HP-β-CD or 
‘5% Suc + 10% HP-β-CD’, instantly (< 5 s) dissolved upon reconstitution. After storage at 
40 °C, the particle size of PP NPs formulated with 10% Suc increased from about 200 nm 
to ~400 nm and to ~300 nm in presence of PS20 and P407 respectively exhibiting PDI 
values of 1.0 (Figure 9). Similarly, SLNs stored at 40 °C revealed drastically increased 
particle sizes in 10% Suc formulations independent of the surfactant type. Furthermore, 
PS20 containing SLNs stored at 25 °C showed an increased particle size of ~400 nm and a 
PDI of 1.0 in presence of 10% Suc while P407 samples remained unchanged. All other NP 





















































































































































































































































































































































































Similar trends were observed for the number of subvisible particles. In general, the number 
of particles ≥1 μm did not change upon storage at 2-8 °C and 25 °C independent of NP type 
and formulation composition, except for PS20 containing SLNs formulated with 10% Suc 
and stored at 25 °C. All samples formulated with 10% Suc revealed dramatically increased 
SVP numbers after storage at 40 °C. Aggregation at 40 °C could be substantially reduced 
or even prevented in HP-β-CD containing formulations. Directly after lyophilization, P407 
stabilized PP NPs showed a higher number of SVPs in 10% HP-β-CD compared to 10% Suc 
and ‘5% Suc + 10% HP-β-CD’ formulations, although particle numbers were similar prior to 
lyophilization. 
The calorimetric events of 10% Suc lyophilizates are summarized in Table 3. Thermograms 
of PP lyophilizates remained unchanged after storage at 2-8 °C (Figure 10). Only one glass 
transition at ~51 °C (PS20) or ~62 °C (P407) was observed in samples stored at 25 °C and 
no Tg and Tc were detected after storage at 40 °C. P407 samples revealed an endotherm at 
~56 °C after storage at 25 °C and 40 °C. In general, SLN lyophilizates exhibited a broad 
endotherm at ~58 °C hindering the detection of further glass transitions and revealed no Tc 
after storage at 40 °C. Furthermore, the Tc was lower in samples stored at 25 °C compared 
to samples stored at 2-8 °C. 




   
Figure 10: Representative DSC profiles of lyophilized PP NPs stored for 6 weeks at 2-8 °C, 25 °C or 

































































Table 3: Calorimetric events of NP lyophilizates formulated with 0.5% PS20 or P407 and 10% Suc 




Tg1 [°C] Tm [°C] Tg2 [°C] Tc [°C] Tm [°C] 
PS20 PP NPs 2-8 48.8 ± 0.3 - 57.1 ± 0.3 83.4 ± 0.7 104.6 ± 0.1 
  25 50.7 ± 4.1 - - 76.0 ± 3.8 104.3 ± 0.3 
  40 - - - - 107.1 ± 0.2 
 SLNs 2-8 - 56.2 ± 0.3 - 86.9 ± 3.8 - 
  25 - 56.2 ± 0.4 - 75.8 ± 5.1 - 
  40 - 56.3 ± 0.5 - - - 
P407 PP NPs 2-8 45.6 ± 2.5 - 61.4 ± 2.1 92.1 ± 0.9 107.0 ± 0.1 
  25 - 55.9 ± 0.2 61.8 ± 0.3 90.0 ± 0.6 106.8 ± 0.1 
  40 - 57.2 ± 0.2 - - 110.4 ± 0.1 
 SLNs 2-8 41.6 ± 0.5 58.3 ± 0.6 64.1 ± 1.3 90.3 ± 1.9 - 
  25 41.9 ± 0.6 58.1 ± 3.1 63.5 ± 2.2 87.8 ± 1.9 - 
  40 - 56.8 ± 0.6 - - - 
 
Thermograms of HP-β-CD containing lyophilizates were characterized by one glass 
transition. After storage, PP NPs lyophilized with 10% HP-β-CD showed Tg values ≥170 °C 
while SLN formulations revealed Tg values ≥140 °C (Table S-3). In comparison, PP NPs and 
SLNs lyophilizates with ‘5% Suc + 10% HP-β-CD’ revealed Tg values of ≥120 °C and 
≥110 °C respectively. Tg values remained unchanged in samples stored at 2-8 °C and only 
slightly decreased after storage at 25 °C or 40 °C.  
Upon storage RM levels remained ≤0.9% in ‘5% Suc + 10% HP-β-CD’ and in 10% Suc 
formulations, but slightly increased up to 1.4% for 10% HP-β-CD samples, most pronounced 
upon 40 °C storage (Table S-4). After storage, all samples formulated with HP-β-CD 
remained fully amorphous according to XRD measurements (Figure S-5). Lyophilizates 
formulated with 10% Suc and stored at 2-8 °C or 25 °C resulted in fully amorphous solids 













Figure 11: XRD patterns of lyophilized PP NPs and SLNs stabilized with 0.5% PS20 or P407 and 
formulated with 10% Suc. Samples were stored for 6 weeks at 2-8 °C, 25 °C or 40 °C. 
 
4 Discussion 
4.1 Formulation aspects 
Several stresses are known to affect NP stability during freeze-drying. The freezing step is 
considered to be the more aggressive step of lyophilization [20] and includes mechanical 
stress by ice crystals, cryo-concentration resulting in increased particle-particle interactions, 
potential phase separation or interactions at the ice-water interface [3]. 
Since the formulation composition is assumed to have the greatest impact on NP stability 
upon freeze-drying [14], FT studies were conducted prior to lyophilization to systematically 
evaluate previously neglected formulation parameters still lacking from comprehensive 
studies including buffer type, pH and ionic strength, in combination with different 
cryoprotectants. 
The impact of buffer type and pH was investigated using NPs stabilized with P407 which 
served as a model for non-ionic surfactants. Na-phosphate is known to cause an acidic pH 
shift upon freezing thereby destabilizing colloids [7]. Therefore, we compared Na-phosphate 
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with K-phosphate and Na-citrate buffers which maintain their pH during freezing [5,21]. The 
buffer type and pH were found to have a negligible effect on FT stability which can be 
attributed to the NP properties. Both, PP NPs and SLNs are stabilized by surfactants which 
are essentially needed for the nanonization of lipophilic compounds in liquid state. Non-ionic 
surfactants provide steric stabilization for lipophilic particles and result in particles with close 
to neutral surface charge which we confirmed by zeta-potential measurements. The surface 
charge was independent of the formulation pH explaining minor effects of the pH shift on 
particle stability in Na-phosphate buffer. 
The addition of cryo- and lyoprotectants is usually necessary to accomplish sufficient 
stabilization of colloids during freezing and freeze-drying. We tested the impact of sucrose 
and mannitol on NP stability upon FT. Both NP types were well preserved in presence of 
10% Suc while particle size, PDI and SVP numbers were increased in 10% Man and in 
formulations without a cryoprotectant. The increase in number of SVPs is mainly attributed 
to aggregation and/or crystal growth of NPs resulting in microparticles. These processes 
may be triggered by the high NP concentration in the freeze concentration and the NP 
enrichment the freeze-concentrate ice interface. 
Sucrose forms an amorphous matrix while mannitol is known to at least partially crystallize 
upon freezing [7,22]. Thus, our study indicates that immobilization of particles in a fully 
vitrified matrix is crucial for sufficient NP stabilization. The particle isolation hypothesis, 
vitrification hypothesis and increased solution viscosity during freezing all explain the 
cryoprotective effect (i.e. polyplexes, liposomes, lipoplexes) [23–25]. The particle isolation 
theory states that separation of individual particles within the unfrozen fraction is crucial for 
NP stabilization. The vitrification theory is related to viscosity effects during freezing and 
states that sugar solutions become highly viscous cryo-concentrates and form a stable 
glassy matrix preventing aggregation through immobilization of particles. 
Interestingly, the NaCl concentration significantly influenced the FT stability of PP NPs and 
SLNs. The addition of NaCl led to decreasing SVP numbers, especially without addition of 
a cryoprotectant and at low sucrose concentrations. NaCl is known to destabilize colloids 
due to the reduction of the surface potential facilitating attractive interactions. However, in 
our study, NPs exhibited a neutral surface charge making charge driven effects unlikely. 
DSC measurements revealed eutectic melting of NaCl in absence of sucrose indicating a 
preceded crystallization during freezing. Thus, salt crystals might serve as a spacer 
separating NPs. Addition of NaCl to sucrose solutions caused a Tg’ reduction as also 
reported previously [26,27]. According to Her et al., NaCl leads to an increasing quantity of 





increase in cryoconcentrate volume, corresponding to a lower NP concentration and thus 
larger NP distance, has a positive effect on particle-particle interaction is up to speculation. 
The study demonstrates that the type of surfactant used for particle stabilization has the 
greatest impact on the formation of SVPs upon NP lyophilization. In case of PP NPs, PS20 
was superior to P407 at lower sucrose concentrations whereas SLNs were best preserved 
in P407 formulations. The suitability of a surfactant for NP stabilization is still not well 
understood and is typically determined experimentally for each NP type. In a screening 
study, van Eerdenbrugh et al. evaluated the efficiency of different stabilizers to produce 
stable nanosuspensions of nine model compounds [28]. Typical physicochemical properties 
such as molecular weight, melting point, log P, solubility and density of a drug substance 
were not able to explain stabilization mechanisms and interactions between particles and 
stabilizers including surfactants. However, they could show that higher stabilizer 
concentrations in general improved NP production and subsequent stability which was 
further seen in lyophilization experiments by Beirowski et al. [14]. Our results propose that 
an insufficient steric stabilizer concentration could be well compensated by a higher 
concentration of cryoprotectant. Thus, recommendations in literature have to be taken with 
a grain of salt; in presence of sufficient other stabilizers, e.g. much sugar as cryoprotectant, 
a detailed surfactant effect may not be noticeable whereas without an adequate stabilizer 
the effect may be drastic. 
4.2 Process aspects 
Three different freezing conditions were compared in order to investigate the impact of the 
freezing step on NP stability. AN showed no clear impact on SVP formation. In contrast, CN 
led to a lower number of SVPs compared to RN indicating surface-induced destabilization 
of NPs at the ice-water and/or solid-air interface during freezing and/or drying. During 
lyophilization, ice crystals are removed by sublimation, and the interface between the solid 
and the voids left behind contribute to the SSA of the lyophilizate [29]. BET measurements 
confirmed that CN led to the smallest solid-ice interface due to a low degree of supercooling 
which leads to large ice crystals [30]. In contrast, RN led to the formation of smaller ice 
crystals and thus larger SSA. Ostwald ripening by annealing fostered ice crystal growth 
resulting in a larger SSA compared to CN samples, but smaller than RN samples. 
The ice-water interfacial area is known to destabilize colloids leading to aggregation. As 
shown for proteins, aggregation depends on the nucleation temperature which determines 
the ice surface area. Aggregation can be inhibited by the addition of surfactants mainly by 





[6,31]. Since unfolding is not relevant for NPs, the closer vicinity of NPs in the 
cryo-concentrated state at the interface appears to foster aggregation. Beirowski et al. 
demonstrated that higher steric stabilizer concentrations substantially improved the 
lyophilization success of drug nanosuspensions [14]. Concluding from our study and 
literature reports, the interfacial area, the steric stabilizer type and concentration and the NP 
aggregation propensity affect aggregation during the freezing step. 
Overall all cakes were pharmaceutically elegant. Annealing resulted in a reduction of cracks 
as it allows the unfrozen fraction to relax resulting in a glass with lower excess free volume 
and decreased internal stress [32,33]. Furthermore, Ostwald ripening leads to a more 
uniform ice structure and favors a homogeneous ice distribution [34,35]. Interestingly, 
substantial vial fogging was observed which can be a critical cosmetic defect and may 
endanger container closure integrity [36,37]. Vial fogging is caused by Marangoni flow driven 
by a surface tension gradient. The high amount of the mandatory surface-active component 
in lipophilic NP formulations facilitates this process. Deposition and partial melting of ice 
crystals at the vial inner surface upon CN via an ‘ice fog’ technique might additionally foster 
creeping of unfrozen components. However, this mechanism needs to be confirmed in future 
studies. The most robust approach to eliminate vial fogging is by using vials with a 
hydrophobic inner surface [37,38]. 
4.3 Storage stability aspects 
The Tg of lyophilizates is one of the major determinants of storage stability [7] and was 
therefore systematically assessed with DSC. The exothermic event observed in all 
formulations is attributable to sucrose crystallization while the endotherm in PP lyophilizates 
is related to API melting [39]. The endotherm in P407 samples is referred to P407 melting 
(Tm = 52-57 °C [40]). Lyophilizates of SLNs, showed an endotherm at approximately 57 °C 
due to melting of the triglyceride [41]. 
The presence of a surfactant has a substantial impact on the thermal properties of 
lyophilizates. Numerous formulations showed two glass transition events. The detection of 
two Tg’s was previously reported by Abdul-Fattah et al. for 5% Suc + 0.2% Poloxamer 188 
and indicates a phase separation with a surfactant-rich and a surfactant-poor phase [42]. 
Freezing polymer solutions may cause phase separation since the polymer solubility is 
altered at low temperatures [7]. This may cause destabilization of the entity in need of 
protection if the stabilizer gets separated [4]. DSC measurements of a sucrose solution 
confirmed that the investigated surfactants contribute to phase separation and a second 





phase due to the surfactants’ plasticizing effect. It is recommended that lyophilizates should 
have a Tg value 20 °C above the intended storage temperature to minimize mobility [43]. 
Referring to this recommendation, the low Tg1 at about 50 °C is assumed to impair the 
storage stability of lyophilizates at room temperature. 
Screening studies with placebo formulations were conducted to elucidate the impact of the 
sucrose and PS20/P407 concentration on the thermal behavior of lyophilizates. Surfactant 
concentrations up to 1.0% are used in commercial drug nanosuspensions (INVEGA 
SUSTENNA®: 1.2% PS20) and were therefore included in the screening study. A 
decreasing sucrose/surfactant mass ratio led to phase separation, and decreasing Tc and 
Tg values which is attributed to the plasticizing effect of the surfactants. A correlation 
between Tg and Tc of sucrose was already reported in previous studies [41]. As a 
consequence of partially overlapped calorimetric events (e.g. 5% Suc/1.0% P407), the Tc 
value of sucrose gains importance for the evaluation of thermograms and may be used as 
a surrogate for Tg. 
Previously, formulations with Suc/HP-β-CD were reported to be superior to pure Suc 
formulations regarding the long-term storage stability of lyophilized proteins at 40 °C due to 
a high Tg [45]. Therefore, we evaluated Suc/HP-β-CD mixtures in presence of high 
PS20/P407 concentrations. Without surfactant addition, the mixture of HP-β-CD and Suc 
revealed one glass transition reflecting a miscible amorphous matrix. In presence of the 
investigated surfactants, a lower Suc/HP-β-CD mass ratio suppressed the formation of a 
second phase which may be highly beneficial for stability of NP products.  
Overall, 10% Suc formulations showed good stability upon storage at 2-8 °C and generally 
acceptable stability at 25 °C. The lyophilizates, however, exhibited poor stability at 40 °C 
which is attributed to sucrose crystallization impairing NP protection in the amorphous 
matrix. We were able to overcome this limited storage stability for both NP types by the 
addition of HP-β-CD. In general, a Suc/HP-β-CD mixture was superior to pure HP-β-CD; the 
disaccharide molecules are more flexible than larger oligosaccharides (i.e. HP-β-CD) and 
therefore better stabilizers for lyophilization [46]. Thus, mixtures of disaccharides with oligo- 
or polysaccharides may benefit from sufficient stabilization and high Tg values improving 
storage stability. A minor increase of the SVP number after storage suggests that rather a 
kinetic than a thermodynamic stabilization is provided with reduced but still residual risk of 
aggregation and/or crystal growth over time. Based on this study, we further assume that 
the aggregation propensity of SLNs stored at 40 °C is related to the melting characteristics 
of the triglyceride. Trimyristin has a melting onset at approximately 50 °C concluding that 
rather Tm than Tg is the stability limiting factor for this NP type. The Tm of lipids is known to 





contributing to the low stability at 40 °C. These aspects and means to overcome this obstacle 
would be of high interest for further studies. 
Overall, we were able to confirm that the model drug nanosuspension and SLNs share basic 
formulation, process, and storage considerations leveraging purposeful lyophilization 
development of these lipophilic NP types. 
 
5 Conclusion 
We investigated crucial aspects for successful lyophilization of lipophilic NPs including 
formulation, process, and storage strategies, i.e. i) comparability of different particle types, 
ii) impact of buffer type, pH, and ionic strength, iii) impact of the freezing step, iv) impact of 
the surfactants PS20 or P407 on the glass transition temperature of lyophilizates. 
PP NPs and SLNs exhibited comparable freezing and lyophilization behavior. At first 
detailed FT studies were performed. Sucrose better stabilized NPs compared to mannitol 
emphasizing the importance of a fully amorphous matrix. We further demonstrated that the 
buffer composition and pH are negligible when NPs are stabilized with an adequate amount 
of non-ionic steric stabilizer. Lyophilization studies revealed surface-induced destabilization 
of NPs which can be addressed by the surfactant type and concentration and the sucrose 
concentration. The combined view on both excipient types is important e.g. an inappropriate 
steric stabilizer selection can be well compensated by increasing the cryoprotectant 
concentration. The surfactant/cryoprotectant mass ratio highly affected the storage stability 
of both PP NPs and SLNs. The steric stabilizer concentration is crucial since it determines 
the Tg and might induce phase separation resulting in a phase of higher mobility. In that 
respect lower surfactant concentrations are beneficial. Suc/HP-β-CD mixtures were even 
more suitable to sufficiently protect NPs upon lyophilization and provide a high Tg improving 
long-term storage stability. Furthermore HP-β-CD can reduce the phase separation effect of 
high PS20/P407 concentrations. 
In conclusion, we successfully lyophilized drug nanosuspensions and SLNs revealing 
important lyophilization principles. Lyophilization of NPs offers improved storage stability 
and facilitates shipping of temperature sensitive nanomedicine. The cryoprotectant and 
surfactant type and concentration are crucial for NP stability. Especially optimization of the 







6 Supplementary Data 
 
Table S-1: ζ-Potential values of three times freeze-thawed PP NPs and SLNs (n=3). 
ζ-Potential [mV]       
  PP NPs    SLNs    
  PS20  P407  PS20  P407  
NaCl [mM] Suc [%] before FT after FT before FT after FT before FT after FT before FT after FT 
0 0 3.2 ± 1.9 2.9 ± 0.4 -1.0 ± 1.2 -1.9 ± 0.4 -2.8 ± 0.2 -2.9 ± 0.3 -1.8 ± 0.4 -1.6 ± 0.3 
2.5 2.9 ± 0.2 2.9 ± 0.2 -0.7 ± 0.4 -0.9 ± 0.2 -1.1 ± 0.3 -1.9 ± 0.9 -2.0 ± 0.9 -1.9 ± 0.7 
5 2.3 ± 1.4 2.6 ± 0.0 -0.2 ± 0.2 -0.6 ± 0.0 -1.9 ± 0.3 -1.6 ± 0.8 -1.2 ± 0.4 -1.2 ± 0.2 
10 2.2 ± 1.2 2.2 ± 0.9 -1.1 ± 0.7 -1.2 ± 0.9 -1.3 ± 0.5 -1.6 ± 0.3 -1.7 ± 0.2 -1.2 ± 0.6 
70 0 2.4 ± 0.9 2.3 ± 0.5 -1.7 ± 0.4 -1.3 ± 0.5 -1.9 ± 0.3 -2.3 ± 0.7 -1.7 ± 0.4 -1.9 ± 0.7 
2.5 2.7 ± 0.2 2.3 ± 1.1 -1.0 ± 0.5 -1.7 ± 1.1 -1.9 ± 0.5 -2.0 ± 0.7 -1.1 ± 0.2 -1.4 ± 0.8 
5 2.6 ± 0.8 2.8 ± 0.2 -1.3 ± 0.5 -1.8 ± 0.2 -1.6 ± 0.3 -1.4 ± 0.8 -1.5 ± 0.5 -1.8 ± 0.2 
10 2.5 ± 0.6 2.0 ± 0.2 -1.2 ± 0.5 -2.0 ± 0.2 -1.2 ± 0.5 -1.5 ± 0.5 -1.2 ± 0.5 -1.7 ± 0.9 
140 0 2.9 ± 0.2 2.2 ± 1.0 -0.0 ± 0.6 -2.2 ± 1.0 -1.6 ± 0.1 -1.9 ± 0.5 -1.0 ± 0.5 -1.4 ± 0.9 
2.5 2.5 ± 1.1 2.1 ± 0.1 -1.5 ± 1.0 -1.5 ± 0.1 -1.6 ± 0.3 -1.4 ± 0.4 -1.7 ± 0.3 -1.8 ± 0.2 
5 2.4 ± 0.6 2.2 ± 1.1 -0.1 ± 1.0 -0.1 ± 1.1 -1.1 ± 1.0 -1.8 ± 0.2 -1.8 ± 0.3 -1.4 ± 0.6 






Figure S-1: Representative DSC profiles of sucrose solutions (0, 2.5, 5, or 10%) in absence or 
presence of 0, 70, or 140 mM NaCl. 
 
 


































Figure S-2: LO measurements of lyophilized PP NPs stabilized with 0.5% or 1.0% P407 in 









   
Figure S-3: Residual moisture levels of lyophilized PP NPs (A) and SLNs (B) stabilized with PS20 
or P407 in presence of 2.5, 5 or 10% Suc (n=3). Conventional ramp freezing (RN), 













































































































   
Figure S-4: Representative DSC profiles of PS20 (A) and P407 (B) solutions in absence or 
presence of 10% Suc. 
 
 
Table S-2: Calorimetric events of NP lyophilizates formulated with 0.5% PS20 or P407 and 2.5, 
5, or 10% Suc (n=3). 
Formulation Suc [%] Tg1 [°C] Tm [°C] Tg2 [°C] Tc [°C] Tm [°C] 
PS20 PP NPs 2.5 43.5 ± 1.0 - 50.6 ± 0.4 66.4 ± 1.4 108.1 ± 1.3 
  5 42.8 ± 1.6 - 55.6 ± 2.2 78.3 ± 0.8 105.6 ± 0.5 
  10 49.8 ± 3.8 - 60.0 ± 2.5 86.2 ± 4.5 105.1 ± 0.6 
 SLNs 2.5 42.2 ± 1.9 57.3 ± 0.3 - 66.7 ± 1.4 - 
  5 45.0 ± 1.8 56.7 ± 0.2 - 71.2 ± 2.9 - 
  10 - 57.5 ± 1.6 - 87.5 ± 3.7 - 
 Placebo 2.5 41.0 ± 3.7 - 57.3 ± 4.5 72.1 ± 2.8 - 
  5 46.5 ± 1.1 - 56.9 ± 0.3 79.1 ± 0.8 - 
  10 49.9 ± 1.3 - 59.6 ± 0.9 85.6 ± 0.9 - 
P407 PP NPs 2.5 45.5 ± 1.8 54.6 ± 0.3 - 64.7 ± 1.9 111.2 ± 1.3 
  5 - 53.9 ± 0.6 62.5 ± 0.1 83.9 ± 1.6 108.2 ± 0.1 
  10 47.8 ± 4.3 - 64.0 ± 1.1 91.3 ± 1.4 107.3 ± 0.2 
 SLNs 2.5 40.0 ± 0.8 57.4 ± 0.3 - 76.6 ± 1.0 - 
  5 41.1 ± 1.3 57.6 ± 0.4 - 86.0 ± 2.6 - 
  10 42.0 ± 0.6 59.3 ± 0.9 66.3 ± 3.0 94.1 ± 2.2 - 
 Placebo 2.5 - 52.5 ± 1.6 - 75.8 ± 1.5 - 
  5 - 53.4 ± 0.4 63.7 ± 1.1 85.9 ± 0.7 - 
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Table S-3: Glass transition temperatures (Tg) of HP-β-CD containing lyophilizates directly after 
freeze-drying (after FD) and after 6 weeks storage at 2-8 °C, 25 °C or 40 °C (n=3). 
Formulation Tg [°C]    
 after FD  2-8 °C 25 °C 40 °C 
PS20 PP NPs 10% HP-β-CD 185.7 ± 0.8 178.4 ± 1.4 175.9 ± 0.6 171.8 ± 2.1 
  
5% Suc + 10% 
HP-β-CD 
132.4 ± 5.9 130.0 ± 3.5 125.1 ± 3.1 122.6 ± 2.3 
 SLNs 10% HP-β-CD 159.8 ± 2.8 157.8 ± 2.1 153.8 ± 1.5 151.9 ± 3.7 
  
5% Suc + 10% 
HP-β-CD 
119.6 ± 3.8 120.1 ± 3.5 116.6 ± 5.6 114.9 ± 5.9 
P407 PP NPs 10% HP-β-CD 180.5 ± 3.5 179.8 ± 0.7 171.3 ± 4.5 171.7 ± 5.4 
  
5% Suc + 10% 
HP-β-CD 
130.8 ± 1.0 131.5 ± 2.8 126.0 ± 4.5 125.7 ± 3.2 
 SLNs 10% HP-β-CD 154.2 ± 2.0 154.6 ± 2.3 145.7 ± 6.4 141.7 ± 3.6 
  
5% Suc + 10% 
HP-β-CD 





Table S-4: Residual moisture levels) of lyophilizates directly after freeze-drying (after FD) and 
after 6 weeks storage at 2-8 °C, 25 °C or 40 °C (n=3). 
RM [%]     
 after FD  2-8 °C 25 °C 40 °C 
PS2
0 
PP NPs 10% Suc 0.5 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.0 ± 0.0 
  10% HP-β-CD 0.8 ± 0.0 1.1 ± 0.1 1.1 ± 0.3 1.4 ± 0.3 
  5% Suc + 10% HP-β-CD 0.6 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.9 ± 0.2 
 SLNs 10% Suc 0.4 ± 0.1 0.6 ± 0.1 0.8 ± 0.1 0.2 ± 0.0 
  10% HP-β-CD 0.7 ± 0.1 0.9 ± 0.0 1.1 ± 0.3 1.3 ± 0.1 
  5% Suc + 10% HP-β-CD 0.5 ± 0.0 0.5 ± 0.0 0.6 ± 0.0 0.9 ± 0.1 
P407 PP NPs 10% Suc 0.4 ± 0.0 0.6 ± 0.1 0.6 ± 0.1 0.0 ± 0.0 
  10% HP-β-CD 0.7 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.3 
  5% Suc + 10% HP-β-CD 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.2 0.8 ± 0.1 
 SLNs 10% Suc 0.3 ± 0.1 0.9 ± 0.0 0.9 ± 0.1 0.0 ± 0.0 
  10% HP-β-CD 0.8 ± 0.1 1.1 ± 0.4 1.1 ± 0.2 1.3 ± 0.1 








A  B 
   
   
Figure S-5: XRD patterns of lyophilized PP NPs (A) and SLNs (B) stabilized with 0.5% PS20 or 
P407 and formulated with 10% HP-β-CD or ‘5% Suc + 10% HP-β-CD’. Samples 
were stored for 6 weeks at 2-8 °C, 25 °C or 40 °C. 
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Extracellular vesicles (EV) are an emerging technology as immune therapeutics and drug 
delivery vehicles. However, EVs are usually stored at −80 °C which limits potential clinical 
applicability. We therefore studied freeze drying of EVs striving for long-term stable 
formulations. The most appropriate formulation parameters were identified in freeze-thawing 
studies with two different EV types. After a freeze-drying feasibility study, four lyophilized EV 
formulations were tested for storage stability up to 6 months. Freeze-thawing studies revealed 
improved EV stability in presence of sucrose or potassium phosphate buffer instead of sodium 
phosphate buffer or phosphate buffered saline. Less aggregation and/or vesicle fusion 
occurred at neutral pH compared to slightly acidic or alkaline pH. EVs could be most 
effectively preserved by addition of low amounts of poloxamer 188. Polyvinyl pyrrolidone 
failed to preserve EVs upon freeze-drying. Particle size and concentration of EVs was 
retained over 6 months at 40 °C in lyophilizates containing 10 mM K- or Na-phosphate buffer, 
0.02% poloxamer 188 and 5% sucrose. The biological activity of encapsulated beta 
glucuronidase was maintained for 1 month, but decreased after 6 months. Here we present 








extracellular vesicles, outer membrane vesicles, freeze-thawing, freeze-drying, long-term 
stability, particle preservation, stability testing 
Abbreviations 
β-Glu Beta glucuronidase 
DLS Dynamic light scattering 
DSC Differential scanning calorimetry 




OMVs Outer membrane vesicles 
PDI Polydispersity index 
P188 Poloxamer 188 
PS20 Polysorbate 20 
PBS Phosphate buffered saline 
RM Residual moisture 
RT Room temperature 
Suc Sucrose 
SVP Subvisible particle 
Tg Glass transition temperature of the freeze-dried cake 
Tg’ Glass transition temperature of the freeze-concentrated solution 








Table of Contents 
Abstract ............................................................................................................................ 112 
Keywords ......................................................................................................................... 113 
Abbreviations .................................................................................................................... 113 
1 Introduction ................................................................................................................ 115 
2 Results ...................................................................................................................... 117 
2.1 Freeze-thawing studies ..................................................................................... 117 
2.1.1 Impact of buffer type, pH and ionic strength ........................................ 117 
2.1.2 Impact of sucrose and surfactant ........................................................ 121 
2.2 Lyophilization of EVs ........................................................................................ 123 
2.3 Long-term stability of lyophilized EVs ............................................................... 125 
2.3.1 Colloidal stability of lyophilized EVs .................................................... 126 
2.3.2 Biological activity of encapsulated β-Glu ............................................. 129 
3 Discussion ................................................................................................................. 130 
4 Conclusion ................................................................................................................. 136 
5 Experimental Section ................................................................................................. 137 
5.1 Materials ........................................................................................................... 137 
5.2 Methods............................................................................................................ 138 
5.2.1 Cell culture .......................................................................................... 138 
5.2.2 Bacterial culture .................................................................................. 138 
5.2.3 FACS of RO EVs ................................................................................ 139 
5.2.4 Beta glucuronidase encapsulation....................................................... 139 
5.2.5 Size exclusion chromatography .......................................................... 140 
5.2.6 Beta glucuronidase assay ................................................................... 140 
5.2.7 Cryo-TEM ........................................................................................... 140 
5.2.8 Formulation preparation ...................................................................... 141 
5.2.9 Freeze-thawing cycle .......................................................................... 141 
5.2.10 Freeze-drying cycle ............................................................................. 141 
5.2.11 Long-term stability testing of lyophilized samples ................................ 142 
5.2.12 Dynamic light scattering ...................................................................... 142 
5.2.13 Tunable resistive pulse sensing .......................................................... 142 
5.2.14 Subvisible particles ............................................................................. 143 
5.2.15 Nanoparticle tracking analysis ............................................................. 143 
5.2.16 Karl-Fischer Titration ........................................................................... 143 
5.2.17 Differential scanning calorimetry ......................................................... 143 
5.2.18 Statistical analysis ............................................................................... 144 
6 Supporting Information .............................................................................................. 144 






Lyophilization is a commonly used method to achieve stable biopharmaceutical products [1]. 
Substantial literature is available on freeze-drying of protein biopharmaceuticals, whereas 
knowledge about lyophilization of nanoparticulate biopharmaceuticals like vaccines, viruses 
or polyplexes is limited [2]. Due to their different particle properties, nanoparticulate systems 
require different colloidal and chemical stabilization mechanisms which increases 
lyophilization complexity. 
EVs are nanoparticles produced by cells from all branches of the phylogenetic tree. They are 
surrounded by a lipid-membrane that contains transmembrane proteins. In their lumen EVs 
can contain a plethora of biomolecules, such as proteins, RNA and DNA [3]. Depending on 
the producing species, the mechanism of their assembly and the composition of their 
membrane differs. Mammalian cells produce two main variants of EVs, exosomes derived 
from multivesicular bodies and microvesicles produced directly by blebbing from the cell-
surface [4]. EVs derived from gram-negative bacteria, the so-called outer membrane vesicles 
(OMVs), are produced by blebbing from the bacterial outer membrane [5]. EVs can 
successfully deliver functional cargo for intercellular communication [6]. This cargo is 
encapsulated in EVs and can be composed of proteins and nucleic acids. EVs are therefore 
intensely investigated as therapeutics [7,8], drug-delivery vehicles [9] and biomarkers for 
various diseases [10–12]. However, to be viable alternatives to established treatment-options 
and to allow for their broad use in clinical settings, many hurdles still need to be 
overcome [13,14]. Besides the reproducibility of their production and purification, storage 
stability is a big challenge [15,16]. EVs may be relatively stable in liquid state for a few weeks 
at room temperature [17,18]; still, clinical use would require extended shelf life. Since physical 
and biological stability is typically rather limited to a shorter time period, the International 
Society of Extracellular Vesicles recommends storage at –80 °C in phosphate buffered saline 
(PBS) [19]. However, this storage condition is unfavorable in terms of energy consumption, 
transportation and most importantly clinical application. In general, freezing-thawing (FT) is 
considered to destabilize EVs, e.g. by changing EV morphology, function, particle size and 
concentration [20–24]. EV stability differs by vesicle source and potentially the preparation 
method [25]. Pieters et al. demonstrated that milk-derived EVs are highly stable upon FT 
while the number of macrophage-derived vesicles was significantly reduced [26–29]. 
Freeze-drying of EVs could accelerate research and offers long-term stabilization which is an 
important step towards their application as therapeutics. Moreover, lyophilizates offer new 
options for administration routes, e.g. pulmonary delivery. Nevertheless, lyophilization 
increases stress during freezing and drying, which can result in EV damage unless 





crystal formation of ice or excipient, exposure to ice-liquid interfaces [31], pH shifts due to 
partial buffer salt precipitation [32–34], and cryo-concentration of the vesicles as well as all 
solutes, leading to a particle-rich phase with increased ionic strength [30,31,35]. During 
drying, the dehydration of the EVs affects their stability. Damage on lyophilized vesicles may 
also result upon rehydration e.g. with swelling of the amphiphilic molecules forming the 
vesicle bilayer or osmotic effects. 
Frank et al. investigated the stability of different types of EVs during lyophilization [36]. 
Particle numbers of lyophilized EVs decreased compared to EVs stored at 4 °C or –80 °C 
indicating particle loss or aggregation. They also found a cell type specific freeze-drying 
behavior. When comparing different cryoprotective agents, trehalose was found to be 
superior to mannitol and polyethylene glycol 400. In earlier studies, it was already shown that 
trehalose is able to protect EVs from freeze-thawing stress [37]. Charoenviriyakul et al. also 
examined the impact of trehalose on aggregation and the biological activity of lyophilized 
exosomes [38]. Lyophilization with 50 mM trehalose had no impact on biological activity and 
polydispersity compared to samples stored at –80 °C. A possible damage already taking 
place during freezing to –80 °C was not considered. Although lyophilization of EVs seems to 
be feasible, there is no comprehensive study on their long-term stability. 
Most EV formulations are based on PBS which is known to be critical upon freezing and 
lyophilization of biopharmaceuticals. During freezing, phosphate buffers cause an acidic pH 
shift which destabilizes proteins [1]. This effect might be relevant for surface and/or 
membrane proteins of EVs. In addition, the pH shift affects the zeta potential and thus the 
colloidal interactions of EVs [39]. Furthermore, the high ionic strength in PBS might foster 
particle aggregation shielding repulsive charge-based interactions of EVs. To the best of our 
knowledge, these effects have not been elucidated yet. 
The aim of this study was to develop a lyophilized formulation for EVs with long-term stability 
of encapsulated cargo up to 6 months at 2-8 °C, including the evaluation of basic formulation 
components such as buffer agent and cryoprotectant. In order to provide a high number of 
different formulations, particle characterization was focused on methods using low vesicle 
concentrations thereby disregarding experiments such as cryo-EM which would have 
required increasing vesicle amounts by up to two orders of magnitude. 
FT studies were performed to investigate the impact of PBS, various buffers and pH values, 
and the addition of sucrose and surfactants on EV stability. Here, OMVs derived from 
SBCy050 myxobacteria and EVs derived from B lymphoblastoid cells (RO cells) were 
evaluated. RO cells were isolated from the blood of a patient with severe combined 





in immunogenicity, as this prevents possible MHC-mismatches [41]. RO cells can be 
cultivated under serum-free conditions which removes the challenges associated with the use 
of fetal bovine serum [42]. Thus, RO cell-derived EVs are a highly interesting basis for 
EV-based drug delivery applications. 
Based on findings from the FT studies, suitable formulations were selected for freeze-drying 
experiments of mammalian RO EVs. The lyophilizates were investigated for their long-term 
colloidal stability over 6 months at different temperatures. Vesicles were characterized with 
respect to their hydrodynamic diameter and polydispersity index (PDI) using dynamic light 
scattering (DLS). Particle number-based size distribution was examined by tunable resistive 
pulse sensing (TRPS), while subvisible particle (SVP) numbers were detected by flow 
cytometry imaging. Lyophilizates were additionally tested for their ability to preserve the 
biological activity of beta glucuronidase (β-Glu) encapsulated into the vesicles as a sensitive 




2.1 Freeze-thawing studies 
2.1.1 Impact of buffer type, pH and ionic strength 
Figure 1 A-D shows cryo-TEM pictures of EVs from RO cells (mammalian) and SBCy050 
OMVs (bacterial) both directly after UC and after an additional step of purification by SEC. 
Before SEC, the samples still contained non-vesicular material that was removed after SEC. 
Purified RO EVs were positive for two typical EV-markers, CD9 and CD63 (Figure 1 E and F) 
and negative for the endoplasmic reticulum marker calnexin (Figure S-1). The hydrodynamic 
particle size and PDI values before formulation preparation, i.e. before dialysis, filtration and 
excipient addition, were measured by DLS and are summarized in Table S-1. The conducted 
purification steps (i.e. ultracentrifugation, SEC and 0.2 µm filtration) help to avoid the 










Figure 1: Characterization of RO EVs and SBCy050 OMVs by Cryo-TEM, both directly after 
ultracentrifugation (A and C) and after an additional step of SEC-purification (B and D). Red 
arrows point to vesicular structures, while white arrows indicate non-vesicular structures 
and cell debris. Panels E and F show the analysis of RO EVs by flow cytometry (FACS). 
RO EVs were positive for both CD9 (E) and CD63 (F). 
 
Different formulation parameters (buffer type, pH, ionic strength) were initially tested in FT 
studies prior to EV freeze-drying and extended stability studies. FT was conducted in a 
freeze-dryer allowing controlled and thus reproducible ramp freezing (200 µL vial fill volume). 
Samples were frozen to a minimum of −50 °C since lower temperatures are not relevant for 
medium and larger scale pharmaceutical freeze-dryers. Buffer type and ionic strength may 
be critical formulation parameters affecting the stability of colloids upon FT and 
freeze-drying [1]. For this purpose, EVs were prepared in 10 mM Na- or K-phosphate buffer 
of different pH values, and in PBS. EVs are usually frozen and stored at pH 7.4 [19]. Thus, 
pH values of 7.4 ± ca. 1 pH unit were investigated in this study. As particle size and 
concentration are important quality criteria, DLS and TRPS measurements were performed 
before and after FT providing information about colloidal stability. In contrast to DLS, TRPS 
measurements provide further insight into number-based particle size distributions. 
Nanopores with two different size ranges were used to identify FT stable vesicles (NP100) as 





exhibited a mean particle size of 120 nm and 127 nm (NP100) respectively. DLS revealed 
particle sizes of 110 nm (SBCy050 OMVs) and 150 nm (RO EVs) with a polydispersity index 
(PDI) below 0.4 (Figure S-2). 
      NP100        NP600 
   








   
Figure 2: Number-based particle size distribution of EVs before FT (mean) or three times freeze-thaw 
stressed SBCy050 OMVs and RO EVs (TRPS, NP100 and NP600) formulated in 
10 mM Na- or K-phosphate buffer at different pH values, and in PBS (mean ± SD; n=3). 
 
After three FT cycles, the number of intact RO EVs decreased more drastically (total particle 
reduction ~96%) compared to bacterial SBCy050 OMVs (Figure 2) indicating a markedly 
lower FT stability of the RO EVs. For both vesicle types, the total number of larger particles 
increased after FT; up to 330-fold for SBCy050 OMVs formulated at pH 8.5, and up to ~4-fold 
for RO EVs in PBS (Figure S-3). Interestingly, the number of larger particles became markedly 
higher for SBCy050 OMVs compared to RO EVs. Thus, SBCy050 OMVs predominantly 
increased in size (e.g. due to aggregation or vesicle fusion) while RO EVs potentially got 
disrupted upon freezing. For both vesicle types, flow imaging measurements revealed the 





























 Na-Ph. pH 6.5     K-Ph. pH 6.0 
 Na-Ph. pH 7.4     K-Ph. pH 7.4
 Na-Ph. pH 8.5     PBS






























 Na-Ph. pH 6.5     K-Ph. pH 6.0 
 Na-Ph. pH 7.4     K-Ph. pH 7.4
 Na-Ph. pH 8.5     PBS































 Na-Ph. pH 6.5     K-Ph. pH 6.0 
 Na-Ph. pH 7.4     K-Ph. pH 7.4
 Na-Ph. pH 8.5     PBS


































 Na-Ph. pH 6.5     K-Ph. pH 6.0 
 Na-Ph. pH 7.4     K-Ph. pH 7.4




















highest number of subvisible particles in PBS-containing samples (Figure S-5). These results 
were in line with DLS (Figure S-2). 
The pH value substantially affected FT stability of EVs. Both vesicle types revealed a lower 
number of large particles in K-phosphate buffer at pH 7.4 compared to pH 6.0; total particle 
reduction ~54% and ~45% for SBCy050 OMVs and RO EVs respectively. SBCy050 OMVs 
exhibited a low number of small particles and simultaneously a high number of large particles 
at pH 8.5. In case of RO EVs, an increasing pH resulted in a higher quantity of large particles 
(total number of particles/mL at pH 6.5: ~5.06E+06; pH 7.4: ~5.90E+06; pH 8.5: ~5.99E+06) 
which was also represented by an increasing particle size in DLS measurements (Figure S-2). 
In general, K-phosphate buffers led to a significantly lower number of large particles 
compared to Na-phosphate buffers. This effect was more pronounced for SBCy050 OMVs 
compared to RO EVs. 
To further evaluate the impact of buffer pH on colloidal stability, EVs were formulated in 
K-phosphate at four different acidic pH values and measured by DLS over 1 h (Figure 3). At 
acidic pH values, larger particle sizes were already measured at T0 indicating low particle 
stability, especially for bacterial SBCy050 OMVs. Over time, the particle size of SBCy050 
OMVs substantially increased at pH 3, 4 and 5. RO EVs showed less particle growth which 
corresponded to the behavior upon FT shown before. Thus, a near-neutral pH proved to be 
most suitable for particle stability. 




   
Figure 3: Hydrodynamic particle size (DLS) of SBCy050 OMVs (A) and RO EVs (B) formulated in 
K-phosphate buffer at different pH values over 1 h at 25 °C (n=3). Each data point 
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2.1.2 Impact of sucrose and surfactant 
Subsequently, different stabilizers were evaluated for their suitability to protect EVs upon 
freezing. PS20 and P188 were chosen as potential surface-active stabilizers while sucrose 
was tested as a cryoprotectant. Vesicles were either formulated in 10 mM Na-phosphate at 
pH 7.4 or in PBS, using more critical buffer conditions than K-phosphate to challenge the 
stabilizer capacity. K-phosphate was tested in combination with P188 in the following storage 
stability study providing a control for the Na-phosphate formulation. FT induced particle 
growth could be reduced in presence of sucrose (Figure 4, for DLS results see Figure S-2). 
The total number of large particles was reduced by ~11% and ~44% for SBCy050 OMVs 
and by ~57% and ~55% for RO EVs in samples formulated in PBS and 10 mM Na-
phosphate respectively (Figure S-3). Still, a pronounced loss of intact vesicles and a high 
number of larger particles were found in PBS-containing samples compared to 
10 mM Na-phosphate. Sucrose better stabilized SBCy050 OMVs compared to RO EVs in 
10 mM Na-phosphate (measured with NP100). However, particle growth was also more 
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Figure 4: Number-based particle size distribution of EVs before FT (mean) or three times freeze-thaw 
stressed SBCy050 OMVs and RO EVs (TRPS, NP100 and NP600) formulated in 10 mM 
Na-phosphate pH 7.4 or PBS with sucrose and/or surfactants (mean ± SD; n=3). 
 
 
The addition of P188 led to preserved EV numbers with a slight increase of larger particles 
(SBCy050 OMVs: ~1.8-fold; RO EVs: ~1.5-fold; Figure S-3). Moreover, P188 combined 
with sucrose as cryoprotectant led to the highest number of intact vesicles and the lowest 
number of aggregated and/or fused particles. The concentration of RO EVs could be 
preserved in samples containing PS20 and 5% sucrose. In contrast, SBCy050 OMVs showed 
a loss of approximately 60% of vesicles (6.87E+08 particles/mL instead of 
~1.70E+09 particles/mL) already before FT and were thus excluded from the mean particle 
size distribution (data not shown). Interestingly, in spite of the initial loss, about 90% of 
SBCy050 OMVs were maintained after FT with an increased number of larger particles 
compared to P188. SBCy050 OMVs exhibited a mean particle size of 55 nm and a PDI of 1.0 
according to the cumulant fit analysis in DLS measurements (Figure S-4). The more suitable 
regularization fit analysis for non-monomodal particle size distributions revealed two particle 
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populations: (i) a population with a particle size of 130 nm which corresponded to intact 
vesicles, and (ii) a population with a particle size of about 23 nm indicating fragments of 
disrupted EVs. This effect was not observed for RO EVs which indicates that this population 
in the 20 nm size range does not reflect PS20 micelles. In DLS, placebos of surfactant 
containing formulations revealed 7 nm sized particles in presence of PS20 representing 
micelles, while no particles were detected in presence of P188 due to a concentration below 
the critical micelle concentration [43] (data not shown). TRPS using NP100 was not suitable 
to detect micelles in placebo formulations. 
Before FT, SBCy050 OMVs and RO EVs revealed a surface charge of ~−25 mV and  
~−30 mV respectively, independent of buffer type, pH, sucrose or surfactant addition 
(Table S-2). After FT, the surface charge increased by up to 80% in formulations causing a 
high number of large particles. In contrast, the surface charge changed to 10-30% in 
surfactant or K-phosphate containing samples. 
2.2 Lyophilization of EVs 
Consequently, mammalian RO EVs and bacterial SBCy050 OMVs formulated in 
10 mM Na-phosphate buffer in combination with 0.02% P188 and 5% sucrose were tested 
for their freeze-drying stability (same EV batches as for FT studies). In addition to the 
assessment of the colloidal stability, unfiltered RO EVs were lyophilized and analyzed for 
vesicle morphology by cryo-TEM and EV markers by FACS. A conservative freeze-drying 
cycle was applied (200 µL vial fill volume). The samples were frozen to –50 °C and the 
product temperature during primary drying was maintained well below the Tg’ of  
sucrose (–32 °C) at 40 mTorr chamber pressure and –20 °C shelf temperature. The 
lyophilized samples showed a good cake appearance and dissolved instantly (< 5 s) upon 
addition of 190 µL HPW (calculation based on the solid content). 
Figure 5 A and B shows cryo-TEM pictures of unfiltered RO EVs after lyophilization and 
subsequent reconstitution. RO EVs were positive for the two typical EV markers, CD9 and 








Figure 5: Characterization of unfiltered RO EVs by cryo-TEM, directly after lyophilization and 
reconstitution (A and B). Red arrows point to vesicular structures. RO EVs were positive for 
both CD9 (C) and CD63 (D) as shown by flow cytometry (FACS) analysis. 
 
The particle concentration of 0.2 µm filtered was well preserved for both vesicle types with a 
slight decrease of small particles for RO EVs (Figure 6). However, lyophilization led to an 
increased number of larger particles compared to FT stressed vesicles; this effect was more 
pronounced for bacterial SBCy050 OMVs (15-fold increase of the total particle number). In 
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Figure 6: Number-based particle size distribution of EVs before FT/FD (mean), three times 
freeze-thaw stressed (FT), and freeze-dried (FD) SBCy050 OMVs and RO EVs (TRPS, 
NP100 and NP600) (mean ± SD; n=3). 
 
2.3 Long-term stability of lyophilized EVs 
Based on the previous results, four formulations of mammalian RO EVs loaded with β-Glu 
were prepared using saponin-based encapsulation, with the enzyme acting as an easily 
quantifiable surrogate for biologically active EV-cargoes. Samples were investigated 
regarding long-term colloidal stability over 6 months at 2-8 °C, 25 °C and 40 °C. After 
reconstitution of the lyophilizates, samples were analyzed for particle size, particle 
concentration, surface charge and the biological activity of the associated model enzyme 
β-Glu. Furthermore, solid-state properties of lyophilized placebo formulations were 
characterized by Karl-Fischer titration and DSC. FT experiments had shown that the addition 
of P188 drastically improved EV stability. Although colloidal stability issues of EVs in 
Na-phosphate buffer can be overcome by the addition of P188, the influence of the buffer salt 
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type on biological activity of the encapsulated enzyme over time was unclear. Therefore, 
formulations in a Na-phosphate and K-phosphate buffer were considered for the long-term 
stability study. Furthermore, PVP (MW ~8.000-10.000 Da) was investigated as a 
surface-active polymer. It is used in lyophilization due to its cryoprotective properties and the 
ability to form elegant lyophilizate cakes [44–46]. Thus, 0.02% PVP was tested as an 
alternative to P188, while 5% PVP was evaluated as a sucrose replacement. 
2.3.1 Colloidal stability of lyophilized EVs 
Upon lyophilization and storage, the particle size and concentration of samples containing 
P188 and sucrose remained stable independently of the used phosphate buffer type 
(Figure 7). According to TRPS NP600 measurements, large particles formed during 
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Figure 7: Particle concentration and size of beta glucuronidase encapsulated RO EVs before 
lyophilization, after lyophilization, and after storage for 1 month and 6 months at 2-8 °C, 
25 °C, and 40 °C measured with TRPS using NP100 and NP600, and DLS. Each data point 
represents mean ± SD, n=3. One-way ANOVA, Bonferroni post-hoc test, *p<0.05, 
ns=non-significant. 
 
Before lyophilization, DLS measurements revealed an EV particle size of about 217 nm in 
samples containing 5% PVP compared to about 150 nm in the other formulations. This 
discrepancy was not observed in TRPS measurements. Furthermore, a PDI of 1.0 for these 
formulations resulted from an additional peak in the low nanometer range in the intensity 
versus size distribution. This peak was reproducible for EVs and placebo formulations (i.e. 
10 mM Na-phosphate + 0.02% P188 + 5% PVP without EVs) and no additional peaks at 
bigger particle diameters were detected (data not shown). The particle number measured by 
TRPS NP100 directly after lyophilization was decreased by 27% and 35% in 0.02% and 
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1 month, but decreased further over 6 months storage. In parallel, a low number of larger 
particles was measured for 0.02% PVP samples while a distinct increase was detected in 
presence of 5% PVP, especially after 6 months at 40 °C. Zeta potential measurements 
revealed similar surface charge in all formulations (~−24 mV) which remained mostly 
unchanged during storage (Table S-3). To ensure that the particles measured were not 
related to aggregated free enzyme, non-encapsulated β-Glu formulated in phosphate buffer 
containing P188 and sucrose was freeze-dried. NTA measurements did not reveal enzyme 
aggregation (Figure S-7). 
The residual moisture levels of all lyophilizates increased with increasing storage temperature 
and longer storage time (Table 1). 5% PVP formulations showed higher water contents 
(0.8 - 3.4%) compared to 5% Suc formulations (0.7 - 2.3%). The Tg values decreased 
corresponding to the increase in moisture. 5% PVP formulations revealed the highest Tg 
values between 111.9 °C and 86.0 °C. 
 
Table 1: Tg’ before lyophilization and Tg and RM directly after lyophilization and after storage for 
1 month or 6 months at 2-8 °C, 25 °C, and 40 °C (mean ± SD; n=3). 
 
 10 mM Na-Ph. 
0.02% P188 + 5% Suc 
 
10 mM K-Ph. 
0.02% P188 + 5% Suc 
 
10 mM Na-Ph. 
0.02% PVP + 5% Suc 
 
10 mM Na-Ph. 
0.02% P188 + 5% PVP 
 Tg‘/Tg [°C] RM [%]  Tg‘/Tg [°C] RM [%]  Tg‘/Tg [°C] RM [%]  Tg‘/Tg [°C] RM [%] 
before lyo -31.9 ± 0.1    -32.1 ± 0.1     -31.6 ± 0.1     -24.5 ± 0.0    
after lyo 65.3 ± 0.9 0.7 ± 0.1  65.5 ± 0.5 0.7 ± 0.0  65.8 ± 1.7 0.7 ± 0.1  111.9 ± 0.7 0.8 ± 0.0 
1 m 2-8 °C 65.6 ± 0.4 0.7 ± 0.1  64.0 ± 0.6 0.7 ± 0.0  65.6 ± 0.4 0.7 ± 0.0  111.1 ± 1.1 0.9 ± 0.0 
1 m 25 °C 59.9 ± 0.7 1.2 ± 0.1  59.4 ± 1.1 1.2 ± 0.1  60.8 ± 0.5 1.3 ± 0.0  103.7 ± 2.3 1.5 ± 0.0 
1 m 40 °C 55.6 ± 0.6 1.8 ± 0.1  54.9 ± 0.4 1.9 ± 0.1  56.1 ± 1.0 1.9 ± 0.1  98.3 ± 0.5 2.8 ± 0.1 
6 m 2-8 °C 54.9 ± 1.5 1.4 ± 0.2  50.6 ± 2.2 1.3 ± 0.0  53.9 ± 1.6 1.4 ± 0.1  95.9 ± 3.5 1.6 ± 0.1 
6 m 25 °C 48.3 ± 2.8 2.1 ± 0.0  46.0 ± 1.3 2.0 ± 0.0  47.9 ± 1.2 2.1 ± 0.1  88.4 ± 5.2 3.1 ± 0.1 







2.3.2 Biological activity of encapsulated β-Glu 
As the assessment of the colloidal vesicle-stability already showed that formulations 
containing the combination of 5% Suc and 0.02% P188 best preserved EVs, they were further 
evaluated regarding the stability of encapsulated β-Glu. Figure 8 shows the activity of 
encapsulated β-Glu before and after lyophilization and storage of the formulations containing 
5% Suc, 0.02% P188 and either 10 mM Na-phosphate or 10 mM K-phosphate. Samples 
were purified by SEC to remove non-encapsulated enzyme and the enzyme-activity in 
EV-containing fractions was measured by the conversion of non-fluorescent 
fluorescein-di-β-D-glucuronide to fluorescent fluorescein. EVs from both formulations showed 
a similar initial fluorescence. After lyophilization, there was a decrease in enzyme activity 
compared to the initial value, which was more pronounced for K-phosphate samples. After 
one month of storage between 66 and 100% enzyme-activity were recovered for 
Na-phosphate and between 52 and 67% for K-phosphate. After 6 months of storage, the 
recovered enzyme activity was reduced for all samples to 15-25% at 2-8 °C and 25 °C. In 
samples containing Na-phosphate, 26% enzyme activity remained at 2-8 °C and 18% at 
25 °C, while no activity remained in samples stored at 40 °C. EV samples containing 
K-phosphate, stored 6 months at 2-8 °C or 40 °C showed a recovery of approx. 20% of the 




Figure 8: Comparison of the stability of beta glucuronidase encapsulated in RO EVs formulated with 
5% Suc, 0.02% P188 and either 10 mM Na-phosphate or 10 mM K phosphate. Enzyme 
activity is expressed as the fluorescence-intensity of fluorescein generated through the 
enzymatic conversion of fluorescein-di-β-D-glucuronide. Percent values indicate the 
recovery rate of active enzyme after lyophilization and after storage for 1 and 6 months 
compared to samples before lyophilization. Placebo indicates samples containing only the 
respective buffers and cryoprotectants and no EVs. Each data point represents mean ± SD, 
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We studied the stabilization of EVs derived from RO cells and SBCy050 bacteria by 
lyophilization. Cryo-TEM showed the typical morphology of EVs and OMVs in the size-range 
reported in literature [42,47,48] and the successful removal of non-vesicular structures from 
the samples. The appearance of fewer vesicles was attributed to the dilution of the vesicles 
due to SEC. The isolated and purified EVs were further processed by dialysis and filtration 
which may lead to vesicle loss due to adsorption processes [49] and exclusion of larger 
vesicles respectively. These steps, however, ensured reliable particle characterization using 
well-established techniques (i.e. TRPS, DLS and SVP measurements). Especially before FT, 
polydisperse samples do not allow comparison of PDI values (all >0.56) and hamper TRPS 
measurements due to nanopore clogging using NP100 as seen in preliminary studies (data 
not shown). TRPS was introduced as a suitable method providing an insight into 
number-based particle size distributions. Nonetheless, this method may not be able to 
discriminate between different types of particles [50], such as intact EVs, protein aggregates 
or vesicle fragments. Furthermore, particles much smaller than the nanopore may not be 
detected resulting in an underestimated particle concentration [51]. 
The stability of EVs can be drastically affected by freezing and drying. Both aspects of 
lyophilization cause several types of stresses, such as cryo-concentration, mechanical 
damage by ice crystals, interaction at the ice-water interfacial area, and loss of a stabilizing 
hydration shell [1]. The effect of freezing itself was investigated prior to lyophilization by FT 
studies and may be the more aggressive step [52]. Three FT cycles were conducted to 
evaluate the stabilizer capacity and the damage promoted by freezing. Recent studies 
showed a correlation of EV particle and cargo stability upon the freezing and lyophilization 
process [36,53]. Nevertheless, FT is also reported as a method enabling drug loading into 
exosomes, however, suffering from low encapsulation efficiency and the formation of large 
particles most likely due to aggregation [54]. 
Maintenance of biological activity is the most important aspect after lyophilization. A loss of 
vesicles or the formation of larger particles indicate inappropriate stabilization and have to be 
avoided, especially as the number of visible particles is restricted in injectable drug 
products [55]. Thus, for the sake of simplicity, FT and FD feasibility were performed using 
unloaded EVs, while EV loading with β-Glu was introduced in the subsequent storage stability 
study. The stabilizer excipients used throughout this study were carefully chosen and are 
approved for various administration routes, including parenteral use [56]. Furthermore, side 





In general, mammalian RO EVs were more prone for colloidal destabilization upon freezing 
compared to SBCy050 EVs. The different compositions of the lipid bilayer and surface and/or 
membrane proteins of EVs originating from mammalian cells and gram-negative bacteria are 
assumed to lead to the divergent stability profiles. The trend could be observed for different 
formulation parameters varying in buffer type, pH, the addition of sucrose and a surfactant. 
Differences in the stability profiles after lyophilization of EVs from different mammalian 
cell-lines were also identified by Frank et al. [36]. 
The formulation itself drastically affected the propensity of EV’s to form larger particles. These 
larger particles may be formed due to aggregation of intact vesicles, or components thereof, 
or fusion into larger vesicles as seen for liposomes [57]. Interestingly, surface charge 
measurements by TRPS revealed no differences between the formulations before FT/FD; this 
might be due to, in fact, little surface charge variations or potential charge shielding in 
presence of 140 mM NaCl. A more detailed investigation of the nature of the particles was 
beyond the scope of the study. It could be executed by cryo-TEM which however requires 
up-concentration bearing a high risk of artefacts. Without other stabilizers, the number of 
larger particles was substantially reduced in K-phosphate compared to Na-phosphate buffer. 
Na-phosphate buffer systems are known to cause an acidic pH shift during freezing due to 
selective crystallization of buffer components while K-phosphate buffers are able to maintain 
the pH [34]. This pH shift appears to destabilize EVs during freezing. Therefore, the impact 
of acidic pH was further investigated in the liquid state. DLS measurements over time showed 
that an acidic pH is unfavorable for colloidal stability leading to the formation of large particles. 
A detrimental effect of an acidic environment was also shown by Cheng et al. when comparing 
EV loss upon storage at pH 4 to pH 7 and 10 [53]. A change in pH also affects the EV surface 
charge and thereby the electrostatic interactions [58]. In case of SBCy050 EVs, after FT a 
higher concentration of larger particles was found at pH 8.5 compared to pH 6.5 and pH 7.4. 
Thus, a pH optimum providing colloidal stability is essential and has to be maintained during 
the freezing process. 
PBS is the most commonly used buffer for the processing of EVs. Therefore, PBS is usually 
used during storage at –80 °C which is the gold standard for preservation of EVs [19]. 
Interestingly, PBS reveals to be unfavorable for both EV types since a high number of large 
particles was measured after FT. This effect might be driven by the aforementioned pH shift 
of Na-phosphate which is part of the buffer system. Furthermore, the salt present in PBS 
(137 mmol NaCl, 2.7 mmol KCl) can be assumed to trigger particle aggregation. During 
freezing, the formation of extracellular ice leads to up-concentration of the extracellular 
solutes. High salt concentrations are known to negatively impact the stability of colloids by 





be prone to salt denaturation. The cryo-concentration of salts also elevates the extracellular 
osmotic pressure and rapid water flux through the bilayer can be responsible for physical 
forces leading to rupture and destabilization [60]. 
Cryo- and lyoprotection is an important means to preserve the stability of proteins and colloids 
during freezing and freeze-drying. We therefore tested the effect of sucrose on the colloidal 
stability of EVs. Both EV types showed less particle growth in presence of sucrose, but this 
effect could not be avoided completely. Various mechanisms, such as the preferential 
exclusion theory, and increased viscosity were discussed in the past in order to explain how 
cryoprotectants preserve colloids during freezing. The preferential exclusion theory was 
originally proposed for proteins and later for liposomes [61]. The theory states that solutes 
are preferentially excluded from protein surfaces or membranes leading to the formation of a 
stabilizing solvent layer. Due to cryo-concentration, the solute concentration drastically 
increases intensifying this mechanism. Furthermore, the increased solution viscosity during 
freezing is assumed to restrict diffusion and thus colloidal interactions slowing down 
aggregation and degradation processes [62]. 
Surfactants are known to protect colloids from surface-induced damage during freezing [1]. 
However, the use of surfactants is generally avoided in lipid delivery vehicles due to the fear 
of disrupting the lipid bilayer. During freezing, this effect is even more critical due to the 
up-concentration of the surfactant. PS20 and P188 are approved in parenteral products and 
were therefore selected in this study [56]. We could demonstrate here that the type of 
surfactant has to be chosen carefully. In contrast to RO EVs, our SBCy050 OMVs showed a 
low number of intact vesicles in presence of PS20 already before FT. The small particles 
measured by DLS are attributed to EV fragments formed upon lysis. The phenomenon of 
differential detergent sensitivity was also reported by Osteikoetxea et al. showing surfactant 
and concentration dependent lysis of EVs [63]. Although surfactants can be detrimental to 
lipid bilayers, Yu et al. showed that the addition of polysorbate 80 could minimize aggregation 
and loss of transfection-activity of lyophilized lipoplexes [64]. 
Interestingly, in presence of P188, size and concentration of EVs were preserved upon FT 
independently of the vesicle type. Furthermore, the detrimental effect of Na-phosphate was 
not observed indicating protective properties of the surfactant in spite of the pH shift during 
freezing. A stabilizing effect of P188 on lipid membranes was reported by Sharma et al. who 
observed that P188 decreased the susceptibility of lipid membranes to electroporation [65]. 
Further studies revealed that P188 directly inserts into lipid monolayers [66]. This mechanism 
was confirmed by later computer simulation studies. It is suggested that hydrophobic chains 
of P188 get inserted into damaged lipid bilayers, ultimately closing pores [67]. A stabilizing 





surface-mitigated aggregation which could be the second mechanism for EV stabilization [70]. 
The addition of sucrose as a cryoprotectant was not mandatory to preserve the size and 
concentration of RO EVs in presence of P188. The combination of P188 and 5% Suc only 
slightly reduced the number of larger particles for SBCy050 EVs. This finding indicates that 
vitrification may be less critical for EV preservation upon freezing. Freezing-induced damage 
is rather promoted at the ice-liquid interface or due to hydrophobic interactions which are 
reduced by surfactants. The differences in molecular weight and hydrophilic/lipophilic balance 
of P188 (MW ~8400 Da, HLB=29) and PS20 (MW ~1200 Da, HLB=16.7) are assumed to lead 
to different interactions with lipid bilayers and therefore different lysing properties. The gained 
information is furthermore helpful for current storage practice, i.e. storage at −80 °C; our 
studies confirm that physical stability can be maintained upon repeated FT which may avoid 
discarding of once thawed but unused sample. 
Since sucrose was suitable to provide vesicle stability in presence of P188, it was used as a 
bulking agent for freeze-drying to render isotonicity and to obtain an elegant macroscopic 
cake appearance. Both EV types were evaluated for their lyophilization feasibility using the 
formulation containing P188 and sucrose in Na-phosphate buffer at pH 7.4. Particle size and 
concentration of EVs were well-preserved after lyophilization showing a negligible increase 
of larger particles compared to three times FT samples. Furthermore, the vesicle morphology 
and the typical markers CD9 and CD63 were maintained, as shown for RO EVs. The drying 
step of lyophilization appears to be less critical compared to freezing and thus FT studies 
prove to be an important formulation screening tool to evaluate physical stability. Storage 
stability studies were conducted with vesicles lyophilized in four different formulations:  
i) a formulation containing P188 and sucrose in Na- phosphate buffer pH 7.4  
ii) a formulation containing P188 and sucrose in K-phosphate buffer pH 7.4 to evaluate 
the criticality of the pH shift for the freeze-dried product with a cargo 
iii) a formulation with 0.02% PVP as an alternative stabilizer to P188 with similar 
molecular weight (PVP ~8.000-10.000 Da) 
iv) a formulation with 5% PVP as an alternative stabilizer, lyoprotectant and bulking 
agent since PVP is commonly used in lyophilization and known for the excellent cake 
appearance of lyophilizates due to the relatively high Tg’ and Tg values 
RO EVs were chosen for the freeze-drying storage stability studies due to the greater 
relevance of EVs derived from mammalian cells in current efforts for clinical translation [8]. 
To assess not only the colloidal stability, but also gain insight into the fate of their cargo, β-Glu 





been used previously without negative impact on EV-morphology [54,71]. Correspondingly, 
we did not observe differences in the physicochemical characterization of freshly lyophilized 
RO EVs with or without encapsulated β-Glu. 
Before freeze-drying, the identity of EVs derived from RO cells was further confirmed by 
assessing typical surface-markers CD9 and CD63 and proving the absence of the 
endoplasmic reticulum marker calnexin by FACS [72]. RO EVs exhibited a larger particle size 
in 5% PVP compared to sucrose formulations. This marked size difference was detected by 
DLS but not in TRPS measurements. The larger size in DLS is attributed to significantly 
different osmolality in 5% Suc and 5% PVP solutions. In contrast, TRPS measurements are 
conducted in presence of 140 mM NaCl which is required to provide sufficient conductivity of 
the solution. Thus, the osmotic effect of the cryoprotectant may become negligible resulting 
in vesicles of similar particle size. 
After lyophilization and storage, the particle concentration of small particles (NP100) 
decreased drastically in PVP containing formulations while the concentration of large particles 
(NP600) increased indicating insufficient particle stabilization. These results are in line with 
findings by El Baradie et al. who observed an EV loss after lyophilization in presence of 
100 mM trehalose/ 5% PVP40 [73]. Thus, the ability of P188 to directly interact with lipid 
membranes is vital for freeze-drying success. Furthermore, we conclude that RO EVs are 
better embedded in sucrose compared to PVP due to enhanced water replacement and 
interactions between the lyoprotectant and vesicles. Our observation is in accordance with 
findings by Mensink et al. who showed that molecularly more flexible disaccharides better 
stabilized proteins during freeze-drying than molecularly more rigid polysaccharides [74]. The 
excess of PVP might furthermore lead to hampered stabilization by P188 due to competitive 
interactions with the vesicle lipid bilayer. 
The solid-state properties of the lyophilizates showed an increase in residual moisture content 
over time up to 3.4% which might be due to i) transfer of moisture from stoppers to the 
formulation, ii) diffusion or transmission of moisture through the stopper, and iii) microleaks 
in the stopper-vial seal [1]. The low fill volume and thus lyophilizate mass contributes to the 
pronounced increase of water content upon uptake of only little absolute water amounts. The 
Tg of the lyophilizates was decreased by about 27% due to the plasticizing effect of water. 
Vitrification becomes the limiting factor for storage stability when the storage temperature is 
closer to or above the Tg. In order to avoid residual viscous flow of the lyophilizate, Franks 
proposed that the Tg value should be 20 °C above of the storage temperature [75]. This 
specification was kept at 2-8 °C and 25 °C storage but was exceeded at 40 °C. Still, we did 





Na- and K-phosphate were both suitable to maintain particle size and concentration of 
lyophilized and 6 months stored RO EVs. Thus, the pH shift of a Na-phosphate buffer does 
not affect particle stability. However, the lyophilization process and further storage led to a 
decrease of the enzyme activity which is in line with previous findings [76,77], as freezing and 
dehydration cause stress to the protein. The increased recovery of β-Glu activity after 1 month 
of storage compared to samples directly after lyophilization speculatively could be an 
indication for reversible conformational changes of the enzyme inside the EVs [78,79]. 
Storage for 1 month at 2-8 °C revealed no statistically significant changes in encapsulated 
enzyme activity in both formulations. However, the mean value for K-phosphate was reduced 
compared to Na-containing formulation, which is in contrast with previous findings, were 
K-phosphate showed better suitability for the preservation of lyophilized enzymes [80]. 
Pikal-Cleland et al., however, looked at free enzyme, while in our study the EV-membrane 
prevents the direct contact between β-Glu and buffer. After 6 months of storage, both 
formulations showed a pronounced reduction in enzyme activity. Storage at 2-8 °C best 
preserved β-Glu revealing an enzyme recovery of 20-26%. In general, Na-phosphate 
samples exhibited slightly higher recovery rates. Only at 40 °C the K-phosphate containing 
samples showed a clear improvement over their Na-phosphate counterpart. Overall, β-Glu 
activity did not correlate with the high colloidal stability. This points to either enzyme leakage 
or enzyme degradation within the vesicle as the main causes for the β-Glu activity loss. The 
high enzyme recovery after 1 month suggests that general leakage of the enzyme during 
freeze-drying or rehydration was not the reason for the activity-reduction after 6 months. 
Thus, we speculate that β-Glu encapsulated in the lyophilized EVs degraded over time [77]. 
Whether activity-reduction is related to lyophilization in general or to the specific environment 
and the conditions inside the EVs should be subject of detailed future studies including 
freeze-drying of free enzyme in different formulations with various stabilizers and 
concentrations. 
To the best of our knowledge, there are no publications, concerning the long-term stability of 
lyophilizates of liposomes or EVs loaded with enzymes that could allow a closer insight. As 
hydrophilic molecules do not readily cross the EV-membrane [71], sucrose and P188 will not 
be present inside the vesicles in sufficient amounts for cryo- and lyoprotection of the 
encapsulated enzyme. Kannan et al. found that during the lyophilization of liposomes, luminal 
sucrose increased stability, by stabilizing the liposomes from the inside [81]. A similar effect 
might be found for EVs if sucrose could be actively encapsulated in sufficient amounts. 
Nonetheless, compared to previous studies, where after two weeks of storage at 4 °C in a 
4% trehalose lyophilizate only 25-50% of enzyme-activity remained [36], we showed a 
substantial improvement in preserving the β-Glu activity in this work. β-Glu only served as a 





structure making it a good indicator of unfavorable storage-conditions. Its facile encapsulation 
into EVs and the straightforward and sensitive evaluation of its stability made it possible to 
screen manifold EV-formulations in parallel. With the knowledge gathered here, the next step 
would be to characterize the EV integrity and apply our recommended formulation parameters 
(see Box 1) to other biomedically relevant EVs. Ideal targets could be mesenchymal stem 
cell-derived EVs that have shown promising results in many applications [82], myxobacterial 
OMVs with antibacterial activity [83] or OMVs with protective effects in inflammatory bowel 
disease [84], where lyophilization could provide an ideal basis for the development of solid 
dosage forms. 
 
Recommended formulation parameters for lyophilization: 
 
▪ Buffer: replace PBS with 10 mM Na- or K-phosphate pH 7.4 
▪ Cryo- and lyoprotection: 0.02% P188 and 5% sucrose 
▪ Proposed lyophilization conditions: 
- Freezing: 1 °C/min to −50 °C 
- Primary drying: −20 °C, 40 mTorr, manometric endpoint determination 
(product temperature below Tg′) 
- Secondary drying: 20 °C, 40 mTorr, 8h 
 
Box 1: Collected formulation parameters for EV-lyophilization 
 
4 Conclusion 
The growing interest in EVs for various pharmaceutical applications rises the demand for 
long-term stable formulations without the need for storage at –80 °C. Lyophilized formulations 
provide easier shipping and storage, and offer new options for administration, such as 
pulmonary delivery. We therefore investigated the long-term stability of lyophilized RO-cell 
derived EVs regarding colloidal and cargo stabilization for up to 6 months stored at 2-8 °C, 
25 °C, and 40 °C. 
Prior to lyophilization, FT studies were performed to select the most effective buffer type and 
stabilizers. Most freezing-induced damage of both SBCy050 OMVs and RO EVs was seen in 
PBS, which is commonly used in EV isolation and preservation. This damage could be 
minimized by using 10 mM phosphate buffer without salts. K-phosphate instead of 
Na-phosphate buffer or the addition of sucrose further improved the FT stability. The colloidal 
stability of both vesicle types could be most effectively preserved by the addition of low 
amounts of the surfactant P188. PS20 was not suitable for SBCy050 EVs since it reduced 





sucrose was found to be appropriate for successful lyophilization. The lyophilized and stored 
RO EVs formulated with P188 and sucrose showed comparable particle size and 
concentrations in Na-phosphate and K-phosphate buffer. Colloidal stability was preserved for 
6 months while in vitro experiments revealed that the activity of encapsulated β-Glu was 
maintained for at least 1 month. PVP was included in the freeze-drying study as an alternative 
stabilizer to either P188 or sucrose, but turned out to be not able to sufficiently preserve 
mammalian RO EVs after lyophilization and storage. 
In conclusion, we could successfully lyophilize mammalian EVs derived from RO cells, 
maintaining their original particle size and concentration without cargo loss. Storage at 2-8 °C 
appears suitable for at least 1 month. We further demonstrated that colloidal stability can be 
provided for at 6 months. Since enzymes are known for their sensitivity during storage, future 
research might focus on more stable cargos (e.g. RNA, DNA) providing further insight into 
content retention. In addition, the stabilizing effect of P188 could be elucidated by testing 
different types of poloxamer. 
 
5 Experimental Section 
5.1 Materials 
RO cells (ACC452) were obtained from DSMZ, Braunschweig, D. Strain SBCy050 of the 
Cystobacterineae order of myxobacteria was kindly provided by Rolf Müller, Department of 
Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research, Saarbrücken. 
RPMI medium and insulin-transferrin-selenium-ethanolamine were obtained from Thermo 
Fisher Scientific (Waltham, MA). 2SWC medium was prepared from Bacto Casitone, Bacto 
Soytone (both Becton, Dickinson, NJ, US), glucose, MgSO4 heptahydrate, CaCl2 dihidrate (all 
Sigma-Aldrich, Steinheim, D), maltose monohydrate, cellobiose (both MP Biomedicals SARL, 
Illkirch-Graffenstaden, FR), HEPES (Carl Roth, Karlsruhe, D) and KOH (Thermo Fisher 
Scientific, Waltham, MA, US). PBS was prepared from tablets (Thermo Fisher Scientific, 
Waltham, MA, US). 10 mM Na-phosphate (Sigma-Aldrich, Steinheim, D) at pH 7.4 was 
prepared for size exclusion chromatography. Both buffers were filtered through a 0.2 µm 
mixed cellulose ester membrane filter (GE Healthcare, Chicago, IL) prior to use. The protein 
content of EV-samples was measured using a QuantiPro BCA assay kit (Sigma-Aldrich, 
Steinheim, D). Bovine serum albumin (BSA) was obtained from Sigma-Aldrich (Steinheim, 
D). To adsorb EVs in FACS experiments, aldehyd/sulfate latex beads with 4 µM diameter 





Stabilizer stock solutions of sucrose (Sigma-Aldrich, Steinheim, D), poloxamer 188 
(Kolliphor® P188, BASF, Ludwigshafen am Rhein, D), polysorbate 20 (Tween 20™, Merck, 
Darmstadt, D), and polyvinylpyrrolidone (Kollidon® 17 PF, BASF, Ludwigshafen am Rhein, 
D) were prepared at various concentrations. 20 mM Na-phosphate and K-phosphate buffers 
(VWR International, Ismaning, D) at different pH values were prepared for dialysis. Stabilizer 
stock solutions were filtered with 0.2 µm polyethersulfone (PES) membrane syringe filters 
(VWR International, Ismaning, D). For the preparation of buffers and stock solutions, HPW 
was used. All excipients had analytical or higher grade and were used without further 
purification. 
Carboxylated polystyrene particle standards with a nominal mean diameter of 110 nm and 
950 nm, denoted as CPC100 and CPC1000 were used for tunable resistive pulse sensing 
instrument calibration (Izon Science Europe, UK). 2R glass vials (Fiolax® clear, Schott, 
Müllheim, D) with igloo rubber stoppers (B2–TR coating, West Pharmaceutical Services, 
Eschweiler, D) were cleaned with HPW and dried for 8 h at 60 °C. 
 
5.2 Methods 
5.2.1 Cell culture 
RO cells (DSMZ, ACC 452) were cultivated as described previously [42]. Briefly, cells were 
cultured in RPMI with 1% (v/v) insulin-transferrin-selinium-ethanolamine and a density of 
0.75×106 cells/mL in 45 mL. 25 mL of the total volume were replaced with 50 mL new medium 
after 3 days. Vesicles were isolated after 7 days from cells cultured until passage 33. RO cell 
supernatants were centrifuged at 300 xg for 8 min to pellet cells. Subsequently, supernatants 
were centrifuged at 9,500 xg for 15 min and then filtered through a 0.45 µm bottletop filter 
with a polyvinylidene fluoride membrane (Steritop®, Merck, Darmstadt, D). Cell free 
conditioned medium was subjected to ultracentrifugation (UC) on the same day. UC was 
performed using a Type 45 Ti rotor (Beckman Coulter, Brea, CA) for 2 h at 100,000 xg with 
70 mL polycarbonate tubes (Beckman Coulter, Brea, CA). The resulting EV pellet was 
resuspended in residual supernatant, left in the tubes after decanting. This resulted in a total 
volume of approx. 800 µL resuspended EV pellet obtained from one UC run with six tubes. 
5.2.2 Bacterial culture 
SBCy050 myxobacteria were cultured in 2SWC medium (0.5% Bacto Casitone, 0.1% Bacto 
Soytone, 0.2% glucose, 0.1% maltose monohydrate, 0.2% cellobiose, 0.05% CaCl2 





4 days, starting with an optical density of 0.04±0.01. To obtain conditioned medium the 
cultures were centrifuged at 9,500 xg for 10 min and then filtered through a 0.45 µm pore size 
bottletop filter (see above). Cell free conditioned medium was subjected to UC on the same 
day. UC was performed using a SW 32 Ti rotor (Beckman Coulter, Brea, US) for 2 h at 
100,000 xg using 32 mL polycarbonate tubes (Beckman Coulter, Brea, US). EV pellets were 
resuspended as described above. 
5.2.3 FACS of RO EVs 
EV evaluation by FACS was based on the protocol of Hoppstaedter et al. [85]. The protein 
content of RO EVs was measured using a bicinchoninic acid assay kit. Then the vesicles 
were mixed 1:1 with FACS beads (µg/mL protein to µL beads), incubated for 15 min at room 
temperature, diluted to 1 mL with PBS and incubated for 1 h applying mild shaking. Next, 
1 mL of a 200 mM glycine stop solution was added to saturate the beads. After 20 min 
incubation, the beads were centrifuged twice at 2000 xg for 4 min and resuspended in 
1% BSA in PBS, in the original volume of FACS beads employed in the initial step. Next, 
10 µL of sample were mixed with 10 µL of FITC-labeled antibody, either anti CD9, anti CD63 
or calnexin or the isotype control and incubated on ice for 30 min in the dark (see Table S-4 
for further information on antibodies). After dilution to 1 mL using 1% BSA in PBS, samples 
were centrifuged twice at 2000 xg for 4 min, then measured by FACS (LRS Fortessa, BD 
Biosciences, NJ) using BD FACSDiva v9.0 software. Data was analyzed using FloJo 
(version 10.7.0). Negative controls were prepared in the same way as EV-containing 
samples, but EVs were replaced with the respective amount of BSA. For the positive calnexin 
and isotype control with RO cells, cells were centrifuged at 300 xg and resuspended in PBS. 
One million cells per 100 µL were fixed with 4% paraformaldehyde for 10 min, washed twice 
with PBS and then incubated with 0.1% saponin and 1 µl calnexin or 2.1 µL of the respective 
isotype for 30 min. Cells were washed once and resuspended in 400 µL PBS for FACS 
analysis. 
5.2.4 Beta glucuronidase encapsulation 
β-Glu was encapsulated in RO EVs as previously described [86]. The resuspended pellet was 
mixed with β-Glu and saponin to final concentrations of 1.5 and 0.1 mg/mL respectively and 





5.2.5 Size exclusion chromatography 
To remove impurities carried over from UC and free glucuronidase, EV samples were purified 
by SEC. SEC was performed using a 1.5 cm diameter glass column (Flex Column®, Kimble 
Chase, Vineland, NJ), filled with 35 mL of sepharose Cl 2b (Cytiva, Marlborough, MA). PBS 
was used as mobile phase with a flow rate of 1 mL/min. Up to 750 µL UC pellet were purified 
per SEC run, purified EVs were collected in 1 mL fractions. The process was automated using 
an ÄKTA start system equipped with a Frac30 fraction collector (both Cytiva, Marlborough, 
MA). The vesicle containing fractions were collected and pooled for subsequent 
characterization and lyophilization. Each SEC run included a 120 mL washing step to ensure 
the removal of all non-encapsulated glucuronidase, before the next sample was injected. 
5.2.6 Beta glucuronidase assay 
Glucuronidase activity was measured as described previously [36]. Free enzyme potentially 
present from EV leakage during storage was removed by SEC after reconstitution of 
lyophilized samples. For this purpose, a 1.0 cm diameter column filled with 10 mL of 
sepharose Cl-2b was used with 10 mM Na-phosphate buffer at pH 7.4 as the mobile phase 
and a flow rate of 1 mL/min. Fractions of 0.5 mL were collected. Glucuronidase activity was 
measured after mixing samples with fluorescein-di-β-D-glucuronide to a final concentration of 
8.3 µg/mL in a total volume of 150 µL. Directly after mixing, the fluorescence was measured 
using a plate reader (Infinite 200Pro, Tecan, Männedorf, CH), with an excitation wavelength 
of 480 nm and an emission wavelength of 516 nm. After 18 h incubation at 37 °C, the 
fluorescence was measured again. The difference between t18 h and t0 h indicated the enzyme 
activity found in the respective sample. PBS treated in the same way as EV-containing 
samples was measured as a control and subtracted from samples values. 
5.2.7 Cryo-TEM 
Cryo-TEM pictures of EV-samples both directly after ultracentrifugation and after SEC 
purification were acquired as previously described [83]. Briefly, a drop of 3 µL of EV 
suspension was placed on a holey carbon film (type S147-4, Plano, Wetzlar, D), blotted for 
2 s, then plunged into liquid ethane at T=108 K with a Gatan cryoplunger model CP3 
(Pleasanton, CA). After transferring the frozen samples to a Gatan model 914 cryo-TEM 






5.2.8 Formulation preparation 
After isolation and SEC purification, EVs were dialyzed with 20 mM Na- or K-phosphate buffer 
in Slide-A-LyzerTM MINI dialysis devices or cassettes (20K MWCO; Thermo Fisher Scientific, 
Waltham, MA). After dialysis, EVs were filtered through a 0.2 µm PES membrane syringe 
filter (VWR International, Ismaning, D) and mixed 1:1 with stabilizer stock solutions to match 
the respective final buffer and stabilizer concentration (see Table S-5). Unloaded and β-Glu 
loaded RO EVs were investigated from different batches. 
5.2.9 Freeze-thawing cycle 
Formulations (200 µL in 2R vials) were freeze-thawed three times on a pilot scale freeze-drier 
(FTS LyoStarTM 3, SP Scientific, Stone Ridge, NY) at –1 °C/min to –50 °C followed by a 
30 min hold at –50 °C and thawing at 1 °C/min to 10 °C followed by a 30 min hold. Before 
freeze-thawing, EV concentrations were determined by TRPS and denoted as ‘before FT’. 
5.2.10 Freeze-drying cycle 
A lyophilization process stability study was conducted using unloaded RO EVs and SBCy050 
OMVs (same batches as for freeze-thawing studies) formulated in 10 mM Na-phosphate 
buffer pH 7.4 in combination with 0.02% P188 and 5% sucrose. Selected formulations of 
β-Glu loaded RO EVs were used for long-term stability studies (Table 2), including placebos 
consisting of identical formulations without EVs. The samples were lyophilized in 2R vials with 
200 µL fill volume. Before lyophilization, EV concentrations were determined by TRPS and 
denoted as ‘before FD’. Lyophilization was performed on a pilot-scale freeze-dryer 
(LyoStarTM 3). After an equilibration step at –5 °C for 15 min, the samples were frozen at  
–1 °C/min to –50 °C and held for 120 min. Primary drying was performed at –20 °C and 
40 mTorr with manometric end point determination. The product temperature, monitored with 
thermocouples, was kept below the glass transition temperature of the maximally frozen 
concentrate (Tg′) which was determined by DSC. Secondary drying was performed at 20 °C 
and 40 mTorr. Samples were stoppered under slight vacuum at 450 Torr nitrogen, and vials 
were crimped with aluminum seals. The lyophilizates were reconstituted by adding 190 µL of 
HPW. The reconstitution volume was calculated based on the solid content. The vials were 







Table 2: Formulations for freeze-drying experiments. 
Formulation# Buffer Cryoprotectant Surfactant 
1 10 mM Na-phosphate pH 7.4 5% Suc 0.02% P188 
2 10 mM K-phosphate pH 7.4 5% Suc 0.02% P188 
3 10 mM Na-phosphate pH 7.4 5% Suc 0.02% PVP 
4 10 mM Na-phosphate pH 7.4 5% PVP 0.02% P188 
 
5.2.11 Long-term stability testing of lyophilized samples 
For long-term stability testing, sealed lyophilizates were stored at 2-8 °C, 25 °C, and 40 °C 
over a period of 1 month and 6 months. 
5.2.12 Dynamic light scattering 
Mean particle sizes and respective polydispersity indices (PDI) were measured using a DLS 
platereader (DynaPro III, Wyatt Technology, D). 20 μL sample (n=3) per well of a 384 UV-well 
plate (CostarTM, Corning, Tewksbury, MA) was analyzed at 25 °C using 10 acquisitions with 
5 s each. The corresponding preset refractive index parameters were used for all samples. 
Viscosities of sucrose and PVP formulations required for DLS measurements were 
determined via an AMVn Automated Micro Viscometer (Anton Paar, Graz, A). 
5.2.13 Tunable resistive pulse sensing 
Concentration-based particle size distributions and zeta potentials were analyzed by TRPS 
(qNano, Izon Science Europe, UK). Adjustment of nanopore stretch and voltage were 
optimized according to manufacturer recommendations. In order to provide sufficient 
conductivity, 27 µL of each sample containing 10 mM phosphate (not PBS) was mixed with 
3 µL of a 1.4 M NaCl solution resulting in 140 mM NaCl and 9 mM phosphate. Samples were 
measured in triplicate with a minimum of 500 particles per analysis. In case of fewer particles 
a maximum measurement time of 10 min was performed. Calibration of the nanopores NP100 
(measurement size range: 50-330 nm) and NP600 (measurement size range: 275-1570 nm) 
was conducted using carboxylated polystyrene particle standards CPC100 and CPC1000 
respectively. Calibration particles were prepared in 10 mM phosphate buffer and mixed with 
a NaCl solution as described before for sample particles. Zeta potential analysis was 
conducted according to IZON’s instruction ‘V3.1 Charge Analysis’ using NP100 and CPC100 
particles. The calibration particles were measured at three applied voltages; particles 





from measured samples and calibration particles were evaluated using the template ‘Zeta 
Template V3.1a’ provided by IZON. 
5.2.14 Subvisible particles 
Subvisible particles were analyzed by flow cytometry imaging (FlowCam® 8100, Fluid 
Imaging Technologies, Inc., Scarborough, ME). A 10x magnification cell was used for the 
measurements. After 1:10 dilution, 160 μL sample solution was measured with a flow rate of 
0.15 mL/min, an auto image frame rate of 28 frames per second, and a run time of 60 s. After 
each measurement, the flow cell was flushed with HPW. Particle identification was set with a 
distance to the nearest neighbor of 3 μm, and a segmentation threshold of 13 and 10 for the 
dark and light pixels respectively. The software VisualSpreadsheet® 4.7.6 was used for 
measurements and evaluation. 
5.2.15 Nanoparticle tracking analysis 
Nanoparticle tracking analysis was performed using a Nanosight LM-10 (Malvern 
Instruments, UK) equipped with a green laser measurement cell. Three videos of 30 s were 
recorded using a camera level of 14–15 and detection threshold 10 and analyzed using NTA 
software (NTA 3.1 Software). 
5.2.16 Karl-Fischer Titration 
The RM of placebo lyophilizates was determined in triplicates by Karl-Fischer titration after 
lyophilization and after storage. Measurements were performed using an Aqua 40.00 titrator 
(Analytik Jena AG, Halle, D) equipped with a headspace oven set at 100 °C. Samples of 10 
to 20 mg crushed lyophilizates were analyzed in stoppered 2R vials. 
5.2.17 Differential scanning calorimetry 
DSC measurements were performed in 40 µL aluminum crucibles using a Mettler Toledo DSC 
822e (Mettler-Toledo GmbH, Giessen, D). In order to determine the glass transition 
temperature of the maximally freeze-concentrated solution (Tg’), 20 µL of the liquid samples 
were cooled at –10 °C/min from 25 °C to –60 °C, held at –60 °C for 1 min, and reheated at 
10 °C/min to 25 °C. For the determination of the glass transition temperature of the lyophilized 
samples (Tg), approximately 10 mg were weighed into the aluminum crucibles. Samples were 
preheated from 0 °C to 70 °C, cooled to 0 °C and heated to 150 °C at a scanning rate of 





scan of the DSC experiment. All analyses were performed in triplicate with placebo 
formulations. 
5.2.18 Statistical analysis 
Unless otherwise stated, results are given as mean value ± standard deviation (SD). 
Statistically significant differences were determined via one-way or two-way ANOVA followed 
by a post-hoc test or via a two-tailed student t-test using Origin 2019b Software (OriginLab 
Corporation, Northampton, MA). Mean values having p-values < 0.05 were judged to be 
significantly different. 
 
6 Supporting Information 
 
Table S-1: Hydrodynamic particle size and PDI values of SBCy050 OMVs and RO EVs before 
dialysis and filtration measured by DLS (mean ± SD; n=3). 
 
Vesicle type  Particle size [nm] PDI 
SBCy050 OMVs  130.0 ± 3.5 multimodal (> 0.56)  





























Table S-2: Zeta potential values of SBCy050 OMVs and RO EVs in different formulations before and 
after FT or FD measured by TRPS (mean ± SD, n=3). Za/Zb represents the ratio of the 
zeta potential after and before FT or FD. 
 
Formulation Zeta potential [mV]  
 SBCy050 OMVs RO EVs 
 before  after Za/Zb before  after Za/Zb 
Na-Ph. pH 6.5 -23.3 ± 0.3 -36.1 ± 0.5 1.6 -30.4 ± 1.0 -41.7 ± 9.3 1.4 
Na-Ph. pH 7.4 -22.5 ± 2.9 -36.4 ± 2.8 1.6 -29.6 ± 1.0 -39.6 ± 1.7 1.3 
Na-Ph. pH 8.5 -23.9 ± 0.3 -40.4 ± 0.4 1.7 -31.2 ± 2.5 -54.4 ± 2.7 1.7 
Na-Ph. pH 7.4 + 
5% Suc 
-24.0 ± 0.9 -38.0 ± 0.5 1.6 -32.6 ± 2.1 -49.4 ± 5.8 1.5 
K-Ph. pH 6.0 -25.3 ± 0.4 -33.1 ± 0.8 1.3 -29.5 ± 0.5 -28.3 ± 1.4 1.0 
K-Ph. pH 7.4 -26.1 ± 0.2 -33.8 ± 1.0 1.3 -32.2 ± 3.3 -29.6 ± 6.6 0.9 
PBS -22.0 ± 0.3 -38.5 ± 0.2 1.7 -28.0 ± 1.7 n.d. - 
PBS + 5% Suc -29.4 ± 1.8 -40.3 ± 0.2 1.4 -27.4 ± 2.7 -49.0 ± 4.9 1.8 
0.02% P188 -21.9 ± 0.4 -28.5 ± 0.5 1.3 -29.7 ± 1.7 -27.8 ± 1.0 0.9 
0.02% P188 + 
5% Suc 
-25.0 ± 0.4 -32.2 ± 0.6 1.3 -30.0 ± 0.8 -26.2 ± 1.5 0.9 
0.02% PS20 + 
5% Suc 
-25.5 ± 0.2 -30.6 ± 0.2 1.2 -27.9 ± 2.2 -32.9 ± 2.8 1.2 
0.02% P188 + 
5% Suc (FD) 
-25.6 ± 0.5 -32.3 ± 0.8 1.3 -30.9 ± 0.9 -27.5 ± 3.3 0.9 




Table S-3: Zeta potential values of beta glucuronidase encapsulated RO EVs before lyophilization, 
after lyophilization, and after storage for 1 month and 6 months at 2-8 °C, 25 °C, and 
40 °C measured by TRPS (mean ± SD; n=3). 
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Table S-5: Formulation preparation; EVs were dialyzed in Component 1 and mixed with Component 
2 (1:1). 
 
Formulation Component 1 Component 2 
10 mM Na-ph. pH 6.5 20 mM Na-ph. pH 6.5 HPW 
10 mM Na-ph. pH 8.5 20 mM Na-ph. pH 8.5 HPW 
10 mM K-ph. pH 6.0 20 mM K-ph. pH 6.0 HPW 
10 mM K-ph. pH 7.4 20 mM K-ph. pH 7.4 HPW 
10 mM Na-ph. pH 7.4 
20 mM Na-ph. pH 7.4 
HPW 
PBS 
274 mmol NaCl + 5.4 mmol 
KCl 
10 mM Na-ph. pH 7.4 + 5% Suc 10% Suc 
PBS + 5% Suc 
274 mmol NaCl + 5.4 mmol 
KCl + 10% Suc 
10 mM Na-ph. pH 7.4 + 0.02% P188 0.04% P188 
10 mM Na-ph. pH 7.4 + 0.02% P188 + 5% 
Suc 
0.04% P188 + 10% Suc 
10 mM Na-ph. pH 7.4 + 0.02% PS20 + 5% 
Suc 
0.04% PS20 + 10% Suc 
10 mM Na-ph. pH 7.4 + 0.02% PVP + 5% Suc 0.04% PVP + 10% Suc 
10 mM Na-ph. pH 7.4 + 0.02% P188 + 5% 
PVP 







Supplier Description Article number 
Biozol FITC anti-human CD9, Mouse IgG1, kappa, Clone: HI9a 25 BLD-312103 
Biozol FITC anti-human CD63, Mouse IgG1, kappa, Clone: H5C6 BLD-353005 
Biozol FITC Mouse IgG1, kappa Isotype Ctrl (FC), Clone: MOPC-21 BLD-400109 
Novus 
Biologicals 
FITC calnexin antibody, Mouse IgG2b kappa, Clone: 1C2.2D11  NBP2-36570F 
Novus 
Biologicals 







Figure S-1: Detection of calnexin as a negative EV marker. Calnexin detected in RO cells with the 








   
 
Figure S-2: Hydrodynamic particle size and PDI from DLS of freshly prepared (before FT) or three 
times freeze-thaw stressed SBCy050 OMVs (A) and RO EVs (B) formulated in 
10 mM Na- or K-phosphate buffer at different pH values, and in PBS. PDI values >0.56 
represent a multimodal size distribution and are therefore stated as ‘1.0’. Each data point 
represents mean ± SD, n=3. Statistical analysis was Student’s t-test. PDI values were not 
evaluated statistically. After FT, all samples were significantly different (p<0.05) compared 
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Figure S-3: Total particle concentration of EVs before FT/FD (mean), three times freeze-thaw 
stressed, and freeze-dried (FD) measured by TRPS NP100 and NP600. Each data point 









































































































































































































































































































































































































































































































































































   
 
Figure S-4: Hydrodynamic particle size and PDI from DLS of freshly prepared (before FT) or three 
times freeze-thaw stressed SBCy050 OMVs (A) and RO EVs (B) formulated in 
10 mM Na-phosphate pH 7.4 or PBS with addition of sucrose and/or surfactant. PDI 
values >0.56 represent a multimodal size distribution and are therefore stated as ‘1.0’. 
Each data point represents mean ± SD, n=3. Statistical analysis was Student’s t-test. PDI 
values were not evaluated statistically. *p<0.05: samples are significantly different 
compared to the corresponding samples before FT. 
 
 







Figure S-5: Number of subvisible particles ≥1 μm of three times freeze-thaw stressed SBCy050 OMVs 
(A) and RO EVs (B) formulated in in 10 mM Na- or K-phosphate buffer at different pH 
values or PBS w/o or with addition of sucrose and/or surfactant (n=3). Samples were 
diluted 1:10 before measurement. Each data point represents mean ± SD, n=3. Statistical 
analysis was Student’s t-test. PDI values were not evaluated statistically. *p<0.05: 






































































































































































































































































































































































   
 
Figure S-6: Hydrodynamic particle size and PDI from DLS of SBCy050 OMVs and RO EVs formulated 
in 10 mM Na phosphate pH 7.4 + 0.02% P188 + 5% Suc, before and after FD. Each data 
point represents mean ± SD, n=3. Statistical analysis was Student’s t-test. PDI values 
were not evaluated statistically. *p<0.05: samples are significantly different compared to 






Figure S-7: Nanoparticle tracking analysis after lyophilization and reconstitution of non-encapsulated 
β-Glu formulated in phosphate buffer, 0.02% P188, and 5% sucrose in comparison to 
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Chapter 6  
 
Final summary and outlook 
Many pharmaceutical nanoparticles (NPs) suffer from poor storage stability hampering 
research and limiting drug developability. Therefore, the present thesis focused on the 
lyophilization of NPs for parenteral application with the main colloidal stability. This colloidal 
stability is highly dependent on the properties of the NPs which are highly divers. Thus, there 
is a need for individual strategies in order to preserve NP properties upon freeze-drying. Still 
we were aiming to arrive at a fundamental understanding of the behavior of NPs during the 
freezing phase and the drying phase of the lyophilization process itself as well as upon 
subsequent storage of the lyophilizates. Chapter 1 summarizes the state of the art on this 
subject, bringing order into rather unstructured literature and giving practical advice on 
formulation and process development for lyophilization of nanoparticulate systems. The 
experimental part of this thesis focused on the investigation of four different NP types: i) 
inorganic NPs; ii) drug nanosuspensions; iii) solid lipid nanoparticles (SLNs); and iv) 
extracellular vesicles (EVs). 
α-Al2O3 NPs served as a chemically, mechanically and thermally stable, non-hydrophobic 
model readily available at larger quantities. The studies with this NP type revealed that initial 
particle stabilization in liquid state may already be a hurdle and depends strongly on the buffer 
type and pH (Chapter 3). Citrate buffer was superior to sodium and potassium phosphate 
buffers both for initial stabilization and during freezing and thawing which is attributed to 
electrostatic interactions. The pH shift of sodium phosphate during freezing caused marked 
NP aggregation which can be avoided by the use of potassium phosphate buffer. The addition 
of further additives can improve freezing and thawing performance; especially gelatin, 
sucrose, and mannitol showed a high cryoprotective potential. 
Lipophilic and therefore surfactant stabilized NPs of paliperidone palmitate and SLNs 
manufactured from trimyristin were investigated in Chapter 4. Initial particle stabilization in 
liquid state requires high amounts of non-ionic surfactants. Because of this surface coverage 
buffer type and pH did not affect FT stability. FT stability was poor in presence of mannitol 
which crystallizes and could be drastically improved by using sucrose which is known to form 
an amorphous matrix during freezing. The higher the sucrose concentration, the less 
aggregation was observed. The freezing step during lyophilization was of minor importance 
compared to the surfactant type used for NP stabilization. Nevertheless, the addition of an 





of subvisible particles. DSC measurements of surfactant containing sucrose formulations 
revealed two glass transition events during freezing indicating a phase separation into a 
surfactant rich and a surfactant poor phase. Consequently, the lyophilizates also exhibited 
two glass transitions, one already at ~50 °C. Accelerated storage stability studies confirmed 
that these formulations suffer from poor stability at 40 °C. HP-β-CD can be added to the 
surfactant/sucrose solution to overcome the limited stability by raising this first glass transition 
temperature. 
In Chapter 5 different formulations aspects were evaluated to improve the freeze-thaw and 
lyophilization stability of EVs. These biological NPs represent a highly fragile particle type due 
to their lipid bilayer membrane which is decorated with proteins. In FT studies, EVs were less 
stable at acidic pH, and in presence of NaCl resulting in marked aggregation which is in sharp 
contrast to the lipophilic NPs of paliperidone palmitate and SLNs. Without further excipients, 
EVs showed less aggregation in potassium phosphate compared to sodium phosphate, 
similarly to α-Al2O3 NPs. The addition of the surfactants polysorbate 20 and poloxamer 188 
(P188) was evaluated subsequently showing complete preservation of particle size and 
concentration after FT in presence of P188. 
In summary, the investigation of four fundamentally different NP types in this thesis provides 
a deeper understanding of crucial particle attributes impacting colloidal stability during 
freezing and lyophilization. The buffer type and ionic strength strongly affect the stability of 
charged particles such as α-Al2O3 NPs and EVs. But the impact is less important in case of 
the lipophilic drug nanosuspensions and SLNs which are protected from electrostatic 
interactions by high non-ionic surfactant concentrations. This effect is especially pronounced 
in presence of high sucrose concentrations. While several surfactants could not improve FT 
stability of α-Al2O3 NPs, surfactants such as polysorbate 20 and poloxamer 188 were highly 
important for successful preservation of lipophilic NPs and EVs. Moreover, the lyophilization 
scientist should be aware of the plasticizing effect of surfactants on the final lyophilizate 
potentially limiting storage stability. As reported in literature and also shown in this thesis, 
formulation aspects rather than process parameters have to be considered for successful NP 
lyophilization. Thus, future studies should further assess critical particle and formulation 
attributes of various NP types. An overall better understanding of these mutually dependent 
aspects will accelerate development of tailor-made formulations and successful freeze-drying 
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